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Abstract
A high number of new chemical entities emerging from the drug devel-
opment process show pharmacological activity, but at the same time are
characterised by poor dissolution and solubility profiles. As a result, there
is a strong push to develop innovative formulations for the delivery of such
compounds so that the desired oral bioavailability and pharmacological
effects are achieved. An increasingly popular class of formulations to im-
prove the dissolution properties of poorly soluble drugs is represented by
amorphous solid dispersions, whereby the drug is molecularly dispersed in
a carrier matrix. One of the key challenges for developing amorphous solid
dispersions in real-world formulations is the understanding of the dissolu-
tion performance. Although this is very important, due to the fact that the
dissolution performance limits the in vivo efficacy, the dissolution mecha-
nisms by which the amorphous solid dispersions dissolve is still not fully
understood.
This thesis investigates the dissolution performance of three solid disper-
sions model systems including felodipine, bicalutamide and indomethacin,
all poorly soluble drugs, with copovidone, a water-soluble polymer. The
complexity of the model systems increases through the chapters, starting
by testing the dissolution of a well-documented poorly soluble drug model,
i.e. felodipine, as a function of the drug loading (5% and 50% w/w) (Chap-
ter 3). In Chapters 4 and 5 the dissolution of bicalutamide, which is known
to exist in at least two different polymorphic forms (form I and form II), is
investigated as a function of three drug loadings (5%, 30% and 50% w/w).
Finally, the dissolution of indomethacin, which presents a pH-variable sol-
ubility and dissolution rate due to its weakly acidic nature (pKa of 4.5), is
probed as a function of both dissolution medium pH (pH 2 and 6.8) and
drug loading (5%, 15%, 30%, 50%, 70% and 90% w/w) (Chapter 6).
The dissolution of amorphous solid dispersions and other oral dosage forms
is commonly tested using the USP dissolution apparatuses (types I, II
iv
vand IV). These methods present a significant limitation, i.e. they can not
provide any directly spatially-resolved chemical information on potential
changes occurring to the solid form (e.g. amorphous to crystalline, poly-
morphs or solvation-related transformations).
In this thesis Raman spectroscopy is employed as primary analytical tech-
nique in an attempt to fill the gaps related to the understanding of the
dissolution mechanisms of amorphous solid dispersions and the limitations
of the conventional USP apparatuses. The novelty of this approach derives
from collecting Raman data directly from the dosage form in real time and
in situ during the course of the dissolution test using a flow-through cell
placed below the Raman microscope. Temporally- and spatially-resolved
chemical Raman maps are generated using a novel mathematical approach
which derives from the use of concatenated maps to explicitly probe the
chemical and physical changes as a function of time as well as space. In-line
ultraviolet spectroscopy is also integrated to the Raman system to directly
relate changes in dissolution behaviour to physicochemical changes that
occur to the solid form during the dissolution test.
A wide range of other state-of-the-art analytical techniques is also used to
complement the Raman data to obtain a clear picture of drug release from
amorphous solid dispersions. This includes a combined magnetic resonance
imaging/ultraviolet flow cell system to allow, similarly to the Raman/ul-
traviolet method, changes in dissolution profile to be related to physical
changes occurring in the solid material, and for the first time quantitative
suppressed-water 1H nuclear magnetic resonance spectroscopy was applied
to amorphous solid dispersions. 1H nuclear magnetic resonance, due to the
high chemical selectivity, provides quantitative data on both the drug and
the polymer. Finally, the rotating disk dissolution rate test, i.e. a modi-
fied version of the conventional intrinsic dissolution rate test, is developed
and employed for the first time to gain information, similarly to 1H nuclear
magnetic resonance spectroscopy, on the dissolution rates of both the drug
and the polymer.
vi
The dissolution performance of all amorphous solid dispersion model sys-
tems is shown to be strongly affected by the drug loading. At low drug
loading the drug and the polymer dissolve with the same rate from the
molecular dispersion, pointing to a drug release dependent on the high wa-
ter solubility of copovidone. At high drug loading, the dissolution rates of
both the drug and the polymer are significantly slower and this is shown to
be ascribed to the formation of an amorphous drug-rich shell around the
compact, followed by the drug re-crystallisation. For the high drug loaded
amorphous solid dispersions, the dissolution performance is strongly de-
pendent on the physicochemical properties of the drug, i.e. low aqueous
solubility and high hydrophobicity. The dissolution behaviour of the amor-
phous indomethacin solid dispersions is also found to be affected by the
dissolution medium pH. Indomethacin from the amorphous solid disper-
sions with 15% or higher drug loading is released only at pH 6.8 due to the
significant increase in its aqueous solubility at this pH.
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Introduction
1.1 Poorly soluble drugs
Oral ingestion is the most commonly used and convenient route of drug
administration due to high patient compliance, cost effectiveness and flex-
ibility in the design of dosage forms.1 However, the major challenge as-
sociated with the oral administration is the low biovailability. The oral
bioavailability depends on a number of factors such as the aqueous solubil-
ity, dissolution rate, drug permeability, first-pass metabolism and suscep-
tibility to eﬄux mechanisms. For orally administered drugs the aqueous
solubility is the most important factor to achieve an adequate bioavailabil-
ity and the required pharmacological response. The drug molecules must
be dissolved in the gastrointestinal (GI) fluids, absorbed through the GI
membrane into the circulatory system and reach the target in sufficient
quantity. For poorly soluble drugs the absorption step is solubility- and
dissolution rate-limited.
Approximately 70% of new chemical entities (NCEs) developed in the
pharmaceutical industry show poor water solubility. This percentage can
be even higher, as high as 90%, for certain drug categories.2 For these
1
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molecules the low aqueous solubility is a limiting factor to achieve the de-
sired concentration in the systemic circulation and thus pharmacological
response. Therefore, improving the oral bioavailability of poorly soluble
drugs represents a major challenge to the pharmaceutical industry. One
way to improve the oral bioavailability of poorly soluble drugs is to in-
crease the drug concentration in the GI fluids and this can be obtained by
increasing the water solubility, dissolution rate or a combination of both.
One of the most important examples of improving the dissolution proper-
ties is represented by converting crystalline solids into amorphous solids.3
In an amorphous material the three-dimensional long-range order which
characterises crystalline materials is lost and as a consequence the energy
barrier for drug molecules to go into solution is lowered.
In 1995 the biopharmaceutics classification system (BCS) was established to
facilitate the development of oral drug products, classifying drug molecules
according to their aqueous solubility and intestinal permeability.4 As shown
in Figure 1.1, a BCS class 1 drug is characterised by high solubility and
high permeability, a class 2 has low solubility and high permeability, a
class 3 has high solubility and low permeability and a class 4 is charac-
terised by low solubility and permeability. Class 1 drugs are the most
attractive candidates to progress to clinical trials as they are characterised
by high solubility and permeability. The bioavailability of class 2 drugs (low
solubility, high permeability) can be improved simply using formulation ap-
proaches that increase the concentration of the drug in the GI fluids, and
this can be achieved by increasing the drug solubility or dissolution rate.
The bioavailability of class 3 drugs (high solubility, low permeability) is
permeability-rate limited, while the dissolution step is likely to be rapid.
Class 4 drugs possess low solubility and permeability, therefore they are
often poor candidates for drug development. Over the past few decades
there has been a significant increase of drug candidates that have fallen
into class 2 and class 4, therefore improving the dissolution properties is a
pressing issue for the pharmaceutical industry.5
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Figure 1.1: The BCS.6
In 2010 a revised classification system for oral drugs termed the devel-
opability classification system (DCS) was introduced using the BCS as a
starting point.7 While the BCS is designed as a regulatory classification
for the assurance of bio-equivalence, the DCS more accurately categorises
drugs according to the factors limiting the oral absorption and therefore
provides a more appropriate classification system for the issues related to
oral product development. The main deviation of the DCS from the BCS
is the introduction of the solubility limited absorbable dose (SLAD) con-
cept and the addition of two sub-classes for class 2 drugs (Figure 1.2). The
SLAD is represented by the boundary between class 2a and class 2b and
it is based on the idea that permeability and solubility are compensatory
for class 2 drugs. For class 2a compounds (dissolution rate-limited), a solid
dosage form containing the crystalline drug can be designed to achieve the
complete oral absorption without the use of complex solubilisation tech-
nologies. This is a result of the compensatory nature of high permeability
on low solubility. For this particular class, however, the drug release from
a standard formulation and absorption will depend on a number of factors
such as particle size, surface area and wettability.
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Figure 1.2: The DCS.7
For class 2b compounds (solubility-limited), the drug will not be absorbed
unless it is formulated in an already solubilised form. Therefore, class 2b
represents a major challenge to formulators.
Griseofulvin (dose of 500 mg) is an example of solubility-limited class 2b
compound. The solubility of griseofulvin in fasted state simulated intestinal
fluid (FaSSIF) has been reported to be 19 µg·mL−1, while absorption and
permeability have been shown to be high.8 Even when the drug is admin-
istred as micronised particles, there is not sufficient dissolution to obtain a
complete absorption.9,10 A solid dispersion of griseofulvin in poly(ethylene
glycol) (PEG) has been used to obtain greater dissolution and oral absorp-
tion compared to the micronised drug.11 However, the complete oral absorp-
tion for griseofulvin and other solubility-limited compounds is very chal-
lenging and requires careful selection of solubilising strategies. Mefenamic
acid (dose of 250 mg) is a nonsteroidal anti-inflammatory drug (NSAID)
with a solubility in FaSSIF of 0.04 mg·mL−1 and a very high intestinal
permeability.7,12 According to the new DCS system, mefenamic acid is a
borderline 2a/2b compound with a SLAD of 280 mg and a recommended
maximum particle size of 42 µm. For mefenamic acid, if the dissolution is
sufficiently rapid, even from a formulation where the drug is not already
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solubilised, a complete absorption will be observed due to the compensatory
effect of high permeability on low solubility.
1.2 Solubility and dissolution rate
Aqueous solubility and dissolution rate are important properties to consider
when developing drugs for oral administration. Solubility is an intrinsic
property of a solid substance which occurs under dynamic equilibrium, i.e.
solubility results from the simultaneous and opposing processes of dissolu-
tion and precipitation of solids. The dissolution rate is an extrinsic property
and it is defined as the rate of solvation. Therefore, changing the chemical
structure of a drug molecule (e.g. pro-drugs, salt formation) will change
the solubility, whilst the dissolution rate can be changed through the use
of formulation strategies (e.g. particle size reduction, complexation).
The correlation between solubility and dissolution rate is described by the
Noyes–Whitney equation (Equation 1.1):13
dC
dt
= kDA(CS − Ct) (1.1)
where dC
dt
is the dissolution rate, kD is the dissolution rate constant (de-
pendent on the stirring rate and the diffusion constant), A is the surface
area of the solid, CS is the solubility of the drug, and Ct is the drug con-
centration dissolved at time t. This equation shows that, all other factors
being constant, the dissolution rate is proportional to the surface area of
the solid and to the solubility of the drug. As a result, poorly soluble drugs
will have a slow dissolution rate and poor bioavailability. A review of the
current formulation strategies to improve the dissolution properties and
oral bioavailability of poorly soluble drugs is outlined in the next sections.
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1.3 Strategies of improving the dissolution
properties
1.3.1 Pro-drugs
The pro-drug approach consists of functionalising a drug with hydrophilic
moieties (e.g. phosphate ester groups), so that the solubility will increase.14
After administration, the inactive substance is metabolised in vivo to pro-
duce the active drug. For example, amprenavir has been phosphorylated
to produce fosamprenavir.14 Fosamprenavir in the form of a calcium salt
was shown to be approximately 10 times more soluble than amprenavir.
Although this approach to improve the oral bioavailability has produced a
number of commercially available products,15 two main requirements must
be satisfied. Firstly, the compound should have a suitable functional group
to make a pro-drug. Secondly, an enzyme in the body is necessary to trans-
form the pro-drug in its active form after administration. A more complex
biopharmaceutical profile and poor chemical stability can be additional
challenges.
1.3.2 Salts
Forming salts of ionisable drugs is one of the most common ways to increase
the dissolution properties.16 The improvement in dissolution compared to
the free acid or free base under the pH conditions of the GI tract is due to
the higher solubility of the free drug in the pH microclimate of the aqueous
diffusion layer surrounding the solid generated by the counterion.17,18 For
example, the dissolution rates of doxycycline hydrochloride at pH 4 and 7
were found to be significantly higher compared to those of the free base
form.16 Similarly, the dissolution rates of sodium salicylate at pH 1.1, 2.1
and 7.0 were shown to be higher than those of salicylic acid.16 The main
disadvantage of this approach is that a drug must contain ionisable groups
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(e.g. carboxylic acids, amines) to form a salt. In addition, salts can poten-
tially revert into aggregates of their free acid or base forms, thus inhibiting
the improvement in bioavailability.
1.3.3 Particle size reduction
It can be seen from Equation 1.1 that the surface area of the solid is a key
parameter that directly affects the dissolution rate. Reducing the particle
size of the drug will increase the surface area and therefore the dissolution
rate. The amount of griseofulvin in the blood was found to be approxi-
mately doubled by reducing the particle size from 10 to 2.7 µm.19 Micro-
nisation is a common method to reduce the particle size and it is done by
milling techniques. Limitations of this technology include the formation
of particles with poor flow properties and the generation of charged and
cohesive particles which can rapidly aggregate.
1.3.4 Amorphous forms and amorphous solid disper-
sions (ASDs)
Converting a crystalline drug into an amorphous drug is considered one
of the most important approaches to improve the dissolution properties
of poorly soluble drugs.3 For example, the dissolution of amorphous in-
domethacin and ritonavir were found to be 5 and 10 fold higher than
that of their crystalline counterparts.20,21 This increase in dissolution typ-
ically will result in an increase in oral absorption and bioavailability. Two
classes of amorphous materials are relevant to the pharmaceutical science:
pure amorphous solids and ASDs. As amorphous solids and ASDs are
the main focus of this thesis, important physicochemical considerations for
their preparation, stability and dissolution improvements will be specifi-
cally discussed in later sections (Sections 1.4 and 1.5).
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1.3.5 Polymorphs
Drugs can exist in several different crystalline forms known as polymorphs.
Polymorphism is defined as the ability of a compound to crystallise as more
than one distinct crystal species. Polymorphs, due to their different pack-
ing arrangements, present significantly different physicochemical properties
such as water solubility and dissolution rate, stability and compactability.22
Selecting a polymorph with higher free energy can increase the dissolution
rate and bioavailability compared to the thermodynamically stable form.
Kobayashi et al. have shown that the dissolution rate and bioavailability
were significantly different between carbamazepine polymorphs.23 The dis-
solution rate of both anhydrates (form I and form III) was found to be 1.5
and 1.6 fold higher than that of the dihydrate form. The plasma concen-
tration level of form I was shown to be approximately twice than that of
form III and the dihydrate form. The main challenge is that metastable
polymorphs can convert into the more stable form during manufacturing,
storage as well as dissolution in the GI fluids, leading to unpredictable per-
formances.24 Polymorph screening is therefore a very important part of the
pharmaceutical development.
1.3.6 Co-crystals
The definition of co-crystals is still under debate in literature, but in general
they can be defined as a crystalline material that consists of two or more
chemical species held together by non-covalent forces.25–27 While according
to some definitions the term co-crystal includes salts, the molecules in a co-
crystal are not necessarily ionically bonded together, i.e. there is not proton
transfer, but they are held together by other non-covalent forces, mostly
through hydrogen bonding and pi–pi stacking. As discussed for polymorphs,
co-crystals often present superior physicochemical properties compared to
those of each of the separate entities. The dissolution rate of a co-crystal
which consists of a sodium channel blocker and saccharin was shown to be
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18 fold higher compared to that of the pure crystalline form.28 In addition,
the plasma concentration level of the co-crystal was found to be 3 fold higher
than that of the pure crystalline form. As with salt formation, however,
co-crystals can suffer from selection problems (e.g. compatible functional
groups are required for inter-molecular interactions).
1.3.7 Microemulsions
Microemulsions are biphasic systems composed of two immiscible liquids
with one dispersed through the other.29,30 Microemulsions are stabilised by
surfactants and can be used for parenteral, topical and oral administration.
Hydrophobic and poorly soluble drugs are incorporated into the microemul-
sion, so that the dissolution step can be avoided. The bioavailability of a
cyclosporine microemulsion has been found to be 6.5 fold higher compared
to the conventional oral solution formulation.31 The main drawback of this
formulation strategy is the chemical and physical instability.
1.3.8 Cyclodextrins
Cyclodextrins are cyclic oligosaccharides with a hydrophilic outer surface
and a hydrophobic inner cavity capable of forming complexes with hy-
drophobic and poorly soluble drugs. They are not only used to improve
the dissolution and bioavailability of poorly soluble drugs, but also for taste
masking. Improvements in solubility from 1.8 to 200 fold for a number of
drugs have been obtained when using cyclodextrin solutions over water.32
The main limitation of cyclodextrins includes the potential nephrotoxicity
after parenteral administration.33
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1.4 Amorphous solids
1.4.1 Formation of the amorphous form
The amorphous phase can be defined as a disordered solid that lacks the
three-dimensional long-range order present in the crystalline phase.34 A
classical free energy-temperature diagram (Figure 1.3) shows that, when the
temperature is increased, there is a significant reduction in free energy of
the crystal, until the melting temperature Tm is reached, where the crystal
undergoes a spontaneous conversion to the liquid form. If the system is
slowly cooled to below the Tm and there is sufficient time for nucleation
and crystal growth to occur, the liquid phase will revert to the crystal.
However, if the liquid is rapidly cooled and the crystallisation is avoided,
the system will maintain the properties of the liquid phase as supercooled
liquid. If the system is further cooled, the viscosity of the supercooled
liquid increases and this results in a distinct discontinuity in the free energy-
diagram, with the formation of the unstable glassy state. The temperature
at which this change occurs is termed glass transition temperature Tg. The
amorphous phase can therefore be prepared by melting the crystalline form
and supercooling the system below the Tm and the Tg. This is indeed the
basis for producing ASDs by hot melt extrusion (HME).
1.4.2 Physical stability of the amorphous form
Figure 1.3 also shows that the amorphous/glassy phase is in a higher free
energy state at all temperatures compared to the crystalline phase. There-
fore, the amorphous form will spontaneously crystallise over time. Such
crystallisation will clearly negate the benefits of using the amorphous form
for enhancing the dissolution properties of poorly water-soluble drugs. Aso
at al. found that for several pharmaceuticals the molecular mobility and
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the re-crystallisation tendency of the amorphous form significantly increases
above the Tg.
35
Figure 1.3: Effect of temperature on free energy for a single-component
system.36
The Tg is therefore an important indicator of the physical stability of an
amorphous material. Storing the amorphous material below the Tg should
lower the risk of crystallisation due to the low molecular mobility. However,
it has been reported that felodipine and nifedipine, while they have similar
Tgs (46.4
◦C for felodipine and 45.5 ◦C for nifedipine), they have a dif-
ferent re-crystallisation behaviour, with nifedipine re-crystallising far more
readily than felodipine.37 This was attributed to a higher thermodynamic
driving force and lower activation energy for crystallisation in nifedipine.
In addition, the presence of water in the storage conditions can lower the
Tg of amorphous materials by plasticisation effect, increasing the rate of
crystallisation.38 The preparation method used to prepare the amorphous
material has been demonstrated to significantly affect the thermodynamic
properties and the re-crystallisation tendency. Karmwar et al. have pre-
pared amorphous indomethacin using melt quenching, spray drying, ball
milling and cryomilling.39 They found that the physical stability of the
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amorphous form decreased in the order: melt quenching > cryomilling >
spray drying > ball milling. The drug particle size has been also shown
to affect the physical stability and re-crystallisation tendency. Particles of
amorphous felodipine with smaller size were shown to crystallise at faster
rates compared to larger particles.40
Homogeneous nucleation and crystal growth from the liquid state can be
used to describe the re-crystallisation of organic molecules from the amor-
phous state.41 This model assumes that the molecules in the liquid state
first undergo spontaneous nucleation, followed by the growth of crystallites.
The free energy difference ∆G between molecules in the amorphous state
and those in the crystalline state is the thermodynamic driving force for
nucleation and crystal growth (Figure 1.4). However, phase separation with
the formation of new surfaces between the nuclei and the amorphous phase
must occur prior to nucleation, and this process is thermodynamically un-
favourable. Thus, there is an increase in ∆G until a critical radius r of
spherical nuclei is reached, above which the spontaneous nucleation occurs.
Nucleation inhibitors can potentially prevent the system from reaching the
critical nucleus radius, thus avoiding the crystal growth.
Figure 1.4: Energies associated with the crystallisation of amorphous
materials.6
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As mentioned before, the main advantages of the amorphous form com-
pared to the crystal are the improved dissolution properties due to the lack
of a well-ordered crystal lattice. However, amorphous pharmaceuticals,
due to their physical instability, have the tendency to quickly re-crystallise
during storage or when exposed to dissolution media,20 leading to an unpre-
dictable bioavailability. Nucleation inhibitors or molecules that reduce the
molecular mobility of the system such as polymers can be used to improve
resistance to crystallisation and enhance the dissolution properties.42
1.5 Amorphous solid dispersions
ASDs can be defined as single-phase amorphous mixtures of one or more
active pharmaceutical ingredients (APIs) and a polymeric carrier.43 The
primary functions of the polymer are to provide stability of the amorphous
form during storage against the solid-state crystallisation and to main-
tain the drug supersaturation in the dissolution medium by inhibiting the
solvent-mediated crystallisation.44
1.5.1 Preparation of amorphous solid dispersions
ASDs can be prepared by two main methods: melt (fusion) and solvent
evaporation. Melt (fusion) methods primarily include HME, direct cap-
sule filling and compression moulding, while solvent evaporation methods
mainly include spray drying and co-precipitation. In HME the material
is melted/softened at elevated temperatures and continuously extruded to
produce small fragments which are then milled and mixed with other for-
mulation components.45 The main advantages of HME are that it is a con-
tinuous and solvent-free process and that it can be scaled up to large-scale
manufacturing. Disadvantages are related to the use of high temperatures
which can lead to thermal degradation and to a poor mixing between the
drug and the polymer because of the high viscosity of the liquid polymer.
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Direct capsule filling consists of directly filling the gelatin capsules with
the melt of solid dispersions, while in compression moulding the mixture
of a drug and a polymer is compressed at elevated temperature. In spray
drying a solution of a drug and a polymer is sprayed through a nozzle into
a drying chamber where the solvent is rapidly evaporated.46 The main ad-
vantages of spray drying are that the particle size of the material can be
controlled and that the process can be easily scaled up for manufacturing.
Disadvantages include potential degradation due to the solvent and diffi-
culty in completely removing the solvent with consequent safety concerns.
Co-precipitation consists of co-precipitating the drug and the carrier as mi-
croparticles by adding a non-solvent to the solution of the drug and the
carrier.
1.5.2 Carrier materials
Typical materials for preparing ASDs are water-soluble or water-swellable
polymers. When selecting a carrier it is important to consider the manu-
facturing method. For example, in HME the carrier must be thermically
stable under the required process conditions. If the preparation is via spray
drying, both the drug and the the polymer should be sufficiently soluble in
the required organic solvent. In addition, the selection of polymer carrier
should also be evaluated based on the drug:polymer miscibility, mechanism
of the inhibition of the crystal growth and the carrier ability to enhance
the dissolution profiles of the dispersed drug. A lack of miscibility can
induce drug re-crystallisation.47,48 For example felodipine was found to be
miscible with PVP and this polymer was very effective to inhibit the drug
re-crystallisation.49 In contrast, felodipine was shown to be only partially
miscible with polyacrylic acid (PAA), and the drug quickly crystallised.48,50
Itraconazole was found to be miscible with Eudragit E100 only up to a drug
loading of 13%, while at higher drug loadings a drug-rich amorphous phase
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and polymer-rich amorphous phase were observed using microthermal anal-
ysis.51
The most commonly used polymers for preparing ASDs include vinyl-
pyrrolidone-based polymers such as poly(vinyl pyrrolidone) (PVP) and
poly(vinyl pyrrolidone)-poly(vinyl acetate) (copovidone)52,53 and cellulose-
based polymers such as hydroxypropyl methylcellulose (HPMC) and hy-
droxypropyl methylcellulose acetate-succinate (HPMCAS).54 Methacrylate-
based polymers such as Eudragit are also used for a pH-dependent drug
release.55
1.5.3 Solid-state characterisation of amorphous solid
dispersions
As previously discussed, the physical stability and the dissolution mecha-
nisms of ASDs have been shown to be strongly affected by the solid-state
properties, therefore the determination of the physical structure is of par-
ticular importance. In this section, common methods for solid-state char-
acterisation of ASDs will be presented.
1.5.3.1 Polarized light microscopy (PLM)
PLM is a contrast-enhancing technique that probes birefringence, which is
a phenomenon that most crystalline APIs display due to their anisotropic
nature. Amorphous materials are isotropic and therefore they do not show
birefringence. Crystalline domains appear as coloured and bright regions,
while amorphous domains show a similar colour to the background. Using
PLM it is possible to readily detect small quantities of crystalline material
in an otherwise amorphous matrix. The key advantage of this technique
is that small amounts of material are required. PLM has been employed
in several studies to evaluate optimum polymers for ASDs and the re-
crystallisation behaviour of amorphous systems.41,49,56,57 In one of these
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studies, for example, PLM was employed to investigate the nucleation rate
of amorphous indomethacin as a function of temperature.41 In other stud-
ies, PLM has been used to evaluate the impact of polymer amount and
storage conditions on the nucleation rate of felodipine.49,57
1.5.3.2 X-ray powder diffraction (XRPD)
XRPD is one of the most common methods to determine and quantify
crystallinity in amorphous systems. The diffractogram of a crystalline ma-
terial contains characteristic peaks, while that of an amorphous material
is characterised by a broad halo. The limits of detection of crystallinity
are typically in the range of 1–5% by weight for laboratory-based diffrac-
tometers,58 while with synchrotron-based systems it is possible to achieve
lower detection limits, as low as 0.2%.59 XRPD has been employed in a
number of reports to evaluate the solid-state structure of ASDs, includ-
ing miscibility.49–51,60 In one of these reports, XRPD was used to follow
the crystallisation kinetics of amorphous felodipine solid dispersions as a
function of polymer type (PVP vs HPMCAS), drug loading and relative
humidity (RH) storage conditions.60
1.5.3.3 Solid-state nuclear magnetic resonance (ss-NMR)
ss-NMR has been applied in several studies to investigate a number of as-
pects of ASDs, including molecular mobility, inter-molecular interactions
and quantification of crystallinity.61–64 19F ss-NMR was employed to deter-
mine the mobility of ASDs of flufenamic acid in PVP and HPMC.63 The
molecular mobility was found to be higher in the HPMC dispersion com-
pared to the PVP dispersion. Due to the lower molecular mobility, the PVP
dispersion was found to be more stable to crystallisation compared to the
HPMC dispersion. 19F ss-NMR has also been used to detect crystallinity
in amorphous systems, with a detection limit of approximately 3%.64
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1.5.3.4 Differential scanning calorimetry (DSC)
One of the most common applications of DSC is the determination of
the Tg. As discussed earlier, the Tg is of particular importance as the
re-crystallisation of amorphous materials is known to be faster above the
Tg than below the Tg.
41 Another application of DSC is the determination
of crystallisation during heating. Yoshihashi et al. have investigated the
induction times for the crystallisation of flurbiprofen and tolbutamide dis-
persions with PVP.65 They observed that the induction time increased with
an increasing amount of PVP, and that PVP was more effective at increas-
ing the induction time for tolbutamide compared to flurbiprofen. DSC can
also be used to estimate the presence of crystalline material arising from
processing or storage through the determination of a melt endotherm.66
This can be done by comparing the melt endotherm of the partially crys-
tallised solid dispersion with the melt endotherm of the pure crystalline
drug, with the ratio giving the amount of re-crystallised material.
1.5.3.5 Raman and infrared (IR) spectroscopy
Both Raman and IR spectroscopy are methods widely used to characterise
ASDs in terms of crystallisation rates and drug-polymer inter-molecular
interactions. The main advantage of Raman is that it is able to readily
discriminate between amorphous and crystalline forms. Raman spectra of
crystalline materials are characterised by sharp peaks, while those from
amorphous materials by broader bands. In addition, drugs typically have a
stronger Raman spectrum than the excipients, which is important for the
determination of low levels of crystallinity in multi-component systems.
For example, Raman has been employed to detect the presence of less then
0.05% weight of crystallinity in ASDs of ibipinabant and PVP.67 Another
key advantage or Raman is that it can be coupled with a microscope to ob-
tain highly spatially-resolved chemical images. Raman mapping was used,
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for example, to discriminate between amorphous and crystalline domains
in troglitazone-PVP ASDs.68
IR is a very useful technique to evaluate the drug-polymer miscibility and
inter-molecular interactions. It has been employed to determine the in-
teractions of ASDs of felodipine with PVP, HPMC and HPMCAS.49 PVP
was shown to form the strongest hydrogen bonds with felodipine. In an-
other study, IR was employed to characterise the interactions in ASDs of
indomethacin and PVP.69 It was observed that the hydrogen bonds be-
tween the carboxylic acid functional group of indomethacin and the car-
bonyl acceptor of PVP (drug-polymer interactions) led to the disruption of
the carboxylic acid dimers formed in the pure amorphous drug (drug-drug
interactions).
1.5.4 Physical stability during storage
The re-crystallisation event during storage depends on a number of factors
such as the temperature,70 water content,57 and type and amount of poly-
mer used.57,71 As previously indicated, polymers have a key role in stabilis-
ing ASDs and preventing the drug re-crystallisation, and this is achieved by
simply keeping the drug molecules apart via steric hindrance, reducing the
molecular mobility of the drug and forming specific drug:polymer chemical
interactions (e.g. hydrogen bonding).36,69,72–74
Polymers used for preparing ASDs typically have a Tg greater than 100
◦C. When a higher Tg polymer is combined with a drug with lower Tg,
the resultant dispersion will have a decreased molecular mobility and re-
crystallisation tendency compared to the pure amorphous material (an-
tiplasticisation effect). Increasing the polymer molecular weight (MW) will
increase the Tg, and this will result in a greater crystallisation inhibitory
effect. It has been shown that the crystallisation inhibition of PVP for a
model compound MK-059 increased with the polymer MW.73
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The formation of chemical interactions between the drug and the polymer
and the disruption of drug-drug interactions are also important for sta-
bilising ASDs. Indomethacin and PVP have been shown by Raman and
IR spectroscopy to form inter-molecular hydrogen bonding interactions in
the solid dispersion.69 The drug-polymer hydrogen bonds prevented the
self-association of indomethacin dimers which characterises the crystal. In
another work, it has been observed that ASDs of acetaminophen and PAA
were stable for longer time compared to ASDs of acetaminophen in PVP.70
This was attributed to the stronger chemical interactions between the car-
boxylic acid group of PAA and the hydroxyl group of acetaminophen com-
pared to the carbonyl group of PVP.
The amount of polymer in ASDs can greatly affect the crystallisation ten-
dency. It has been shown that ASDs of indomethacin and PVP containing
only 5% w/w of polymer were stable up to a period of six months.75 Increas-
ing the amount of polymer to 30% w/w prevented nucleation and crystal
growth for over two years.
Temperature significantly affects the physical stability of ASDs. Storing
an ASD at elevated temperatures above the Tg will increase the molecular
mobility, enhancing phase separation and/or re-crystallisation potential. A
recommendation is to keep the storage temperature at Tg – 50
◦C, so that
the molecular mobility can be practically neglected due to the high viscosity
of the system.36,76
Another important consideration is that when an ASD is exposed to ele-
vated RH conditions, the material will absorb the water vapour with con-
sequent effects on the bulk properties of the solid such as the Tg and the
molecular mobility.77 The water molecules act as an excellent plasticiser,
significantly reducing the Tg of amorphous solids and therefore increasing
the re-crystallisation tendency.78 Figure 1.5 shows the water vapour ab-
sorption for PVP, HPMC and HPMCAS at room temperature. PVP was
shown to be the most hygroscopic polymer with 26% w/w of water vapour
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absorption at 75% RH, while the water uptake of HPMC and HPMCAS
were found to be 10% w/w and 7% w/w respectively.79
Figure 1.5: Water vapour absorption for PVP, HPMC and HPMCAS
at room temperature.79
Although ASDs represent a very promising platform for increasing the dis-
solution properties of poorly soluble drugs, to date only a limited number
of products have been brought to market (Table 1.1).80 The main concern
is the possibility of drug re-crystallisation during manufacturing, storage
and dissolution which can lead to unpredictable performance in the patient
with potentially harmful consequences.
Product Compound Polymer Process Approval
Sporanox Itraconazole HPMC Fluid bed bead layering 1992
Prograf Tacrolimus HPMC Spray drying 1994
Kaletra Lopinavir/ritonavir Copovidone HME 2007
Intelence Etravirine HPMC Spray drying 2008
Zortress Everolimus HPMC Spray drying 2010
Onmel Itraconazole HPMC HME 2010
Norvir Ritonavir Copovidone HME 2010
Incivek Telaprevir HPMCAS Spray drying 2011
Zelboraf Vemurafenib HPMCAS Solvent/antisolvent precipitation 2011
Kalydeco Ivacaftor HPMCAS Spray drying 2012
Table 1.1: Solid dispersion products in the market.80
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1.5.5 Dissolution performance in aqueous media
The main advantages of using ASDs are the increased dissolution and im-
proved bioavailability compared to the crystalline form. A drug in an ASD,
when immersed in an aqueous dissolution medium, will rapidly dissolve
and reach some level of supersaturation. However, the amorphous drug
molecules due to their physical instability are likely to crystallise over time,
thus depleting the solution of dissolved drug and reducing the bioavailabil-
ity.
There are two potential re-crystallisation routes in aqueous media: direct
solid-solid and solution-mediated crystallisation.6 In aqueous media the wa-
ter penetration into the amorphous material increases the molecular mo-
bility due to plasticisation effect (same as during storage), thus facilitating
the direct solid-solid transformation within the material. However, the
most important crystallisation process in aqueous media is the solution-
mediated crystallisation. The drug in the crystalline form dissolves until
the thermodynamic solubility of the drug is reached, after which the con-
centration of the drug remains constant. On the other hand, the amorphous
drug dissolves more rapidly than the crystalline form and reaches higher
concentrations. However, the solution is supersaturated with respect to
the crystalline state and therefore it is thermodynamically viable for the
drug to precipitate into the crystalline form until the concentration equals
the solubility of the crystalline drug. The generation and stabilisation of
a metastable supersaturated state can be described using the “spring and
parachute” model (Figure 1.6).81 The amorphous form can be associated to
the “spring”. The lack of three-dimensional long-range order results in an
increased dissolution rate, but there is a thermodynamic driving force for
crystallisation due to the saturation solubility of the crystalline form being
exceeded. The higher the level of supersaturation is achieved, the higher
the rates of nucleation and crystal growth are.82 Polymers or other addi-
tives that act as crystallisation inhibitors are described as “parachutes”.
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They maintain the supersaturation for a longer time period, increasing the
absorption and bioavailability.
Figure 1.6: Schematic illustration of the “spring and parachute”
model.81
The parachute effect of the polymer is due to a combination of mecha-
nisms. Polymers can form complexes with the drug molecules in solution,
via electrostatic bonds, van der Waals forces and hydrogen bonding, thus
inhibiting nucleation and crystal growth.83 In addition, the viscosity of the
polymer can also have an effect on nucleation and crystal growth.84 The
impact on crystal nucleation of various polymers has been evaluated for a
number of drugs.85 For example, the induction time for crystallisation of
celecoxib was about 20 min in presence of the polymer, compared to less
than 5 min in absence of the polymer. HPMC was also found to reduce the
nucleation rate of felodipine by a factor of 1000.86
The dissolution performance of ASDs depends on a number of factors such
as the physicochemical properties of the drug and the polymer, and the
drug:polymer ratio. Craig classified the drug release from ASDs as drug-
controlled or polymer-controlled.87 For a carrier-controlled release, the rate-
limiting step for drug dissolution is the release of the polymer itself.88
The drug is released into solution at a rate dictated by the carrier. For a
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drug-controlled release, the dissolution will depend on the physicochemical
properties of the drug. The drug is released into the dissolution medium at
a rate proportional to its aqueous solubility.89 In this case, the low aqueous
solubility can induce physical instability and drug re-crystallisation.
1.6 Dissolution measurements
By far the most common method of investigating the drug release from
ASDs and other oral dosage forms is the use of US pharmacopeia (USP)
apparatuses (types I, II and IV).90 These solution-based tests consist in
dissolving the material in water or in other physiologically relevant fluids
which are kept in motion at a constant speed, and measuring the drug
content in solution as a function of time using ultraviolet-visible (UV-Vis)
spectroscopy or high performance liquid chromatography (HPLC). These
in vitro dissolution testing methods are robust, easy to operate and widely
available, and can be used to determine the key factors that influence the
performance of products. However the mechanism of dissolution is inferred
indirectly, with no data being collected directly from the dosage form. In
addition, they can not provide any direct spatially-resolved information on
potential changes occurring to the solid form (e.g. amorphous to crystalline,
polymorphs or solvation-related transformations), which can be extremely
important for better understanding the dissolution performance of ASDs.
Due to the outlined limitations of the USP tests, solution-based and solid-
based techniques have been developed and employed to characterise the
drug release from pharmaceutical products.
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1.6.1 Solution-based methods
1.6.1.1 Quantitative suppressed-water 1H nuclear magnetic res-
onance
Quantitative suppressed-water 1H NMR is an example of solution-based
technique that has been recently employed to obtain additional informa-
tion on the drug release of pharmaceutical products.91 For chemical species
lacking a UV chromophore (e.g. soluble fillers), or medicines containing
more than one active ingredient, quantification can be challenging using
UV absorbance data. 1H NMR offers high chemical selectivity and there-
fore is capable of resolving signals from components through differences in
their chemical shifts. The increased resolution of NMR reduces the chance
of overlapping signals compared to UV. In addition, as 1H NMR spec-
tra obtained from a dissolution test can be referenced against a spectrum
of a solution with known concentration, quantification is possible.92,93 An
important consideration with 1H NMR is that signals from protonated sol-
vents can interfere with the samples. However, high quality spectra can
be now easily obtained using water suppression and gradient shimming 1H
NMR experiments.91
1.6.2 Solid-based methods
Solid-based techniques have been also developed with strong focus on ob-
taining in real time and in situ spatially-resolved and chemically-detailed
information. Methods have included UV imaging,94–96 IR97–105 and Raman
spectroscopy,106–112 and also magnetic resonance imaging (MRI).113–116
1.6.2.1 Ultraviolet imaging
In a UV imaging set-up, the dissolution medium is pumped into a flow-
through cell that is equipped with a light source and a charge-coupled device
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(CCD) camera chip. UV imaging can provide spatially- and temporally-
resolved information, and in addition enables real time dissolution rates to
be obtained. In a UV imaging experiment, the intensity of the light passing
through a quartz cell is measured as a function of position and time, and
therefore absorbance and concentration maps can be generated. Hulse at
al. have compared the dissolution rates obtained by UV imaging for α and γ
indomethacin, theophylline anhydrate and hydrate, and ibuprofen free acid
and its sodium salt.94 The ratio in dissolution rate between the α form over
the γ form of indomethacin was found to be approximately 1.7, while that
for the anhydrate form over the hydrate form of theophylline was 2.1. A
46.5 fold increase in dissolution rate was observed for the sodium salt of
ibuprofen over the free acid form. UV imaging was used in another study to
monitor the dissolution behaviour of amlodipine besylate in three different
solid forms: amorphous, dihydrate and free base.95 UV imaging combined
with Raman spectroscopy indicated the re-crystallisation of the amorphous
form into the monohydrate form. UV imaging has been also employed to
study the dissolution of the amorphous both sodium salt and free acid of
furosemide compared to the corresponding crystalline forms.96 The salts
were shown to have a higher dissolution rate compared to the free acids.
Raman spectroscopy indicated the transformation of amorphous acid into
crystalline acid, while the salt forms of furosemide were shown by PLM to
convert into a trihydrate form during dissolution.
1.6.2.2 Infrared and Raman spectroscopy
IR and Raman spectroscopy used in combination with multivariate data
analysis approaches (e.g. multivariate curve resolution (MCR) and princi-
pal component analysis (PCA)) can be very useful for mechanistic studies
of drug dissolution. Both techniques present high chemical specificity and
therefore they can be used to monitor solvent-mediated phase transforma-
tions that occur during the dissolution.
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Fourier transform (FT) IR has been employed to investigate the drug re-
lease mechanisms of testosterone-poly(ethylene oxide) dispersions.97 Two
different types of drug release were observed depending on the drug load-
ing. At low drug loading the dissolution was polymer-controlled, while at
higher drug loading the dissolution of the drug was the controlling factor.
Kazarian and Chan employed attenuated total reflection (ATR) FT-IR to
image the crystallisation of ibuprofen molecularly dispersed in PEG dur-
ing the dissolution in water.98 Combining ATR spectroscopy with FT-IR
resulted in a method with high both chemical specificity and spatial reso-
lution. They have also built a combined compaction and flow-through cell
to study the dissolution of a tablet composed of caffeine and HPMC.99 The
main advantages of this special cell were the good contact between the ATR
surface and the sample for improving the quality of the images, and a more
controlled water penetration into the compact. In another work by the
same group, the combined compaction and flow-through cell was linked to
a UV detector to quantify, similarly to the conventional dissolution tests,
the amount of niacinamide released from HPMC tablets.100 Later, ATR
FT-IR and UV were employed to evaluate the drug precipitation in buffers
at different pH conditions from tablets containing diclofenac sodium and
HPMC.104 In another work, ATR FT-IR and visible macro-photography
were employed to evaluate the water ingress fronts into a tablet containing
buflomedil pyridoxal phosphate and HPMC.101 The correct assignment of
these fronts was shown to be important for understanding the drug release
mechanisms. In a recent work by Keles et al., ATR FT-IR imaging has
been used to monitor during dissolution in deuterated water the release of
growth hormone (hGH) from poly(lactide-co-glycolide) (PLGA)/polylactic
acid (PLA) microparticles and Poloxamer 407 excipient, and to study the
effects of γ-radiation on the release kinetics of such system.102 The γ-
radiation was shown to increase the number of oxygenated components
in the Poloxamer 407, thus increasing the rate of hydration and leading
to a faster and more pronounced initial burst release of hGH. One of the
main limitations of IR for investigating the dissolution is that its radiation
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is strongly absorbed by the water molecules. However, this can be worked
around by integrating only bands for each component which appear distant
from the absorption of water, as Kazarian et al. have shown in a number
of reports.103–105
Raman spectroscopy, unlike IR, is relatively insensitive to water,117 which
is clearly an advantage for testing the dissolution in aqueous environments.
One of the key advantages of Raman spectroscopy is the access to the low-
wavenumber region that has been demonstrated to be extremely sensitive to
differences between amorphous and crystalline forms and among different
polymorphic forms.118–120 The ability to differentiate between amorphous
and crystalline forms is particularly relevant as it is known that the physical
form of the drug substance can change during the course of the dissolution
test, and this can limit the performance.103,113,121 Aaltonen et al. studied the
solvent-mediated phase transformations of theophylline and nitrofurantoin
using in situ Raman spectroscopy.106 It was shown that both theophylline
and nitrofurantoin anhydrates underwent to a transformation to the corre-
sponding monohydrates, with a decrease in dissolution rate for theophylline.
In another work, in situ Raman spectroscopy was used to monitor the solid-
phase transitions during the dissolution of indomethacin.107 The decrease
in dissolution rate for amorphous indomethacin was shown to be related to
the drug re-crystallisation into the α form. Raman spectroscopy has been
also employed to investigate during dissolution the different component
distribution and structural changes of extrudates containing theophylline
anhydrate, tripalmitin and PEG.108 It was observed that the lipid struc-
ture remained intact, while the water-soluble polymer rapidly dissolved
from the matrix, leaving pores that facilitated the water ingress, thus ac-
celerating the drug release. Choi et al. have used Raman spectroscopy to
evaluate the distribution and movement of a model drug (tamsulosin HCl
dihydrate) during the swelling of three-layer tablets.109 In another report,
in situ Raman spectroscopy was used to study the precipitation of dipyri-
damole during trasfer from a simulated gastric medium into a simulated
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intestinal medium.110 Due to the higher pH of the latter, dipyridamole
precipitated from solution and it was possible to build based on the Ra-
man data a theoretical model of drug nucleation and crystal growth during
transfer tests.
Coherent anti-Stokes Raman scattering (CARS) spectroscopy has been also
employed to monitor the solid-state changes during the dissolution of phar-
maceutical formulations. In CARS, compared to spontaneous Raman spec-
troscopy, two pulsed lasers are focused on the sample to generate a coherent
anti-Stokes signal. CARS requires very specialised equipment, while con-
ventional Raman requires only one laser and is therefore much more readily
accessible. Kang et al. have used CARS to characterise the spatial organ-
isation during dissolution of paclitaxel, PEG and PLGA in spray-coated
blend films.111 It was observed that PEG accelerated the burst release of
paclitaxel through dissolution of PEG and paclitaxel at the film surface.
The release of the drug inside the film was retarded due to the presence of
PLGA. In a more recent work, in situ CARS combined with UV absorption
spectroscopy was used to monitor the solid-state changes in oral dosage
forms containing theophylline anhydrate.112 The CARS results indicated
that theophylline anhydrate converted into theophylline monohydrate, re-
sulting in a decrease of the dissolution rate.
1.6.2.3 Magnetic resonance imaging
MRI offers relatively low chemical selectivity, measuring the concentration
of a particular nucleus, typically hydrogen. However, it is the only tech-
nique of those described that can provide three-dimensional information
on molecular mobility. In a work by Langham et al.,113 MRI was used to
monitor the physical processes occurring during the dissolution of various
compositions of felodipine and copovidone ASDs compacts inside a flow-
through cell installed in the MRI magnete. The temporal changes in longer
and shorter dimensions of the compacts in one-dimensional cross-sectioned
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images were measured to obtain information on the erosion and swelling
processes. It was observed that the dissolution of the 5% and 15% drug
loadings followed a linear erosion of both the short and long dimensions,
indicating a polymer-controlled drug release. In contrast, for the 30% and
50% drug loadings swelling due to hydration was apparent. The residue
of the 50% drug loading was recovered after 52 h and shown by XRPD
to contain crystalline felodipine, pointing to the drug re-crystallisation. In
another work, MRI has been employed to identify morphological details in
hydrating HPMC tablets during dissolution.114 Five different regions were
identified, i.e. dry glassy, hydrated solid like, two interface layers and gel
layer. These regions were found to be separated by four evolving fronts,
i.e. penetration, full hydration, total gelification and apparent erosion.
1.7 Motivation and aims of the work
Although ASDs represent a very promising formulation platform for im-
proving the dissolution properties of poorly water-soluble drugs, often this
approach fails to achieve the required biovailability due to the drug re-
crystallising during manufacturing, storage as well as dissolution in the GI
fluids. The dissolution performance of ASDs is of particular importance as
it underpins the in vivo efficacy. Gaps in the current knowledge of ASDs
include a lack of understanding of the dissolution mechanisms due to a
number of processes being involved. The drug re-crystallisation from a su-
persaturated state in solution or in the solid-state, the formation of nano
or microparticles, and also the dissolution behaviour of the carrier itself,
contribute to the complexity of the dissolution performance.
Three solid dispersions were employed in this thesis as model systems,
which include felodipine, bicalutamide and indomethacin, all poorly solu-
ble drugs, dispersed in a copovidone matrix. Felodipine, bicalutamide and
indomethacin all belong to class 2 of the BCS as they are characterised
Chapter 1. Introduction 30
by low aqueous solubility and high intestinal permeability. Copovidone
is a water-soluble polymer which was used in this work in an attempt
to improve the dissolution properties of felodipine, bicalutamide and in-
domethacin. However, as mentioned, the dissolution of these systems can
be complicated. In particular, previous studies have shown that the drug-
to-polymer ratio strongly affects the dissolution behaviour of ASDs.87,113
The dissolution performance of all the solid dispersion models was therefore
tested as a function of the drug loading. Two drug loadings were prepared
for felodipine (5% and 50% w/w), three for bicalutamide (5%, 30% and
50% w/w), and the full range of drug loadings was manufactured for in-
domethacin (5%, 15%, 30%, 50%, 70% and 90% w/w). In addition, as
indomethacin presents a pH-variable solubility and dissolution rate due to
its weakly acidic nature (pKa of 4.5), the dissolution performance of this
drug was also tested as a function of the pH of the dissolution medium (pH
2 and 6.8).
The research detailed in this thesis aims to fill the gaps related to the un-
derstanding of the dissolution mechanisms of ASDs and the outlined lim-
itations of the conventional USP apparatuses for testing the dissolution.
This was attempted by using Raman spectroscopy as primary analytical
technique. Raman spectroscopy provides a number of advantages: i) speed
(millisecond acquisition); ii) lack of sensitivity to water; iii) spatial (sub-
micron) and spectral resolution; iv) strong chemical specificity; v) ability
to readily differentiate between crystalline and amorphous forms. The nov-
elty of this method for testing the dissolution derives from collecting Raman
data in real time and in situ during the course of the dissolution experiment
using a flow-through cell, as will be shown in the study of felodipine (Chap-
ter 3). Raman data were analysed using a novel mathematical approach
which derives from the use of concatenated maps to explicitly probe the
changes as a function of time as well as space (Chapter 3). The dissolution
medium pumped through the flow-through cell can be easily switched to
another, for example in the study of indomethacin the dissolution medium
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was switched from pH 2 to 6.8 to mimic the stomach and small intestine
conditions (Chapter 6). In that study Raman spectroscopy integrated with
in-line UV-Vis spectroscopy was also employed to directly relate changes
in dissolution behaviour to physicochemical changes that occur to the ASD
during the dissolution test. In the studies of bicalutamide the use of a
combined suite of state-of-the-art analytical techniques was explored, in-
cluding an integrated MRI UV-Vis flow cell system and a novel quantitative
suppressed-water 1H NMR method to complement the Raman data (Chap-
ters 4 and 5). In Chapters 3, 4 and 6 the rotating disk dissolution rate
(RDDR) test (a modified version of the conventional intrinsic dissolution
rate (IDR) test) was employed for the first time to gain information on the
dissolution rates of both the drug and the polymer.
The new knowledge on the drug release mechanisms obtained from Raman
spectroscopy and the other complementary techniques could be used to
recognise potential risks or benefits of ASDs during dissolution, and enables
formulators to design more effective and reliable formulation systems.
Chapter 2
Materials and experimental
techniques
The aim of this chapter is to provide an overview of the materials and
the main experimental techniques employed in this thesis to produce and
analyse the ASDs under investigation. In this chapter the theory behind
the techniques as well as the reasons for their use will be briefly discussed.
Full experimental details will not be discussed in this chapter, but in the
“Materials and methods” sections of Chapters 3, 4, 5 and 6.
2.1 Materials
2.1.1 Copovidone
Copovidone (Figure 2.1) is a highly water-soluble polymer (solubility higher
than 100 µg·mL−1),122 commonly used in the tabletting process as a granu-
lating and film forming agent. Copovidone is recognised as a chemical ana-
logue of PVP, which has been employed in several studies to both inhibit
the re-crystallisation and improve the dissolution performance of poorly
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soluble drugs formulated as ASDs.49,52,60,69,123 Copovidone, due to the sim-
ilarities in chemical structure and physical properties with PVP, may be
another suitable choice for preparing ASDs, with the advantage of being
less hygroscopic than PVP.
Figure 2.1: Chemical structures of felodipine, bicalutamide, in-
domethacin and copovidone.
2.1.2 Felodipine
Felodipine (Figure 2.1) is a calcium-channel blocker which is predominantly
used for the treatment of hypertension. It is characterised by low water sol-
ubility (lower than 0.5 µg·mL−1),123 and it belongs to class 2 of the BCS
(low solubility, high intestinal permeability). One-phase ASDs of felodip-
ine with PVP or copovidone have been successfully prepared over a range
of composition (0-70% drug loading), showing some improvements in both
physical stability and dissolution performance.50,60,113,123–126 The informa-
tion available on felodipine from these studies made this drug an ideal
model compound for the experiments, as will be discussed in Chapter 3.
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2.1.3 Bicalutamide
Bicalutamide (Figure 2.1) is an important front-line treatment for prostate
cancer. It is a non-steroidal anti-androgen that has a low aqueous solubility
(lower than 5 µg·mL−1) and belongs to class II of the BCS. ASDs of bica-
lutamide with PVP or PEO have shown significantly enhanced dissolution
properties compared to the crystalline material.52,127 Bicalutamide exists
in two known crystalline phases (polymorphs I and II). Form I is currently
marketed, form II is metastable and therefore can convert into form I in
appropriate conditions (e.g. mechanical treatment, high temperatures).128
The polymorphic forms of bicalutamide have been thoroughly characterised
by Vega et al.129 They have reported single crystal X-ray structures and
shown that low energy form I relates monotropically to metastable form
II, i.e. under standard conditions form I is more stable than form II at all
temperatures. Due to the different crystal structures, forms I and II have
different physicochemical properties. The melting points have been found
by Vega et al. to be 192 ◦C for form I and 189 ◦C for form II, and form
II has been demonstrated to be 2.4 times more water-soluble than form I
at room temperature. They have also characterised forms I and II using
Raman spectroscopy. They observed several differences between the two
polymorphic forms in the fingerprint region because the two polymorphs
contain different conformations of bicalutamide. The existence of at least
three bicalutamide solid forms with different physicochemical properties,
i.e. amorphous, form I and form II, made this compound an interesting
poorly soluble drug model for monitoring solid-phase changes during dis-
solution, as will be detailed in Chapters 4 and 5.
2.1.4 Indomethacin
Indomethacin (Figure 2.1) is a NSAID drug widely used for pain relief. It
is poorly water-soluble and belongs to class 2 of the BCS.130 Indomethacin
formulated as pure amorphous material or as ASD has shown significantly
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improved dissolution properties compared to the crystalline form.20,55,131–133
Due to its weakly acidic nature (pKa of 4.5), indomethacin presents a pH-
dependent solubility and dissolution rate.55,132,134–136 The aqueous solubility
of indomethacin has been reported to increase from 1.5 µg·mL−1 at pH 1.2
to 105.2 µg·mL−1 at pH 7.4.137 Due to the significant change in aqueous
solubility between acidic to neutral/alkaline pH conditions, indomethacin
represents an ideal model compound for studying the effects of the envi-
ronmental pH on the dissolution performance, as will be discussed further
in Chapter 6.
2.2 Experimental techniques
2.2.1 Hot melt extrusion
HME, as previously described, is a fusion method employed to manufacture
ASDs. An extruder consists of three sections: the feed zone, the compres-
sion zone and the metering zone (Figure 2.2).6,45 After the feeding stage,
the material is moved through the extruder via one or two rotating screws
which are located inside a cylindrical barrel. At this stage, the material is
melted, homogenised and compressed. In the metering zone the thickness
of the product can be controlled by stabilisation of the flow of the extru-
date. In most of extruders the sections in the barrel are interchangeable
to allow different configurations to be used and therefore more flexibility
during manufacturing. The molten material is then passed through the die
plate and, following the exit from the die, it is cooled and subject to further
down-stream processing (e.g. milling). The shape of the final product is de-
termined by the design of the die plate. HME has been used to prepare
ASDs in a number of previous studies, several of which used felodipine,
bicalutamide and indomethacin as drug models.6,45,52,126,127,133
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Figure 2.2: Schematic representation of a common hot melt extruder.
2.2.2 X-ray powder diffraction
XRPD is a powerful technique for determining the crystal packing of mate-
rials and the level of crystallinity in ASDs. The wavelength of X-rays is of
the same magnitude as the interatomic spacings of molecules and therefore
X-ray diffraction is possible. However, for diffracted X-rays to be intense
enough for detection, a constructive interference according to the Bragg’s
law must occur.138 W. L. Bragg considered the X-rays diffraction from a
set of different crystal planes characterised by different positions (h, k, l).
For a constructive interference to occur, the path difference between the
beams must differ by an integer number of wavelengths. In other words,
the Bragg’s law (Equation 2.1) needs to be satisfied:
nλ = 2dhklsinθ (2.1)
where n is an integer, λ is the wavelength of the incident light, d is the
distance between the planes and θ is the incident angle with respect to the
crystal planes. Based on this, the diffractograms of a crystalline material
are characterised by a number of peaks which are unique to its crystal struc-
ture. In contrast, amorphous materials can not fulfil the Bragg condition
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as they do not possess the regular repeating structures which are present
in the crystalline materials. As a result, the diffractograms of amorphous
materials do not contain the Bragg peaks, but they are characterised by a
broad halo.
2.2.3 Raman spectroscopy
2.2.3.1 Principles of Raman spectroscopy
The Raman effect was first reported in 1928 by Raman and Krishnan and
can be described as the inelastic scattering of light from a sample.139 In
inelastic scattering the frequency and energy of photons in monochromatic
light change upon interaction with a sample. As shown in Figure 2.3, when
a sample is irradiated, molecules are promoted to a virtual state. When
molecules relax, they return to the ground state emitting light with the
same frequency as the excitation source (Rayleigh scattering) or with a
different frequency (Raman scattering). Raman scattering can be either
Stokes (i.e. molecules are initially in the ground state) or anti-Stokes (i.e.
molecules are initially in the excited state) scattering. In Stokes scattering
part of the energy of the photon is transferred to the molecular vibration
and the resulting frequency of the scattered light is reduced. In anti-Stokes
scattering the excess of energy of the excited molecular vibration is re-
leased and as a consequence the frequency of the scattered light is increased.
Rayleigh scattering is the more probable event (scattered intensity is ap-
proximately 10−3 less than that of the original incident radiation) compared
to Raman scattering (intensity is approximately 10−6 less than that of the
incident light for strong Raman scattering). In terms of Raman scatter-
ing, the intensity ratio between Stokes and anti-Stokes scattering depends
on the absolute temperature of the sample. Since most molecules exist in
the ground state at ambient temperature (Boltzmann equation),140 Stokes
scattering is a much stronger effect compared to anti-Stokes scattering.
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Figure 2.3: Scheme of the energy levels changes in IR, near-IR,
Rayleigh scattering, Raman scattering and fluorescence.139
Raman spectroscopy therefore measures the vibrational energies of the
molecules in a sample, which in turn are related to the type of chemi-
cal bonds. IR spectroscopy probes the same range of energies as Raman,
however it is based on absorption rather than scattering. The frequencies of
the molecular vibrations in IR and Raman spectra depend on the masses
of the atoms and the strength of their chemical bonds. In addition, the
selection rules for IR transitions differ from Raman. A vibration is IR ac-
tive when there is a change in dipole moment, and is Raman active when
there is a change in polarisability. The difference in selection rules means
that strong IR vibrations are not necessarily intense in Raman spectra and
vice versa. For example, water has a strong dipole moment, thus its IR
spectrum is intense, whilst the electrons are not easily polarised and as a
consequence the Raman scattering is weak. Another important considera-
tion is that most APIs contain pi-electrons which are easily polarised, and
therefore they show strong Raman scattering. In contrast, excipients are
primarily σ-bonded molecules with weak Raman scattering. This can be-
come important, for example, when detecting low levels of drug crystallinity
in multi-component pharmaceutical products.67
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2.2.3.2 Raman microscopy
Raman microscopy refers to the combination of Raman spectroscopy and
optical microscopy. As schematically reported in Figure 2.4, the excitation
laser beam is directed onto the sample through the objective lens, and the
scattered light is collected using the same objective (180◦ back-scattered
configuration). The Raman light is then directed into a spectrograph and
diffracted across a CCD detector. The use of pinhole apertures situated
between the objective and the detector in a confocal microscope allows
depth of field to be controlled, by removing unwanted signal from outside
the focal point (Figure 2.5). Using a confocal approach may also help to
reduce the fluorescence emission.
Figure 2.4: Diagram of a CCD-based Raman microscope.139
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Figure 2.5: Scheme showing the effect of the confocal aperture on the
Raman scattering.139
The laser choice is very important and can have a major impact on the
spatial resolution and fluorescence. The diameter of the laser spot can be
described using the Abbe equation (Equation 2.2):
d =
λ
2NA
(2.2)
in which d is the laser spot diameter, λ is the laser wavelength and NA
is the numerical aperture of the objective. Therefore, using a laser with a
longer wavelength will generate a larger spot diameter. The use of a longer
wavelength laser (e.g. near-IR) will also reduce fluorescence, by preventing
excitation to the higher electronic energy state.
2.2.3.3 Raman mapping
Raman mapping involves collecting Raman spectra from a section of a sur-
face. A Raman spectrum is collected from a specific point in coordinate
space, then the sample is moved and another spectrum is acquired. This
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method is called point-by-point mapping (Figure 2.6a).139,141 The experi-
ment can be made faster by using an irradiating line rather than a point
(line-scanning, Figure 2.6b). This can be achieved using cylindrical optics
or moving mirrors.
Figure 2.6: Point-by-point (a) and line-scanning (b) Raman map-
ping.139
2.2.3.4 Data analysis
The amount of data generated using Raman spectroscopy/microscopy can
be rather large (tens/hundreds of thousands of spectra), thus it is necessary
to use appropriate statistical analyses to obtain unambiguous and mean-
ingful outputs. Data analysis can be divided into two main stages: data
pre-processing and processing.
Pre-processing Data pre-processing consists of reducing interference ef-
fects from, for instance, sample focus or detector artefacts. This step is of
particular importance for multivariate data analysis techniques. A multi-
variate analysis without adequate pre-processing will likely result in models
containing differences associated to the experimental set-up (e.g. sample
focus) rather than changes in chemical composition. Variance-scaling the
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data is a simple way to reduce the effect of variations in Raman scatter-
ing efficiency.117 The CCD detectors are able to detect subatomic particles
which can give a far more intense signal than Raman scattering (cosmic
events). These signals appear as sharp and very narrow spikes that can be
automatically removed using most commercial software.
Data processing Data processing can be done using univariate or mul-
tivariate methods. Univariate methods consist in selecting a band of the
chemical of interest in the spectral region which is not masked by other
component spectral features to determine the spatial distribution of that
chemical entity.142–145 The band width/position can be used, for exam-
ple, to follow the potential drug re-crystallisation during manufacturing or
storage.142,146 The ratio between two different bands, i.e. bivariate analy-
sis, can also be used to give an insight into how the relative amount of two
chemicals changes across the surface of the same sample.147–149 A major
drawback of the univariate approach is that selecting a specific band in
multi-component systems can be challenging due to overlapping. In ad-
dition, prior knowledge on the chemical composition of the formulation is
required. Finally, as most of the data are not used, important information
can be lost.
The main advantage of multivariate analysis is that the false-colour images
produced are based on the entire spectrum and not on one single band.
PCA119,120,150–152 and MCR-ALS (alternating least-squares)152–154 are es-
tablished multivariate analysis techniques to deconvolute Raman data from
pharmaceutical samples. PCA operates through rotation of a large number
of data onto a smaller number of orthogonal variables, known as principal
components (PCs).151 The first of these components, i.e. PC1, accounts
for the greatest amount of variance between datasets, and the subsequent
PCs correspond to increasingly smaller amount of variance. Each PC is
characterised by a single value known as score and a loading which com-
prises as many values as in the original spectrum. PCA does not require a
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definition of the number of components, however the loadings can be both
positive or negative and therefore the spectral interpretation may result
difficult. The MCR-ALS method attempts to deconvolute the data into
the individual spectral components and their concentration. This can be
achieved through an initial estimation of the spectral and concentration ma-
trices followed by an iterative optimisation using the ALS algorithm.155,156
Constraints such as non-negativity, unimodality and closure are commonly
employed to reduce the ambiguity linked to the MCR results and thus
to generate meaningful solutions. Non-negativity forces concentration or
response profiles to be positive (e.g. UV absorption, mass spectra). Uni-
modality allows profiles to have a single maximum (e.g. chromatographic
peaks). Finally, closure or mass balance forces concentration profiles to add
up to a certain constant value. MCR-ALS is the main statistical method
employed in this work to analyse Raman data as it provides more readily
interpretable spectral traces compared to PCA.
2.2.4 Quantitative suppressed-water 1H nuclear mag-
netic resonance spectroscopy
NMR is an analytical technique commonly employed to elucidate the struc-
ture of small and macro molecules. NMR can be also employed for quan-
titative analysis in in-line processes such as reaction monitoring.93 In situ
reaction monitoring by NMR consists of following the reaction progress with
the ultimate goal to optimise such process in terms of predictability and re-
liability. The most important feature of quantitative NMR is that the peak
area in the NMR spectrum is directly proportional to the number of nuclei
responsible for that particular resonance.92 Quantitative analysis requires
a reference compound for measuring the concentration of the analyte. This
can be done using internal or external standards. An internal standard is a
compound with known concentration or weight that is dissolved in a known
volume of analyte solution. The main challenges of internal standards are
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the potential insufficient solubility in a particular solvent, peak overlapping
and chemical interactions with the analyte. External standards can be a
valid alternative to internal standards as they are not added to the solu-
tion. External standards provide a clear advantage for monitoring in-line
processes as it is possible to quantify samples generated from a process (e.g.
chemical reaction, dissolution) against a sample of known concentration.91
Another important consideration for quantitative NMR is that the solvents
in most in-line processes are not deuterated, therefore the signals of the
solvents can obscure the spectral features of the analyte, compromising the
analysis. Solvent-suppression techniques can be employed to preserve the
signals of the analyte. Solvent-suppression can be done by perturbing the
solvent magnetisation (e.g. by pre-saturation) or using selective excitation
techniques such as WET (water suppression by T1 effect) or WATERGATE
(water suppression by gradient tailored excitation).93
2.2.5 Magnetic resonance imaging
MRI is a technique commonly employed in clinical diagnosis due to its abil-
ity to differentiate between soft tissues. However, in the last two decades
there has been a growing body of work describing the use of MRI to study
the dissolution of pharmaceutical formulations.116,157,158 The magnetisation
of the nuclei after excitation by a radio-frequency pulse returns to an equi-
librium state via relaxation. The relaxation event is characterised by two
relaxation times: the spin lattice relaxation time (T1) and the spin–spin
relaxation time (T2). T1 describes the exponential recovery of the equi-
librium, while T2 describes the exponential decay of the NMR signal. T2
strongly depends on the molecular mobility. As shown in Figure 2.7, pro-
tons in a solid environment have a faster T2 relaxation time and therefore
the solid materials appear dark in the images. In contrast, protons in solu-
tion have a significantly slower T2 relaxation time and thereby they generate
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a bright image. Protons in a hydrating layer give an intermediate bright-
ness. MRI has been used to assess and quantify the dimensional properties
(e.g. thickness, area, volume) of the water movement and its effects on the
polymeric matrix (e.g. gelation, swelling, erosion).113,115,116,157
Figure 2.7: Scheme showing the decay of the NMR signal after exci-
tation by a radio-frequency pulse.158
2.2.6 Rotating disk dissolution rate test
The intrinsic dissolution rate (IDR) test is an important screening tool
which has been widely used in biopharmaceutics for measuring the disso-
lution rate of pure active ingredients.159–161
The IDR test requires far less material than a traditional USP dissolution
test. The IDR is defined as the dissolution rate of a pure active substance,
where the conditions of surface area, temperature, agitation, medium pH
and ionic strength are all constant.90,162 The IDR is commonly measured
using the rotating disk system, also known as “Wood’s apparatus”. The
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system includes a punch and a matrix (die) with a cavity of known sur-
face area for placing the drug. The system is immersed in the dissolution
medium in a conventional USP dissolution bath and rotated at a constant
rate (Figure 2.8). IDR measurements yield a dissolution rate normalised
to the exposed surface area of the material. Formally, IDR applies only to
pure drug substances. In this thesis, the IDR concept has been extended to
formulations. By analogy with the disk IDR, a “rotating disk dissolution
rate” (RDDR) was defined. By simply coupling an IDR apparatus to a
HPLC system, the partial RDDR of both the drug substance and the ex-
cipients (in the present case copovidone) can be simultaneously measured
and compared for different formulations. The dissolution profile of the
polymeric carrier can provide valuable information in the case of binary
systems such as ASDs, as the carrier has been shown to significantly affect
the dissolution performance of poorly soluble active ingredients.20,87,88,163
Figure 2.8: Rotating disk system in the dissolution equipment.
Chapter 3
Raman mapping to understand
the dissolution performance of
amorphous felodipine
extrudates
3.1 Introduction
As discussed in Chapter 1, despite the large number of works in literature
reporting the dissolution enhancements of ASDs compared to the free drugs,
the dissolution mechanisms are still not fully understood. Obtaining a
good dissolution profile is extremely important as it directly influences the
amount of drug available for absorption, i.e. oral bioavailability.
In this chapter, felodipine and copovidone ASDs were used as a model sys-
tem to investigate the dissolution mechanisms using Raman spectroscopy.
Previous studies have shown that the dissolution properties of poorly water-
soluble felodipine can be enhanced by using ASDs.50,60,113,123–126 In one of
these studies,113 a combined MRI UV-Vis flow-through cell system was em-
ployed to test the dissolution performance of felodipine:copovidone ASDs
47
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prepared in different compositions (5%, 15%, 30% and 50% w/w) using
spray drying. Erosion and dissolution were observed for the low drug-
loaded compacts (5% and 15%), pointing to a polymer-controlled disso-
lution process. In contrast, for the high drug-loaded compacts (30% and
50%) the water ingress was much slower and the physical behaviour was
characterised by swelling rather than erosion, pointing to a dissolution per-
formance dependent on the low water solubility of felodipine. The 50%
drug-loaded compact remained essentially intact at the end of the test and
the residue was shown by XRPD to contain crystalline felodipine.
The dissolution performance of felodipine-copovidone ASDs was investi-
gated as a function of the drug loading (5% and 50%), with the aim of
studying the effects of increasing the amount of active ingredient on the
dissolution mechanisms. Real time in situ Raman mapping was employed
as primary technique in an attempt to gain additional spatially-detailed
chemical information during dissolution. The RDDR test was also used to
simultaneously track the dissolution trend of both the drug and the polymer
from the ASD.
3.2 Materials and methods
3.2.1 Materials
Crystalline felodipine was provided by AstraZeneca (Macclesfield, United
Kingdom). Copovidone was supplied by BASF (Ludwigshafen, Germany).
Both materials were used as received, without any further purification.
Chapter 3. The study of felodipine extrudates 49
3.2.2 Preparation of the amorphous form of felodip-
ine and the extrudates
The amorphous form of felodipine was obtained by heating the drug as re-
ceived in the oven to 160 ◦C and, after melting, cooling back to room tem-
perature. Raman spectroscopy confirmed the formation of the amorphous
form and the absence of crystalline material, as will be shown in Section
3.3.3.1. 5% and 50% drug-loaded extrudates of felodipine in copovidone
were prepared using a co-rotating twin-screw extruder (Thermo Scientific
HAAKE MiniLab II). Felodipine and copovidone were pre-mixed for 20
min in a Turbula T2F mixer (Willy A. Bachofen AG Mashinefabrik). The
extruder was manually fed with the blends. The screw speed was set to 150
rpm and the temperature to 160 ◦C. The extrudates with spaghetti shape
were then collected, cooled to room temperature and manually milled with
a T&G CrushGrind mill to fine powder. XRPD confirmed the formation of
the amorphous form within the extrudates and the absence of crystalline
material (Figure A.1 of the Appendix A).
3.2.3 Analytical methods
3.2.3.1 X-ray powder diffraction
XRPD patterns were obtained using a PANalytical CubiX PRO diffrac-
tometer. Samples were spun at 30 rpm and exposed to a Cu-Kα radiation
at a voltage of 45 kV and a current of 40 mA. After being smeared onto
the holder, samples were scanned from 2◦ to 40◦ 2θ, with a 25 s exposure
per 0.02◦ 2θ increment.
3.2.3.2 Rotating disk dissolution rate test
RDDR testing was carried on using the “Wood’s apparatus”. The die cav-
ity has a diameter of 8 mm with subsequent exposed sample surface area
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of approximately 0.5 cm2. About 250 mg of extrudate powder was com-
pressed under a compression force of ca. 20 kN using a manual IR press
(Specac). The experiment was performed in a Sotax AT7 semi-automated
dissolution bath equipped with an automated sample collector. Compressed
disks were immersed in 500 mL of deionised water at 37 ◦C (±0.5), at 100
rpm rotational speed. The automated sample collector removed aliquots of
sample from the dissolution medium at regular time intervals over 120 min.
The samples were then analysed by HPLC. Both the experiments for the
5% and 50% extrudates were performed in triplicate. Analysis was carried
out using an Agilent 1100 HPLC with UV detection at 210 nm, equipped
with an Agilent PLRP-S 300 A˚ 3 µm 50 mm column (polystyrene/divinyl-
benzene stationary phase). The flow rate was set to 1 mL·min−1 and the
temperature of the column was kept at 40 ◦C. A linear gradient elution
was used starting at 40% acetonitrile/60% deionised water and ending at
90% acetonitrile/10% deionised water after 3.5 min, with chromatograms
collected up to 5 min. A series of standard solutions of felodipine and
copovidone were prepared to generate a calibration curve covering the con-
centration range of the dissolved sample. The partial RDDR of both the
drug and the polymer was calculated applying linear regression analysis
using the first 20 min time period, where the trend is linear, in accordance
with Pharmacopoeia procedures.90,162 The partial RDDR of the material
tested was determined from the slope of the regression line.
3.2.3.3 Raman spectroscopy
The dissolution performance of compressed extrudate powder was investi-
gated. Circular compacts with a diameter of 5 mm and a weight of ap-
proximately 50 mg were prepared with a manual IR press (Specac) using
a compression force of ca. 20 kN. The dissolution test was performed in a
flow cell, which is illustrated in Figure 3.1.
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Figure 3.1: Schematic diagram and photographic image of the flow cell
employed in the Raman and optical imaging experiments. The compact
(1) can be placed in the flow cell due to the presence of a removable
sealing cap (2). Two small apertures (3 and 4) allow a continuous flow
of the dissolution medium. The flow cell is placed on the automated xyz
stage (5) under the objective (6) of the Raman microscope (7).
Deionised water was used as dissolution medium and the flow rate was
set to 10 mL·min−1. The flow cell was placed under the objective of the
Raman microscope and data were collected as a function of time using a
Horiba LabRAM HR confocal microscope/spectrometer. The system has
an automated xyz stage (Ma¨rzha¨user) for mapping. In all the experiments,
a near-IR laser (785 nm) of 250 mW power was employed. Spectra were ac-
quired using a 50× objective and a 300 µm confocal hole. A 600 lines/mm
rotatable diffraction grating along a path length of 800 mm was used to si-
multaneously scan a range of Raman shifts. Raman spectra were collected
using a SYNAPSE CCD detector (1024 pixels). During the dissolution
experiment, before each map being acquired, the z-axis position of the
sample was adjusted to maximise the Raman signal. For both extrudates
(5% and 50% felodipine), spectra were obtained mapping an area of 500 ×
500 µm with a grid spacing of 50 µm along both x-axis and y-axis, a total of
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121 spectra per map. As each individual spectrum was collected for 1 s, re-
peated once in order to automatically remove the spikes due to cosmic rays,
the whole map required only 5 min. For the 5% extrudate compact, eight
maps were acquired across a 70 min time frame in the spectral range from
1100 to 1750 cm−1 (fingerprint region). For the 50% extrudate compact,
eight maps were acquired over 1705 min (28 h 25 min) in the phonon-mode
(40–400 cm−1) and fingerprint (1100–1750 cm−1) regions using a fixed grat-
ing to allow relatively rapid mapping. In the latter case, the phonon-mode
range was also scanned because it is extremely sensitive to the different
solid forms (amorphous, crystalline, etc.) and therefore the potential drug
re-crystallisation can be readily detected.119,120 All the spectra from each
map were integrated to produce a single averaged spectrum corresponding
to each time point. In this way, it was possible to determine any spectral
changes occurring during the dissolution test.
To obtain spatially-resolved information from the 50% extrudate, the disso-
lution experiment was repeated increasing significantly the spatial resolu-
tion. Seven maps were acquired over 1705 min (28 h 25 min) in the spectral
range between 1100 and 1750 cm−1, across a 500 × 1000 µm area at a grid
spacing of 15 µm along the x-axis, and 30 µm along the y-axis, a total
of 1156 spectra per map. As the data acquisition time was 2 s for each
spectrum, repeated once, each map required 1.5 h for acquisition. False
colour maps were generated using MCR. A single data matrix, compris-
ing all the spectra collected across the entire dissolution experiment (8092
spectra), was produced in order to probe changes as a function of both xy-
position and time. Numerical codes for statistical analyses were written in
the “R” language, which is open-source and freely available.164 Data were
scaled prior to analysis and plotting using variance-scaling standard meth-
ods, as per standard practice to reduce the effect of variability in Raman
scattering efficiency.117 For MCR analysis, the “ALS-MCR” module was
employed, while hierarchical agglomerative clustering (HAC) is part of the
standard package in R. All numerical routines along with the raw data have
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been published.165
3.2.3.4 Optical imaging
Photographic images of the compact during the dissolution test were taken
at regular time intervals using a CoolSNAP-Pro CF camera (Media Cyber-
netics) equipped with a Nikon AF Micro NIKKOR 60 mm lens. The same
experimental set-up described in Section 3.2.3.3 was used, with the flow cell
placed under the camera instead of the Raman microscope. For the disso-
lution test of the 50% extrudate, the “imgThreshold” function part of the
“biOps” package in R was employed to count the number of pixels above a
pre-defined colour threshold of the images collected during the dissolution
experiment.164 In this way, it was possible to focus only on the pixels of
the compact and build a trend which shows how the surface area of the
compact changes as a function of time.
3.3 Results and discussion
3.3.1 Optical imaging
Before commencing a full discussion of the RDDR and Raman data, it
is important to observe the optical images taken through the dissolution
experiment for the 5% and 50% drug-loaded extrudates (Figure 3.2). Prior
to the dissolution test, both extrudates appear similar, being yellowish
materials. It is important to notice the different experimental time-scale
used for the two extrudates.
The 5% extrudate dissolution experiment was carried out for 80 min after
which time the images show that the compact is completely dissolved. For
the 50% drug-loaded extrudate, the time-scale was significantly longer.
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Figure 3.2: Optical images taken through the dissolution experiment
of the 5% extrudate (a) and 50% extrudate (b).
In total, the compact was observed in the flow cell for 1705 min, remaining
intact even after the end of this period. An in depth observation of the
images from the 50% extrudate shows that the compact swells and increases
in size during the first 316 min, then slightly reduces and remains intact
until the end of the experiment. This suggests that the initial hydration
leads to swelling of the compact rather than to dissolution/erosion, due to
the high content of poorly water-soluble felodipine in the extrudate (images
until 316 min). This behaviour was previously described by Langham et
al.113 In Figure 7 of their paper, they reported MRI sequences showing
that the 50% felodipine-loaded spray-dried material swells as a result of
water ingress from the dissolution medium. The visual observation of the
optical images of the 50% extrudate is confirmed by the trend generated
by measuring the surface area of the compact during the dissolution test
(Figure 3.3). The trend is characterised by an increase in surface area until
316 min, which corresponds to the observed increase in the compact size.
Following this, the surface area decreases with the rate of decrease falling
to near-zero between 1093 and 1705 min, confirming that the size of the
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compact reduces after an initial swelling. The reduction of the compact
size after an initial swelling was not previously seen in the MRI images
reported by Langham et al.113 This change in behaviour may be related
to the different conditions during preparation via HME compared to spray
drying (e.g. high temperatures, absence of solvents) which may affect the
final physicochemical properties of the ASDs and thus their performance
in aqueous media.
Figure 3.3: Trend obtained by plotting the surface area of the 50%
extrudate compact in water vs. time.
3.3.2 Rotating disk dissolution rate test
The dissolution rate values for the 5% and 50% drug-loaded extrudates
are summarised in Table 3.1, while the dissolution profiles are presented in
Figure 3.4.
Looking at the formulation with 5% drug loading, the partial RDDR value
for felodipine is 0.17 mg/(min · cm2), while the partial RDDR for copovi-
done is 3.10 mg/(min · cm2).
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RDDR, mg/(min · cm2)
Felodipine Copovidone Total Index of performance
5% extrudate 0.17 (±0.02) 3.10 (±0.43) 3.26 (±0.43) 1.03 (±0.18)
50% extrudate 0.01 (±0.01) 0.25 (±0.01) 0.26 (±0.01) 0.07 (±0.08)
Table 3.1: Partial RDDR values of felodipine and copovidone for the
5% and 50% extrudates, along with the index of performance.
The IDR value of pure crystalline felodipine has been previously found to be
0.00064 mg/(min · cm2) in pH 6.5 FaSSIF medium, so in comparison the 5%
extrudate exhibits approximately a 265 fold increase in dissolution rate.161
The significant improvement in dissolution is concurrent with literature on
felodipine ASDs.126
The dissolution rate of the drug and the polymer allows an index of dis-
solution performance to be readily calculated. This essentially shows how
the two components of the extrudate behave during the dissolution process.
The index of performance was obtained dividing the partial RDDR value
of felodipine by the total RDDR value of the extrudate (felodipine plus
copovidone) and then normalising by the felodipine mass fraction (Equa-
tion 3.1):
Index of performance =
Partial RDDR drug / Total RDDR
drug mass fraction
(3.1)
The index of performance for the low drug-loaded extrudate results in a
value of approximately 1, indicating that felodipine and copovidone have
the same dissolution trend and thus they effectively dissolve as a single
entity, the molecular dispersion of felodipine in copovidone. Given the
very low aqueous solubility of felodipine, the release of the 5% extrudate is
clearly dependent on high water-soluble copovidone.
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Figure 3.4: Dissolution profiles of the 5% extrudate in water (a), 50%
extrudate in water (b) and pure copovidone in pH 6.8 blank FaSSIF
medium (c).
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Turning now to the extrudate with high drug loading, it is immediately
evident that both felodipine and copovidone have partial RDDR values
significantly lower when compared to those calculated for the 5% extrudate
(Table 3.1). The index of performance is also very low (0.07), indicating
that the dissolution rates of felodipine and copovidone are in this case very
different, suggesting that the drug and the polymer are not behaving as a
single entity but as two separate components. Compared to the IDR value
of pure extruded copovidone (5.20 mg/(min · cm2) in pH 6.8 blank FaSSIF
medium, Figure 3.4c), copovidone present in the 50% extrudate shows ap-
proximately a 21 fold decrease in dissolution rate. RDDR data suggest that
the drug release is felodipine-dependent, where the low solubility in water
and high hydrophobicity of the drug contribute to decrease the wettability
and to slow the water uptake in the material.
Summarising, the 5% drug-loaded extrudate showed a polymer-dependent
dissolution behaviour with felodipine dissolving simultaneously with copovi-
done. For the 50% extrudate, the rate of felodipine released is considerably
lower than that observed for the 5% drug-loaded extrudate. Although the
RDDR test gives a comprehensive explanation on the dissolution trend ob-
served for the low drug-loaded formulation, it does not clearly explain why
felodipine shows a very low dissolution rate for the 50% extrudate. To ob-
tain a better understanding of the chemical changes that occur during the
dissolution of the extrudates, Raman spectroscopic mapping was used to
test the samples.
3.3.3 Raman spectroscopy results
3.3.3.1 Dry raw materials spectra: visual observation
The Raman spectra of the raw materials are shown in Figure 3.5a (1100–
1750 cm−1 fingerprint region) and 3.5b (40–400 cm−1 phonon-mode re-
gion).
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Figure 3.5: 1100–1750 cm−1 fingerprint (a) and 40–400 cm−1 (b)
regions of raw materials spectra with reference spectra in red. Y-axis
offsets were employed for presentational purposes and differ between
panels.
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Starting with the pure components, it is evident that the spectrum of
felodipine is characterised by sharp bands and a good signal/noise ratio,
whereas the spectrum of copovidone shows less-defined bands. At first ap-
proximation, the extrudate spectra appear as a linear combination of melt
quenched felodipine (amorphous reference form) and copovidone. In the 5%
extrudate spectrum, copovidone bands are predominant, while in the 50%
extrudate bands related to felodipine prevail. In the latter case two slight
shifts appear when comparing to the spectrum of melt quenched felodipine:
the band at 1209 cm−1 moves to a lower wavenumber, while the band at
1497 cm−1 appears at higher wavenumber. These changes can be ascribed
to the formation of a hydrogen bond between the dihydropyridine N–H
group (proton donor) of felodipine and the carbonyl group of copovidone
(proton acceptor), coupled with minor conformational changes, as has been
previously reported for ASDs of felodipine and PVP.49,53
Turning now to the felodipine spectra, it is possible to see significant dif-
ferences between the amorphous (melt quenched felodipine) and the crys-
talline (felodipine as received) solid forms. Firstly, the bands of the crys-
talline form appear sharper than those of the amorphous form, due to the
disorganised molecular environment of the amorphous solid state. Further-
more, a detailed observation highlights that the intra-molecular vibration
bands at 1213, 1492 and 1645 cm−1 of the amorphous form slightly shift
to higher wavenumber. This has been shown to be due to the presence
of different intra-molecular hydrogen bonds within the amorphous solid
compared to the crystalline form.49 In the phonon-mode region, which re-
sults from the inter-molecular vibrations, the two felodipine solid forms
have different spectra. The amorphous form spectrum is characterised by
broad bands and a continuous distribution of inter-molecular vibrations.
In the crystalline form, sharp bands are present at 94 and 168 cm−1, due
to the quantised nature of the inter-molecular vibrations in the crystalline
material. Thus, as reported in literature,119,120 the phonon-mode region
represents an area of the Raman spectrum where it is possible to rapidly
Chapter 3. The study of felodipine extrudates 61
distinguish between different solid forms.
3.3.3.2 Dissolution experiments
Averaged spectra: visual observation Averaged Raman spectra of
the 5% extrudate dissolution are presented in Figure 3.6. Examination of
the data does not reveal significant changes in the spectra across the entire
period covered by these data (0-70 min), beyond a reduction in spectral in-
tensity as the compact dissolves (as seen in the optical images, Figure 3.2a).
The ratio between the band of felodipine at 1650 cm−1 (ring stretching
mode) and that of copovidone at 1426 cm−1 (bending modes of methylene
functional groups) is preserved throughout the whole dissolution test. The
Raman data essentially show that felodipine and copovidone dissolve as a
single entity rather than as two separate components. This is in accordance
with the RDDR data, which illustrated that felodipine and copovidone dis-
solve with the same rate. Therefore, it seems reasonable to suggest that the
dissolution occurs from the molecular dispersion, with the overall behaviour
being dependent on the highly water-soluble polymer (Figure 3.6).
Raman data of the 50% extrudate dissolution are shown in Figure 3.7a
(1100–1750 cm−1 fingerprint region) and 3.7b (40–400 cm−1 phonon-mode
region). Raman data show that the spectrum does not change after 10 min
(Figure 3.7a, 10 mins). Bands of felodipine (1497 cm−1) and copovidone
(1426 cm−1) preserve the same ratio as in the spectrum of the compact
“Dry”. Proceeding with the analysis, after 65 min the intensity of the
copovidone band at 1426 cm−1 appears to decrease in relation to that of
felodipine at 1497 cm−1. A comparison with the “50% extrudate” reference
spectrum reveals that the band at 1209 cm−1 moves to slightly higher
wavenumber and that at 1497 cm−1 shifts to lower wavenumber. Spectra
collected between 65 and 316 min show a strong correlation with the melt
quenched (amorphous) felodipine spectrum.
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Figure 3.6: Scaled (a) and unscaled (b) averaged Raman spectra
(1100–1750 cm−1) of the dissolution of the 5% extrudate, with raw
materials spectra in red. Y-axis offsets were applied for presentational
purposes.
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Figure 3.7: 1100–1750 cm−1 fingerprint (a) and 40–400 cm−1 (b)
regions of the averaged Raman spectra collected during the dissolution
of the 50% extrudate, with raw materials spectra in red. Y-axis offsets
have been applied for presentational purposes and differ between panels.
Chapter 3. The study of felodipine extrudates 64
It is likely that the faster dissolution of copovidone with respect to felodip-
ine from the extrudate leads to a build-up of felodipine-rich amorphous ma-
terial on the surface of the compact. The second important change occurs
at 522 min. It is immediately apparent that the averaged spectrum, after
522 min, corresponds to the crystalline form of felodipine. When compared
to melt quenched felodipine, intra-molecular bands at 1202, 1484 and 1642
cm−1 shift to lower wavenumber as well as become sharper. These spectral
changes were previously seen in Figure 3.5a, revealing the formation of crys-
talline felodipine. In the phonon-mode region (Figure 3.7b), well-defined
bands appear at 94 and 168 cm−1 after 522 min, essentially confirming that
amorphous felodipine begins to re-crystallise after this time-point.
Averaged spectra: hierarchical agglomerative clustering In this
section the use of an objective statistical analysis method to validate the
subjective interpretation of the Raman data is described. HAC is an au-
tomated method of cluster analysis which calculates a distance, also called
“degree of dissimilarity”, between datasets,166 including Raman spectra.120
The dendrogram obtained applying HAC to the 21 datasets is shown in
Figure 3.8. It is immediately evident that the overall structure of the
dendrogram is governed by two branches: spectra of the dissolution of the
5% extrudate with the 5% extrudate and copovidone reference spectra, and
spectra of the dissolution of the 50% extrudate with the remaining reference
spectra (“50% extrudate”, “Melt quenched felodipine” and “Felodipine as
received”). Starting with the branch of the 5% extrudate (LHS of plot), it
is clear that all the spectra of the dissolution can be classified by only one
cluster, as they are characterised by a high degree of similarity. This trend
is in a good agreement with the visual inspection of the data. As noted
earlier (Figure 3.6), significant changes were not observed in the spectra
collected during the dissolution of the 5% extrudate compact. Turning
now to the other portion of the dendrogram, that of the high drug-loaded
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extrudate (RHS of plot), the presence of three main clusters is immediately
apparent.
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Figure 3.8: Similarity dendrogram with clusters indicated by red
boxes. Raw data were variance-scaled before performing HAC. The
Euclidean distance measure was employed to define clusters.
The first includes “50% extrudate dry” and “50% extrudate 10 mins” spec-
tra. The second cluster includes spectra collected between 65 and 361
min, with the reference spectrum of melt quenched (amorphous) felodip-
ine. The last cluster includes spectra collected from 522 min until the end
of the experiment along with the reference crystalline form of felodipine.
Again, HAC confirms the visual inspection of the data, further demon-
strating that two transformations occur during the dissolution of the high
drug-loaded extrudate. The first involves the conversion, via dissolution
of copovidone, of mixed extrudate into a felodipine-rich amorphous ma-
terial on the surface of the compact, indeed spectra collected between 65
and 361 min showed high similarity for the melt quenched reference form.
The other is the re-crystallisation of amorphous felodipine after 522 min.
The first transformation clearly explains the extremely low partial RDDR
values observed during the dissolution of the 50% extrudate. Copovidone
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can not drive the dissolution of felodipine due to an insufficient polymer to
drug ratio, resulting in formation of felodipine-rich amorphous areas on the
compact surface. The disruption of the drug-polymer molecular dispersion
system through loss of copovidone then induces the drug re-crystallisation.
In conclusion, HAC widely validated all the subjective observations of the
Raman data, adding to them an objective and impartial component.
Multivariate curve resolution analysis In this section temporally-
and spatially-resolved maps of the crystallisation event observed for felodip-
ine present in the high drug-loaded extrudate are presented (Figure 3.9).
The MCR model was employed to spatially and spectrally deconvolute the
changes in the patterns. MCR is a very well-established component analysis
method, and has been used to resolve ToF-SIMS, IR and Raman data from
pharmaceutical samples.167–170 MCR requires input of a body of spectral
data in a matrix format, each spectrum being tagged with a set of labels
(e.g. x, y position), which is resolved by the MCR method into a number of
components. The only user input is the requested number of components,
i.e. MCR is a model-free method. Outputs from MCR include loadings
(which in the present case correspond to Raman spectra of the resolved
components) and scores (which provide the spectral weighting of a given
component for the relevant unique set of labels). Labels typically comprise
x and y position, but there is no reason why they can not include more in-
formation. To include time in the analysis, all xy spectral maps were simply
concatenated together and a time label included for each input spectrum, in
addition to the usual x and y labels. The MCR results are reproducible for
multiple runs, despite a different randomly generated set of numbers being
employed as a starting model for each run. This provides confidence that
the results are robust, which is important in the context of the well-known
rotational ambiguities present in the MCR methodology.155,156
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Figure 3.9: Raman maps of the 50% extrudate compact as a function
of time, generated by MCR analysis.
Three components were required to deconvolute the mapped data. Com-
parison with the reference spectra unambiguously indicates that the first
component, MCR1, can be associated with the extrudate and the second,
MCR2, with the crystalline form of felodipine. The excellent peak to peak
correlation between loadings and reference spectra confirms the utility of
MCR as statistical method to analyse spatial-temporal Raman data. MCR3
mostly picked up the background noise which characterises areas where no
compact is present. The scores plots show that the extrudate (MCR1) is
homogeneously distributed throughout the mapped compact surface before
immersion in water. Corresponding MCR2 scores plot indicated no traces
of crystalline material in the mapped area of the dry compact. Then, af-
ter 316 min the amount of crystalline felodipine (MCR2) rapidly increases
at the expense of the extrudate (MCR1), and this is reflected by the re-
crystallisation kinetic shown in Figure 3.10. It is interesting to notice the
complementarity of MCR1 and MCR2 scores plots at 316 and 522 min,
which denotes the coexistence of the extrudate and crystalline felodipine.
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Figure 3.10: Crystallisation kinetic generated by plotting the MCR
components weighting in each map as a function of time.
Regions where the extrudate (MCR1) is present to its maximum are indi-
cated by yellow colour, while the corresponding crystalline regions (MCR2)
are characterised by blue colour, and vice versa. The crystallisation pro-
cess is likely linked with loss of copovidone from the extrudate. It is well
known that the polymeric carrier in ASDs has not only the function to
improve the dissolution properties of poorly soluble drugs, but also in-
hibits crystal growth of the amorphous form, via antiplasticisation effect
or hydrogen-bonding interactions between the drug and the polymer.69 It
is therefore likely that the loss of copovidone during the first 316 min, pre-
viously observed in the averaged Raman spectra (Figure 3.7), promotes
the crystallisation of felodipine-rich amorphous material in the compact
surface.
At the end of the experiment, after 1705 min, the residue of the compact
was recovered and analysed using Raman and XRPD. MCR maps of the
core (after breaking the compact into two parts) and surface are presented
in Figure 3.11. Two components were required in this case to deconvolute
the data, with the first component (MCR1) corresponding to amorphous
felodipine and the second (MCR2) corresponding to crystalline felodipine.
The scores plots show that felodipine is predominantly amorphous in the
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core, whereas in the surface is crystalline. Raman data suggest that the
crystallisation begins from the compact surface exposed to water and prop-
agates towards the core, where only a little amount of crystalline drug was
found. The XRPD pattern of the compact after grinding it into powder
can be seen in Figure 3.12. The pattern appears as a combination of sharp
bands, typical of the crystalline materials, and a broad halo which charac-
terises the amorphous materials. XRPD therefore indicates that felodipine
sampled from the entire compact after the dissolution experiment is a mix-
ture of crystalline and amorphous. This is in full agreement with the Raman
results, which indicated a crystalline outer section and an amorphous inner
section of the compact.
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Figure 3.11: MCR loadings and scores plots of the 50% extrudate
compact core and surface after the dissolution test.
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Figure 3.12: XRPD patterns of the crystalline reference form
(“Felodipine as received”) and the 50% extrudate residue recovered after
the dissolution experiment.
3.4 Conclusions
This chapter showed that real time in situ Raman mapping is ideal for pro-
viding additional spatially-resolved chemical information on changes occur-
ring to the ASD, which suggested dissolution mechanisms. In addition, the
RDDR methodology was successfully employed to simultaneously track the
dissolution profiles of both the drug and the polymer, and ultimately mea-
sure the dissolution performance in multi-component systems. The disso-
lution performance of the low drug-loaded extrudate (5% w/w) was depen-
dent on the high water solubility of copovidone. Felodipine and copovidone
were shown to dissolve with the same rate from the dispersion, and Raman
data did not show any significant changes in all the spectra collected during
the course of the dissolution test. In contrast, the dissolution performance
of the high drug-loaded extrudate (50% w/w) was strongly dependent on
the physicochemical properties of the drug, e.g. low water solubility and
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high hydrophobicity. Raman data indicated the formation of an amor-
phous drug-rich shell in the early time-points of the experiment, followed
by the drug re-crystallisation. The MCR model applied to the concate-
nated Raman maps was demonstrated to be a robust method to analyse
temporally- and spatially-resolved Raman data. The re-crystallisation of
felodipine leaded to large variations in the Raman spectra and thus it was
readily detectable. In particular in the phonon-mode region, the spectrum
of the crystalline form was characterised by clear and sharp bands, while
that of the amorphous form by a broad halo. The crystallisation process
proceeded from the surface towards the core and was likely linked to loss
of copovidone from the extrudate.
Chapter 4
Monitoring the dissolution
mechanisms of bicalutamide
extrudates via Raman
mapping
4.1 Introduction
The overall aim of this thesis, as outlined in Chapter 1, was to obtain
additional information on the dissolution mechanisms of ASDs by using
Raman spectroscopy as primary characterisation technique. In Chapter 3
it was found that the dissolution performance of felodipine and copovidone
ASDs is strongly dependent on the drug loading. Raman and RDDR data
indicated that felodipine and copovidone in the 5% extrudate dissolved with
the same rate, pointing to a polymer-controlled drug release. In contrast,
the dissolution rates of both the drug and the polymer in the 50% extrudate
were significantly slower compared to the 5% extrudate, and this was shown
by Raman spectroscopy to be due to a build-up of a drug-rich amorphous
material followed by the drug re-crystallisation. Raman spectroscopy was
72
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demonstrated to be a very useful technique for gaining temporally- and
spatially-resolved information on the drug release.
The same combination of analytical techniques employed in Chapter 3,
i.e. optical imaging, RDDR and Raman spectroscopy, was used to investi-
gate the dissolution performance of another solid dispersion model which
consists of poorly soluble bicalutamide with copovidone. The dissolution
behaviour was tested as a function of the drug loading (5% and 50% w/w),
which has been shown in Chapter 3 to be a key factor in determining the
dissolution mechanisms. The aim of this chapter is to gain additional chem-
ical information on the drug release of amorphous bicalutamide solid dis-
persions, and potentially correlate the dissolution mechanisms with those
hypothesised from the felodipine study.
4.2 Materials and methods
4.2.1 Materials
Crystalline bicalutamide form I was provided by AstraZeneca (Macclesfield,
United Kingdom) and used as received, without any further purification.
The polymorphic purity of form I was verified by XRPD (Figure B.1 of
the Appendix B). Details for copovidone can be seen in Chapter 3, Section
3.2.1.
4.2.2 Samples preparation
4.2.2.1 Preparation of the amorphous form and crystalline bica-
lutamide form II
Amorphous bicalutamide was obtained by heating form I to 200 ◦C, re-
moving the melt from the oven and leaving it in the bench to cool at room
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temperature. XRPD confirmed the formation of the amorphous form and
the absence of crystalline material (Figure B.1 of the Appendix B). Crys-
talline bicalutamide form II was produced according to patent, by heating
the amorphous form to 175 ◦C.171 XRPD confirmed the formation of poly-
morphic form II (Figure B.1 of the Appendix B).
4.2.2.2 Preparation of the bicalutamide-copovidone extrudates
5% and 50% w/w drug-loaded bicalutamide-copovidone extrudates were
prepared according to the method reported in Chapter 3, Section 3.2.2.
The temperature was set to 170 ◦C. XRPD confirmed the formation of the
amorphous form and the absence of crystalline material (Figure B.1 of the
Appendix B).
4.2.3 Analytical methods
4.2.3.1 X-ray powder diffraction
The XRPD method is reported in Chapter 3, Section 3.2.3.1.
4.2.3.2 Rotating disk dissolution rate test
The RDDR test was conducted as previously described in Chapter 3, Sec-
tion 3.2.3.2. For the HPLC, a linear gradient elution was used starting at
40% acetonitrile/60% deionised water and ending at 70% acetonitrile/30%
deionised water after 2 min, with chromatograms collected for 3.5 min. The
partial RDDR of both drug and polymer was calculated using linear regres-
sion analysis. The partial RDDR of the materials was obtained from the
slope of the regression line. For the 5% extrudate, the RDDR was calcu-
lated using the first 20 min time period, where the trend is linear. For the
50% extrudate, the RDDR was obtained using the time interval between
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40 and 120 min, where the trend of both bicalutamide and copovidone is
linear, in accordance with Pharmacopoeia procedures.90,162
4.2.3.3 Raman spectroscopy
The same Raman system and dissolution set-up previously described in
Chapter 3, Section 3.2.3.3 was employed. Deionised water was used as
dissolution medium with the flow rate set to 5 mL·min−1. The time frames,
dimensions of the mapped areas and acquisition times for the 5% and 50%
extrudate experiments are depicted in Table 4.1.
5% extrudate 50% extrudate
Time frame (min) 80 2946
Total number of maps 7 14
Total number of spectra per map 121 1156
Acquisition time per spectrum (s) 2 2
Acquisition time per map (min) 8 90
Mapped area (µm) 500 × 500 500 × 1000
Grid spacing x-axis (µm) 50 15
Grid spacing y-axis (µm) 50 30
Table 4.1: Experimental details of the Raman map acquisition during
the dissolution experiments of the 5% and 50% extrudates.
For Raman data analysis, to obtain spatial information for the 50% extru-
date dissolution experiment, false colour maps were generated using MCR.
In order to monitor changes as function of both time and xy-position, a
single data matrix was generated which includes all the spectra collected
across the entire dissolution experiment time scale (16184 spectra). All the
raw data and the numerical routines written in the R language have been
published.172
4.2.3.4 Optical imaging
The optical imaging method has been previously described in Chapter 3,
Section 3.2.3.4.
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4.3 Results and discussion
4.3.1 Optical imaging and rotating disk dissolution
rate
Before commencing a full discussion of the results, a key point needs to be
made. Extrinsic factors such as hydrodynamics (e.g. disk rotation speed
and fluid flow) and test conditions (e.g. temperature and pH of the medium)
certainly differ between the RDDR test and Raman/optical imaging ex-
periments. The primary aim of the present work is simply to investigate
whether or not the combination of these techniques can provide a full and
clear understanding of the bicalutamide release from the extrudates.
Figure 4.1 shows the optical images observed during the dissolution of the
5% and 50% drug-loaded extrudates. It is important to note the different
time-scales between the two experiments which is due to the difference in
dissolution rates. The 5% extrudate is completely dissolved after approx-
imately 85 min, whereas the 50% drug-loaded extrudate remains intact
after 3000 min. The optical imaging experiment clearly shows that the
two different drug loadings behave very differently in aqueous media. The
5% extrudate compact undergoes erosion and is completely dissolved by 85
min from the beginning of the experiment. The 50% extrudate compact
swells during the first 600 min of the dissolution experiment and remains
intact even after 3000 min. The initial swelling is confirmed by the trend
generated by plotting the surface area of the compact vs time (Figure 4.2).
The dissolution/erosion of the 5% extrudate and the swelling of the 50%
extrudate are consistent with the behaviours previously observed for ASDs
of felodipine and copovidone (Chapter 3, Section 3.3.1).
RDDR measurements were then carried out in order to determine the
amount of drug and polymer released into solution as a function of time.
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Figure 4.1: Optical images collected through the dissolution experi-
ment for the 5% (a) and 50% (b) extrudates.
Figure 4.2: Trend showing the variation in the surface area of the 50%
extrudate compact in water (Figure 4.1b) as a function of time.
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The RDDR values for both the 5% and 50% extrudates are shown in Table
4.2, while the dissolution profiles are presented in Figure 4.3.
RDDR, mg/(min · cm2)
Drug loading Bicalutamide Copovidone Total Index of performance
5% 0.24 (±0.005) 4.85 (±0.127) 5.09 (±0.127) 0.94 (±0.030)
50% 0.008 (±0.001) 0.025 (±0.001) 0.033 (±0.001) 0.48 (±0.064)
Table 4.2: Partial RDDR values along with the index of performance
for the 5% and 50% extrudates.
For the 5% extrudate, the partial RDDR value for bicalutamide is 0.24
mg/(min · cm2) and that for copovidone is 4.85 mg/(min · cm2). Compared
to the IDR of pure crystalline bicalutamide (0.003 mg/(min · cm2), Figure
4.3), bicalutamide present in the 5% extrudate shows a 80 fold increase in
dissolution rate. The index of performance results in a value close to unity,
indicating that the two components have a very similar dissolution trend
and thus they dissolve simultaneously from the molecular dispersion. An
index of performance close to unity has been obtained also for the 5% extru-
date of felodipine and copovidone (Chapter 3, Section 3.3.2). In accordance
with previous works,87,113 the overall behaviour of the 5% bicalutamide-
loaded extrudate is clearly dominated by water-soluble copovidone. Con-
sidering the 50% extrudate, it is immediately apparent that the partial
RDDR values of both bicalutamide and copovidone are much lower than
those observed for the 5% extrudate. The partial RDDR of bicalutamide
(0.008 mg/(min · cm2)) is comparable with the IDR of pure crystalline bica-
lutamide (0.003 mg/(min · cm2)). Optical images and RDDR data therefore
suggest that the dissolution behaviour of the 50% extrudate is dominated
by the physicochemical properties of bicalutamide, and this is consistent
with the behaviour previously observed for high drug-loaded extrudates
of felodipine and copovidone (Chapter 3, Section 3.3.2). The low water
solubility and high hydrophobicity of the drug prevent the wetting and
water uptake of the compact due to an insufficient ratio of copovidone to
bicalutamide at the diffusion layer. As a result, the dissolution of both
bicalutamide and copovidone is very limited.
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Figure 4.3: RDDR trends for the 5% (a) and 50% extrudates (b). The
IDR trend of pure crystalline bicalutamide is presented in (c).
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Summarising, the dissolution performance of the amorphous bicalutamide
solid dispersions was found to be very similar to that previously observed
for the amorphous felodipine solid dispersions, being strongly dependent on
the drug:polymer ratio. The drug release of the 5% drug-loaded extrudate
is clearly polymer-dependent, with bicalutamide dissolving simultaneously
with the hydrophilic polymer. For the 50% extrudate, optical images and
RDDR measurements indicated that its behaviour in water is dependent on
the physicochemical properties of the hydrophobic bicalutamide. However,
this does not clearly explain which processes occur during the course of the
dissolution test, as data are not being collected directly from the dosage
form, nor do the RDDR data provide any direct chemical explanation of
the differences in dissolution rates between the 5% and 50% extrudates.
For this reason, real time in situ Raman spectroscopic mapping along with
off-line XRPD were used to investigate the samples.
4.3.2 Raman spectroscopy results
4.3.2.1 Raman spectra of “dry” raw materials
Raman spectra of the dry raw materials are available in Figure 4.4. The
three solid forms of bicalutamide present spectra with clear and obvious
differences. Considering the region between 1055 and 1724 cm−1 (Figure
4.4a), the differences between the crystalline forms are reasonable, given
that they are known to be conformational polymorphs. The band deriving
from the stretching mode of the carbonyl group moves to higher wavenum-
ber in form II (1709 cm−1) compared to form I (1686 cm−1). Due to the
different conformation of forms I and II, the oxygen of the carbonyl group
is involved in different intra-molecular hydrogen bond interactions, which
lead to the observed peak shift. Atoms are also involved in inter-molecular
interactions. The hydrogen bonding between the N–H of the amide group
and one of the oxygen atoms of the sulfonyl group determines the formation
of a dimer in the molecules of form II.
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Figure 4.4: 1055–1724 cm−1 (a) and 40–400 cm−1 (b) regions of the
Raman spectra of “dry” raw materials. Data were variance-scaled before
plotting. Y-axis offsets have been applied for presentation purpose and
differ between the two panels.
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This interaction would explain why an intense single band at 1517 cm−1
corresponding to the N–H bending and C–N stretching modes of the amide
group is replaced by three peaks with inferior intensity appearing at 1428,
1493 and 1520 cm−1 in form II. In addition, the particular conformation of
form II enables pi–pi stacking interactions between the two rings. Due to this
extra interaction form II presents a small peak at 1579 cm−1 (ring stretch-
ing mode) which is not present in the spectrum of form I. The schematic
representation of the structural conformations of forms I and II is shown
in Figure 4.5. Raman spectra from form I, II and the amorphous form of
bicalutamide are consistent with those previously reported by other work-
ers.52,127–129
Figure 4.5: Scheme of the structural conformations of form I (a) and
form II (b), with the functional groups involved in chemical interactions
shown in red.
The amorphous (melt quench) form presents a spectrum more similar to
that of crystalline form II than form I (e.g. bands at 1428 and 1493 cm−1
are present in the amorphous spectrum and the form II spectrum but not
in the form I spectrum). This spectral similarity with form II suggests
that the molecular conformation of the amorphous form is more similar
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to that of the metastable form II than that of highly stable form I. The
amorphous form also exhibits greater peak widths when compared to the
crystalline forms I and II, which is expected due to the molecular disorder
inherent in the amorphous form but not present in the two crystalline forms.
The spectra for the two extrudates are at first approximation simply a
linear combination of the spectra for the amorphous drug and the polymer.
A detailed inspection reveals some subtle differences, including a shift of
the bands of the N–H bending mode at 1490 and 1516 cm−1 for the 50%
extrudate, and at 1490 cm−1 for the 5% extrudate. These likely arise from
the inter-molecular hydrogen bonding interactions between the amide of
bicalutamide (N–H, proton donor) and the oxygen atoms of the carbonyl
groups of copovidone (proton acceptor).52
In the low-wavenumber region between 40 and 400 cm−1 (Figure 4.4b) the
two crystalline forms of bicalutamide present clear, well-resolved bands,
and the spectra are easily distinguishable from each other. This is wholly
consistent with previous work by other workers on low-wavenumber Ra-
man spectroscopy applied to polymorphs.118,119 The melt-quenched bicalu-
tamide, the two extrudates and the pure polymer exhibit the typical broad
halo at low wavenumber expected for amorphous materials,118,119 with the
differences between these amorphous forms being subtle in this spectral
region.
In summary, the various pure forms of bicalutamide and the extrudates can
be distinguished using the reference Raman spectra, especially the region
from 1055 to 1724 cm−1. The low-wavenumber data (40–400 cm−1) allow
the crystalline forms to be distinguished both from each other and from the
various amorphous forms. Bicalutamide form II and the amorphous form
present similar spectra in the region between 1055 and 1724 cm−1 and all
amorphous forms (pure bicalutamide and the extrudates) exhibit similar
spectra at low wavenumber.
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4.3.2.2 Raman spectroscopic mapping
In order to gain chemical and spatial detail on the dissolution processes in
the extrudates, Raman mapping was undertaken as a function of time in
the region between 1055 and 1724 cm−1. The data for the 5% extrudate are
presented in Figure 4.6. No changes were observed during the dissolution
beyond a reduction in the overall Raman intensity, which may result from
the presence of the medium, loss of focus and the surface changing from
flat and even to relatively rounded and uneven as the dissolution proceeds.
These factors reduce the amount of sample in the Raman confocal plane
and lead to a reduction in signal. These data, similarly to those obtained
from the low drug-loaded amorphous felodipine solid dispersions (Chapter
3, Section 3.3.3.2), indicate that bicalutamide and copovidone dissolve with
the same rate from the molecular dispersion, with the overall dissolution
performance being dependent on the high water solubility of copovidone.
For the 50% extrudate, averaging the spectra from each map indicated that
some changes occurred as the dissolution progressed (Figure B.2 in the Ap-
pendix B). However, averaged spectra are difficult to interpret in this case
due to the similarity in the bicalutamide spectra already noted between
forms II and the amorphous form, as well as due to the multi-component
nature of the formulation. Therefore, MCR was used to spatially and spec-
trally deconvolute the changes in the patterns for the 50% extrudate. In the
analysis, trial runs indicated that a suitable choice for number of compo-
nents was three, and intensity thresholding was employed so that only the
spectra from the compact were included in the analysis, i.e. the surround-
ing solution was excluded. The results of the MCR analysis are presented
graphically in Figure 4.7. Note that half the maps are shown for reasons of
space, i.e. every second one starting at 9 min, however the analysis included
all maps and the remaining time-point maps can be found in the Appendix
B (Figure B.3).
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Figure 4.6: Averaged Raman spectra (1055–1724 cm−1) collected
during the dissolution of the 5% extrudate. Presented in (a) are the
variance-scaled Raman spectra and in (b) are the un-scaled Raman spec-
tra. Y-axis offsets have been applied and differ between the two panels.
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Comparison of the MCR loadings with reference spectra clearly indicates
that the data have been resolved into components which correspond re-
markably well with crystalline bicalutamide forms I and II, and the bicalu-
tamide:copovidone extrudate. The variation in the scores as a function of
space (within each map) and time (between maps, vertically descending)
indicates that the starting material, the extrudate, decreases in weighting
as time passes. In the early stages of the experiment crystalline form II
appears and grows in weighting, while after approximately the 592-min
time-point the weighting of form I increases. Form I continues to increase
in weighting at the expense of both the extrudate and form II, with the lat-
ter reducing in weighting after 889 min. The crystallisation of amorphous
bicalutamide into form II has been previously reported,128,129 and the hy-
pothetical sequence amorphous → metastable form II → stable form I is
in accord with the long-standing Ostwald’s rule of stages. However, from
the results presented so far it is not possible to distinguish between the
linear pathway amorphous→ form II→ form I, and an alternative parallel
pathway whereby amorphous → form II and amorphous → form I occur
independently, with the crystallisation to form I having a longer induction
period than the crystallisation to form II.
At the end of the experiment the remaining compact was removed from
the flow cell, cut through the centre and analysed by Raman spectroscopy
and visually. Data are presented in Figure 4.8. The re-crystallisation of the
drug to a mixture of forms I (dominant at the end of the experiment) and II
occurs from the outside of the compact, with the interior being unchanged
bicalutamide/copovidone extrudate. XRPD data from the entire compact
recovered after the dissolution experiment (Figure 4.9) are in full accord
with these ex situ Raman data, showing that bicalutamide is predominantly
a mixture of crystalline form I and amorphous.
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Figure 4.7: MCR Raman maps collected as a function of time through
the dissolution experiment for the 50% extrudate. Here presented are
the loadings (with reference spectra in black) and the scores plots for the
first three MCR components. White/red colours indicate areas where
a phase is present to its maximum, while black/blue colours represent
areas where it is present at its minimum. Areas with variable weighting
of that phase are indicated by a continuum of white-red-orange-yellow-
cyan-blue-black colours. Raw data were variance-scaled before perform-
ing MCR analysis.
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Figure 4.8: MCR Raman maps of the inner and outer sections of the
compact. Here presented are the loadings (with reference spectra in
black) and the scores plots of the first three MCR components, with
data being variance-scaled prior to plotting.
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Figure 4.9: XRPD patterns of crystalline bicalutamide form I (ref-
erence) and the 50% extrudate residue recovered after the dissolution
experiment.
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The Raman mapping results, for the 50% extrudate, considered alongside
the RDDR analysis and the previous data on high-drug loaded amorphous
felodipine solid dispersions (Chapter 3, Section 3.3.3.2), suggest that the hy-
drophilic polymer preferentially dissolves from the exterior of the compact.
This leaves a drug-rich (therefore hydrophobic) shell on the outside of the
compact, which is initially amorphous. The decrease in polymer concentra-
tion and increase in (amorphous) drug naturally leads to the crystallisation
of the drug. To address directly the question of the crystallisation mecha-
nism, a kinetic analysis of the crystallisation processes was undertaken, as
outlined below.
While the MCR results are very useful for gaining a qualitative understand-
ing of the spectral changes occurring, they are less useful for a quantitative
analysis as the proportion of the spectral weighting cannot be related to
the actual concentration without suitable standards. Therefore, a simple
three-level classification procedure was undertaken and each spectrum at
every x-y-time point was assigned to extrudate, form I or form II, based
upon the calculated correlations between the three reference spectra and
the relevant experimental spectrum with its unique x-y-time labels. To re-
move the effect of the compact expanding/moving, the results are reported
as percentages. Only the area corresponding to the compact was included
in this analysis.
Results for the kinetic analysis are presented in Figure 4.10 for both the
classification (i.e. experimental data) and for the kinetic model. The kinetic
model included first-order rate constants for the processes A → II, A → I
and II→ I, which were adjusted according to the least-squares method until
an optimised model was arrived at. To summarise, the rates of conversion
A→ II and A→ I are similar, both being around 10−3 min−1. The rate of
conversion II→ I is found to be approximately an order of magnitude lower
and therefore the analysis distinctly points towards a mixed crystallisation
mechanism. The appearance of form I directly from the amorphous form is
favoured compared to the conversion II→ I. The robustness of the analysis
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was cross-checked by constraining the rate constant for A → I to be 0
min−1, and the resulting model (Figure B.4 of Appendix B) is clearly far
inferior to the unconstrained model in which the rate constant for A→ I is
found to be of order 10−3 min−1. Therefore, it can be concluded that the
parallel crystallisation mechanism is dominant compared to the serial one
in terms of kinetics.
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Figure 4.10: Experimental (dotted plots) and fitted (line plots) data
of the three-step kinetic model. The induction period represents the
first 360 min of the experiment. Estimated uncertainties are shown in
parentheses.
To summarise, kinetic modelling of the classification data pointed towards
the predominance of a non-Ostwald “parallel” crystallisation mechanism,
in which crystalline form I bicalutamide nucleates directly from the amor-
phous form rather than from form II. Given that the amount of form II
decreases after 889 min the pathway II → I clearly has some importance,
but the main route for formation of form I appears to be direct random
nucleation from the amorphous form.
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4.4 Conclusions
This chapter showed that the drug-to-polymer ratio is a key factor for
determining the dissolution mechanisms of the amorphous bicalutamide
solid dispersions, and this is consistent with the previous work on felodip-
ine reported in Chapter 3. The 5% sample dissolution mechanism in-
volved the hydrophilic polymer and the hydrophobic drug dissolving at
the same rate and the compact was completely dissolved after 85 min. The
same behaviour was observed for the low drug-loaded amorphous felodip-
ine solid dispersions (Chapter 3). In contrast, the 50% sample remained
intact even after 3000 min. It was hypothesised, based on the previous
findings on the high drug-loaded felodipine ASDs, that the preferential
dissolution of the hydrophilic polymer leaded to a shell of amorphous hy-
drophobic drug around the exterior of the compact. Highly chemically-
and spatially-detailed Raman maps indicated that this shell transformed
firstly to metastable crystalline form II, then to stable form I. The com-
bination of Raman spectroscopy and MCR analysis was demonstrated to
be very useful for discriminating between the different solid forms of bica-
lutamide, i.e. amorphous, form II and form I. By fitting a kinetic model
to the data extracted from the Raman maps it was possible to understand
the re-crystallisation mechanisms by which the low energy form I appeared.
Form I was shown to crystallise preferentially from the amorphous form in
a random nucleation mechanism, rather than from the crystalline form II.
The interior of the compact was protected from water ingress by the shell
of hydrophobic drug and remained a copovidone/bicalutamide molecular
dispersion even after ca. 50 h of immersion in flowing water.
Chapter 5
Magnetic resonance imaging
and 1H nuclear magnetic
resonance for studying the
dissolution of bicalutamide
extrudates
5.1 Introduction
In Chapter 4 Raman spectroscopy along with the RDDR test and the op-
tical observation were employed to gain additional chemical information
on the dissolution performance of the bicalutamide extrudates. The dis-
solution performance, similarly to the felodipine ASDs, was shown to be
strongly affected by the drug loading. In the 5% drug loading, bicalutamide
and copovidone dissolved with the same rate from the molecular dispersion,
pointing to a polymer-controlled drug release mechanism. In contrast, for
the 50% extrudate the dissolution rates of both bicalutamide and copovi-
done were found to be extremely low due to the formation of an amorphous
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drug-rich shell followed by the drug re-crystallisation, pointing to a drug
release dependent on the low aqueous solubility and high hydrophobicity
of bicalutamide.
In this chapter the dissolution mechanisms of the bicalutamide:copovidone
ASDs were further explored using a combined suite of analytical techniques,
in an attempt to complement the Raman data shown in Chapter 4. The
dissolution of the 5% extrudate (low drug loading) and this time the 30%
extrudate (intermediate drug loading) was tested, with the aim of obtain-
ing additional information on how the drug amount affects the dissolution
performance and mechanisms. A combined MRI/UV-Vis flow cell system
was used, allowing changes in dissolution profile to be related to physical
changes occurring in the solid material. Off-line quantitative suppressed-
water 1H NMR was also employed to, similarly to the RDDR test, simul-
taneously measure the dissolution profiles and rates of both the drug and
the polymer from the molecular dispersion.
5.2 Materials and methods
5.2.1 Materials
Details of bicalutamide were discussed in Chapter 4, Section 4.2.1, while
information on copovidone in Chapter 3, Section 3.2.1.
5.2.2 Samples preparation
The details for the preparation of the extrudates (5% and 30% drug load-
ing) were discussed in Chapter 4, Section 4.2.2. The XRPD pattern and
Raman spectrum of the 5% extrudate were shown in Figures B.1 and 4.4
respectively, while those of the 30% extrudate are presented in Figures C.1
and C.2 of the Appendix C.
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5.2.3 Analytical methods
5.2.3.1 X-ray powder diffraction
The XRPD method is reported in Chapter 3, Section 3.2.3.1.
5.2.3.2 Raman spectroscopy
The same Raman system previously described in Chapter 3, Section 3.2.3.3
was employed.
5.2.3.3 Magnetic resonance imaging ultraviolet-visible flow cell
system
The dissolution performance of circular compacts with a diameter of 10
mm and a weight of approximately 290 mg was investigated. Powders were
compressed using a Specac manual hydraulic press using a compression
force of ca. 50 kN. The difference in compression force compared to the
Raman studies derives from the use of different dies (10 mm vs 5 mm) which
allow different maximum compression forces to be used, i.e. ca. 50 kN for
the 10 mm die and ca. 20 kN for the 5 mm die. The dissolution tests were
performed in a USP IV-type flow cell previously described by Langham
et al.113 1 L of pH 6.5 phosphate buffer dissolution medium maintained
at a temperature of 37 ◦C using a temperature-controlled water bath was
circulated continuously at a flow rate of 15 mL·min−1.
The dissolution profile of bicalutamide was obtained by recording the ab-
sorbance of the unfiltered dissolution medium at 275 nm (wavelength max-
ima of bicalutamide) and 350 nm (no observed absorbance, for correction for
any suspended particles) at regular time intervals using a Agilent 8453 UV-
Vis spectrophotometer with a 10 mm quartz flow cell (Starna Scientific).
The dissolution data were calibrated against the absorbance of a series of
standard solutions of bicalutamide in water-acetonitrile 75/25 (v/v).
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The flow cell was sited in the probe of a 400 MHz Bruker Avance NMR
spectrometer fitted with a Micro2.5 imaging accessory fitted with a 25 mm
O.D. RF coil. The images were collected as a function of time using a
FLASH protocol to generate 16 × 1 mm2 concatenated axial slices with a
field of view of 25 mm. The echo time was 3.0 ms and the repetition time
was 500 ms giving a scan time of 1 min 4 s for each 16 slice experiment.
A data matrix size of 128 × 128 pixels was recorded giving a resolution of
0.0195 cm/pixel in the read direction. Data were processed using ParaVi-
sion software v4.0. Changes in the size of the compacts were followed by
measuring the dimensions of a single slice as a function of time.
5.2.3.4 1H nuclear magnetic resonance
All NMR measurements were performed on a Bruker Avance III 500 MHz
NMR spectrometer fitted with a 5 mm QCI cryoprobe. The spectra from
the dissolution samples and the reference solutions were acquired at 300.0
K with a spectral width of 10 kHz, with 64k data points in the time domain.
A recycle delay of 4 s was used and the peak due to water was suppressed
using a 1D NOESY pulse program with presaturation and spoil gradients
(noesygppr1d) and with irradiation at the water frequency during the recy-
cle and mixing time delays. The receiver gain was set to 128 and kept the
same for each experiment. Data were processed using the Bruker Topspin
3.0 software. Interactive zero order phase correction was applied to all the
spectra and the “Use lastscale for calibration” functionality was employed
to directly compare integrals across multiple spectra.
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5.3 Results and discussion
5.3.1 Solution-state assays
5.3.1.1 Ultraviolet-visible flow cell experiments
The UV-Vis dissolution profiles of the 5% and 30% extrudates are pre-
sented in Figure 5.1. The experiments were repeated twice for each drug
loading to obtain an indication of the reproducibility in dissolution per-
formance. A good reproducibility was observed of the two experiments of
the 5% extrudate. Both profiles are characterised by two regions which
correspond to the dissolving bicalutamide followed by the drug precipita-
tion. In contrast, the two dissolution profiles of the 30% extrudate appear
highly non-reproducible, i.e. they are characterised by a different number
of regions, but both show two pronounced “turning points” at 350 and 700
min (first experiment) and 250 and 500 min (second experiment) where the
rate of drug dissolution increases. Overall, the UV-Vis data indicate a lack
of controlled release for the 30% extrudate compared to the 5% extrudate.
These data indicate that there is a significant difference in dissolution be-
haviour between the two drug loadings. In the first experiment the 5%
extrudate reaches a maximum concentration of 8.5 µg·mL−1 (which corre-
sponds to approximately 59% of cumulative drug amount in solution) at
95 min, with an initial dissolution rate of 0.12 µg·mL−1·min−1. The 30%
extrudate achieves a maximum concentration in solution of 14.1 µg·mL−1
(≈ 16% of cumulative drug amount in solution) at 1179 min and an ini-
tial dissolution rate of 0.01 µg·mL−1·min−1. For both drug loadings, the
concentration of bicalutamide in solution declines after reaching the max-
imum concentration. The final measured concentration at 1319 min is 4.1
µg·mL−1 (≈ 28% of cumulative drug amount in solution) and 13.6 µg·mL−1
(≈ 15% of cumulative drug amount in solution) for the 5% extrudate and
30% extrudate respectively.
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Figure 5.1: UV-Vis dissolution profiles of bicalutamide released from
the 5% and 30% extrudates. The dissolution rates of the initial time-
points were calculated using linear regression analysis. Linear best fits
for the 5% and 30% dissolution experiments are included.
In accordance with the previous data on felodipine (Chapter 3, Section
3.3.2) and bicalutamide (Chapter 4, Section 4.3.1), the dissolution be-
haviour of the bicalutamide extrudates is clearly dependent on the drug
loading. At low drug loading (i.e. 5% extrudate), the performance is de-
pendent on the high aqueous solubility of the polymer. The drug is quickly
released and the maximum concentration corresponding to approximately
59% of cumulative drug amount in solution is reached within 95 min. For
the extrudate containing a higher proportion of bicalutamide (i.e. 30% ex-
trudate), the dissolution performance is dominated by the physicochemical
properties of the drug (e.g. low aqueous solubility and high hydrophobic-
ity). As a result, the initial dissolution rate is approximately one order of
magnitude lower (0.01 µg·mL−1·min−1 vs 0.12 µg·mL−1·min−1) and the
maximum concentration corresponding to 16% of cumulative drug amount
in solution is achieved only after 1179 min.
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The UV-Vis data also show that the bicalutamide content in solution for
both the 5% and 30% extrudates decreases after achieving the maximum
concentration at 95 and 1179 min respectively, indicating that the drug su-
persaturation in solution is not maintained by the presence of copovidone
across the entire dissolution test. In addition, in both experiments this re-
duction is accompanied by an increase of the absorbance at 350 nm (Figure
5.2), which is related to the scattering as well as absorption contributions
of insoluble particles.173 The formation of these particles, which cause the
subsequent reduction in solution concentration, has been previously ob-
served also for amorphous spray-dried solid dispersions of felodipine and
copovidone.113
Figure 5.2: Absorbance UV-Vis values at 350 nm acquired during the
dissolution of the 5% and 30% extrudates.
It is also important to note that the 30% bicalutamide extrudate exhib-
ited a markedly superior dissolution profile compared to the corresponding
drug loading of amorphous spray-dried solid dispersions of felodipine and
copovidone.113 This can be ascribed to the higher dissolution rate of bi-
calutamide over felodipine,161 although the manufacturing route (hot melt
extrusion vs spray drying) may also be a factor.
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5.3.1.2 1H nuclear magnetic resonance
In this section 1H NMR is employed to complement the UV-Vis data for
understanding the dissolution performance of the bicalutamide extrudates.
With respect to standard UV-Vis measurements, by 1H NMR it is possible
to simultaneously determine the amount of drug and polymer in solution.
As the dissolution performance of poorly soluble drugs can be largely de-
pendent on that of the polymeric carrier, quantitative measurements of
the latter provide valuable information.20,163 In addition, similarly to the
previously employed RDDR methodology, the dissolution rate of the drug
and the polymer can be used to determine an index of dissolution per-
formance of the extrudate (Chapter 3, Section 3.3.2, Equation 3.1). The
temporal evolution of NMR spectra for the 5% and 30% extrudates are
presented in Figure 5.3, while the spectra from the reference solutions are
shown in Figure C.3 of the Appendix C. For each spectrum, two integrals
from bicalutamide and copovidone were generated and then scaled to in-
tegrals obtained from the reference solutions of known concentration. The
spectra from the reference solutions were obtained using identical experi-
mental conditions. The release profiles of the individual species are shown
in Figure 5.4.
For the 5% extrudate (e.g. first experiment), bicalutamide exhibits an ini-
tial dissolution rate of 0.16 µg·mL−1·min−1 and that of copovidone is 3.84
µg·mL−1·min−1. The index of performance resulted in a value of 0.8, in-
dicating that the drug and polymer dissolve approximately with the same
rate from the dispersion. The index of performance obtained from the 1H
NMR system is similar to that previously obtained from the RDDR test
(value of 0.94, Chapter 4, Section 4.3.1, Table 4.2).
For the 30% extrudate, the dissolution rates of both bicalutamide and
copovidone are lower with values of 0.009 and 0.18 µg·mL−1·min−1 re-
spectively.
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Figure 5.3: Portions of the 1H NMR spectra acquired during the dis-
solution of the 5% and 30% extrudates. Bicalutamide and copovidone
data were obtained from single integrals at 7.06–7.14 ppm (two aromatic
protons of fluorobenzene) and 1.2–2.6 ppm (protons of pyrrolidone ring
and methylene chains) respectively.
In agreement with these data, the dissolution rates of bicalutamide and
copovidone from the 50% extrudate were also found extremely low using the
RDDR test (Chapter 4, Section 4.3.1, Table 4.2). The index of performance
of the 30% extrudate is also far inferior (0.15) compared to that of the
5% extrudate, indicating that for this drug loading the higher content of
bicalutamide limits the dissolution performance of both bicalutamide and
copovidone.
The dissolution rates of bicalutamide obtained from the 1H NMR experi-
ments (0.16 mL−1·min−1 for the 5% extrudate and 0.009 mL−1·min−1 for
the 30% extrudate) are in good agreement with those obtained from the
UV-Vis (0.12 mL−1·min−1 for the 5% extrudate and 0.009 mL−1·min−1
for the 30% extrudate).
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Figure 5.4: Release profiles obtained from the 1H NMR spectra of
bicalutamide and copovidone from the 5% and 30% extrudates. Data
were scaled using the reference standard solutions. Linear best fits for
the dissolution profiles of the 5% and 30% extrudates are included.
Figure 5.4 also shows that for both the 5% and 30% extrudates, whilst
copovidone achieves a dissolution release plateau, the bicalutamide con-
centration declines after reaching a maximum. In addition, for the 5%
extrudate the bicalutamide precipitation begins before the copovidone dis-
solution is complete. This, in agreement with the previous UV-Vis data,
clearly indicates that the supersaturation of the drug is not maintained by
the polymer across the entire dissolution test.
5.3.2 Solid-state analysis
5.3.2.1 Magnetic resonance imaging flow cell experiments
The solution-state measurements obtained from the UV-Vis and 1H NMR
data were then complemented with the solid-state measurements, i.e. MRI.
The magnetic resonance images showing the temporal changes in one cross
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sectional slice of the 5% and 30% extrudates during the dissolution test are
shown in Figure 5.5 (first experiment) and Figure C.4 of the Appendix C
(second experiment). In this MRI experiment the image contrast is due
to differences in molecular mobility. As a result, protons in a solid envi-
ronment have a faster T2 relaxation time and therefore the solid materials
appear dark in the images. Protons in solution have a significantly slower
T2 relaxation time and thereby they generate a bright image, while, for
example, protons in a hydrating gel give an intermediate brightness.113
The images presented in Figure 5.5 show significantly different dissolution
behaviours for the 5% extrudate (Figure 5.5a) and 30% extrudate (Figure
5.5b). The 5% extrudate undergoes erosion and it is almost entirely dis-
solved over a period of 56 min, while the 30% extrudate swells and remains
intact after 265 min (it is then no longer attached to the support due to its
swelling and expansion and as a consequence it is out of the instrumental
field of view).
Figure 5.5: Magnetic resonance images (first experiment) showing the
changes as a function of time in one cross sectional slice of the extrudates
containing 5% (a) and 30% (b) of bicalutamide.
Chapter 5. The study of bicalutamide extrudates via NMR 103
Throughout the experiments, the 30% extrudate exhibits a well-defined
region of intermediate MRI contrast, which is either not present, or hardly
present, in the 5% extrudate (Figure 5.6). This region is due to water
ingress into the compact. It is clear that for the 5% sample the rates of
water ingress and dissolution are similar, which prevents the formation of
the intermediate contrast region, whereas for the 30% compact dissolution
is markedly slower than water ingress.
Figure 5.6: Zoom of the images collected for the 5% extrudate (28
min) and 30% extrudate (162 min) to highlight the well-defined region
of intermediate MRI contrast present in the 30% extrudate.
Previous Raman data on a 50% sample indicated that the preferential dis-
solution of copovidone led to formation of an amorphous drug-rich shell
which crystallised and appeared to strongly inhibit further erosion and dis-
solution of the compact (Chapter 3, Section 3.3.3.2 and Chapter 4, Section
4.3.2.2). Therefore, it is reasonable to suggest that this region of inter-
mediate contrast in the magnetic resonance images of the 30% sample is
due to water partially diffused in the copovidone matrix, which does not
lead to dissolution and drug release due to a drug-rich shell which prevents
further water ingress, and thus greatly reduces the dissolution rate of the
compact. The formation of an amorphous drug-rich shell and the drug
re-crystallisation are likely to be the main factors which determine lack of
controlled release observed in the UV-Vis profiles for the 30% drug loading.
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The difference in dissolution performance between the two drug loadings
is reflected in Figure 5.7. The 5% extrudate quickly erodes with a linear
erosion rate of 1.1 mm2·min−1, while the erosion rate for the 30% extrudate
is slower and not linear due to the presence of the hydrating layer.
Figure 5.7: Evolution of the compact dimensions as a function of
time for the 5% extrudate and 30% extrudate. Linear best fit to the
data for the 5% extrudate is included. For the 30% extrudate, the
dimensions of the compact core (solid material) were measured without
considering those of the hydrated layer, to facilitate the comparison
with the 5% extrudate. Data were collected only up to approximately
300 min due to the compact falling off from the support and being out
of the instrumental field of view after this time-point.
At the end of the dissolution test of the 30% extrudate (approximately
after 1700 min), a significant amount of undissolved material was present
in the flow cell. This residue was removed from the flow cell and showed
by Raman spectroscopy to contain crystalline bicalutamide form I (Figure
5.8), pointing to the drug re-crystallisation. The drug re-crystallistion was
also observed during the dissolution experiment of the 50% drug-loaded
extrudate (Chapter 4, Section 4.3.2.2).
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The MRI images are in agreement the UV-Vis and 1H NMR data, indi-
cating that for the 5% extrudate the release of bicalutamide is a polymer-
controlled process whereby the dissolution is governed by the fast hydration
of the highly water-soluble copovidone. For the 30% extrudate, the disso-
lution is dependent on the physicochemical properties of bicalutamide.
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Figure 5.8: Raman spectra of crystalline bicalutamide form I (ref-
erence) and the 30% extrudate residue recovered after the dissolution
experiment.
The low aqueous solubility and high hydrophobicity of the drug contribute
to a slower water uptake into the compact which corresponds to a slower
dissolution rate of both bicalutamide and copovidone.
5.4 Conclusions
In this chapter a combination of solution-state and solid-state analytical
techniques was employed to complement the Raman data previously shown
in Chapter 4 on amorphous bicalutamide solid dispersions. The MRI data
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indicated that the 5% extrudate eroded linearly, which can be linked to
the Raman data showing bicalutamide and copovidone dissolving with the
same rate from the molecular dispersion (Chapter 4). In contrast, for the
30% extrudate the water ingress was significantly slower and this is thought
to be due to the formation of an amorphous drug-rich shell (as shown by
Raman in Chapters 3 and 4) which prevented further water ingress and thus
greatly reduced the dissolution. 1H NMR has been proved to be a valid
alternative to the previously employed RDDR methodology for tracking
the dissolution profiles of different materials in multi-component systems.
Quantitative 1H NMR data showed that for the 5% extrudate, bicalutamide
and copovidone dissolved with approximately the same rate pointing to a
matrix-controlled release, while for the 30% drug loading they dissolved at a
significantly lower rate. For the 30% extrudate the dissolution performance,
as previously seen in Chapter 4, was dominated by the physicochemical
properties of the drug. It is important to compare the two solid-state
analytical techniques used in this work, i.e. MRI and Raman spectroscopy.
MRI can provide useful physical information on the dissolution processes
(e.g. gel formation, matrix erosion, polymer swelling), by directly measuring
the molecular mobility of water. However, the main limitation of MRI is
the relatively low chemical selectivity. In contrast, Raman spectroscopy is
able to readily discriminate between different chemical species (e.g. drug
vs excipients) and solid forms (e.g. amorphous vs crystalline, polymorphic
forms). However, compared to MRI, Raman spectroscopy can not provide
any direct physical information on water ingress and hydrating polymeric
matrices. Overall, only the chemical and physical data generated by the
combination of these two advanced analytical techniques can provide a clear
understanding of the drug release mechanisms from ASD formulations.
Chapter 6
Indomethacin-copovidone
extrudates: a mechanistic
study of pH-dependent
controlled release
6.1 Introduction
As discussed in Chapters 3, 4 and 5 the dissolution performance of both
felodipine and bicalutamide ASDs is strongly dependent on the drug load-
ing. Raman spectroscopy along with a combination of other analytical tech-
niques were successfully employed to identify the solid-state and solution-
state changes and therefore draw potential mechanisms by which the dis-
solution occurred. For both APIs, at low drug loading the drug and the
polymer dissolved with the same rate, with the overall behaviour being de-
pendent on the high aqueous solubility of the polymer. In contrast, both
amorphous felodipine and bicalutamide in the high drug-loaded extrudates
re-crystallised, and the drug re-crystallisation was shown to follow the for-
mation of an amorphous drug-rich shell.
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In this chapter the dissolution behaviour of another ASD model which con-
sists of poorly soluble indomethacin and copovidone was investigated. The
aqueous solubility of indomethacin has been reported to increase from 1.5
µg·mL−1 at pH 1.2 to 105.2 µg·mL−1 at pH 7.4.137 Previous dissolution
studies on this drug have typically used a single constant pH,39,42,86,174,175
which is un-representative of the in vivo situation, in which the pH typ-
ically differs between GI compartments, being 1.7-3.3 (median of 2.5) in
the stomach and 5.6-7.0 (median of 6.3) in the duodenum (Figure 6.1).176
In a recent work, however, ASDs of indomethacin and a range of poly-
mers were tested in two independent experiments at pH 1.2 and 7.4 using
the USP II apparatus.137 In this chapter, the dissolution tests was per-
formed in the flow-through cell previously described in Chapter 3. The
flow-through cell is ideal for changing the dissolution medium during the
test and this can be easily accomplished by directing the input from a dif-
ferent source. The materials were tested in pH 2 HCl dissolution medium
to mimic the stomach conditions followed by a switch during the test to
pH 6.8 phosphate buffer to simulate the post-stomach conditions, with the
aim of probing the interactions between environmental pH and extrudate
components. The dissolution behaviour of the indomethacin:copovidone
extrudates was also studied as a function of the drug loading (from 5% to
90%). A Raman UV-Vis flow cell system along with optical observation
and the RDDR test were used. The flow cell system includes an in-line
UV-Vis spectrophotometer which enables changes in the amount of drug
in solution (monitored by UV-Vis) to be directly related to physicochem-
ical changes that occur in the solid-state to the extrudate (monitored by
Raman).
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Figure 6.1: Scheme of the body showing the pH values in the stomach
and in the duodenum.
6.2 Materials and methods
6.2.1 Materials
Indomethacin (≥ 99% purity) was purchased from Sigma-Aldrich (St. Louis,
USA) and found by XRPD and Raman spectroscopy to be the γ polymorph
(Figures D.1 and D.2 of the Appendix D). Indomethacin was used as re-
ceived and without any further purification. Details of copovidone were
provided in Chapter 3, Section 3.2.1.
6.2.2 Samples preparation
6.2.2.1 Preparation of the amorphous and α forms of indomethacin
The amorphous form of indomethacin was prepared by heating the γ form
to 170 ◦C and cooling the melt to room temperature. The formation of the
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amorphous form was confirmed by XRPD and Raman spectroscopy (Fig-
ures D.3 and D.4 of the Appendix D). The α form was prepared according
to literature by the addition of deionised water to a saturated solution of
γ indomethacin in ethanol at 80 ◦C.177 The precipitated crystals were re-
moved by filtration and dried under vacuum at room temperature. XRPD
and Raman spectroscopy confirmed the formation of the α form (Figures
D.1 and D.2 of the Appendix D).47,69
6.2.2.2 Preparation of the indomethacin-copovidone extrudates
The extrudates of indomethacin and copovidone at a different drug-to-
polymer ratio (5% w/w, 15% w/w, 30% w/w, 50% w/w, 70% w/w and 90%
w/w indomethacin) were prepared using the method reported in Chapter 3,
Section 3.2.2. The temperature was set to 170 ◦C. XRPD and Raman spec-
troscopy confirmed the formation of the amorphous form and the absence
of the γ form (Figures D.3 and D.4 of the Appendix D).
6.2.3 Analytical methods
6.2.3.1 X-ray powder diffraction
The XRPD method is reported in Chapter 3, Section 3.2.3.1.
6.2.3.2 Rotating disk dissolution rate test
The RDDR test was conducted as previously described in Chapter 3, Sec-
tion 3.2.3.2. The dissolution experiments were performed in a relevant
dissolution medium (pH 2 HCl and pH 6.8 phosphate buffer) at a temper-
ature of 25 ◦C (±0.5). All the experiments were carried out in duplicate.
For the HPLC, acetonitrile/deionised water containing 0.025% of ammonia
water was selected as the optimal mobile phase. A linear gradient elution
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was used starting at 5% acetonitrile/95% deionised water and ending at
90% acetonitrile/10% deionised water after 3.5 min, with chromatograms
collected up to 5 min. Standard solutions of indomethacin and copovidone
were prepared to generate a calibration curve covering the concentration
range of the dissolved samples and analysed alongside the RDDR samples.
The partial RDDR of indomethacin and copovidone from all materials was
calculated using linear regression analysis of the first 20 min, where the
trend is linear, in accordance with Pharmacopoeia procedures.90,162
6.2.3.3 Raman ultraviolet-visible flow cell system
Raman spectroscopy The same Raman system and dissolution set-up
previously described in Chapter 3, Section 3.2.3.3 was employed. All ex-
periments were performed in 500 mL of pH 2 HCl water solution which was
replaced after 120 min by 500 mL of pH 6.8 phosphate buffer. The flow
rate was set to 5 mL·min−1.
Raman spectra of the reference materials were acquired from 40 to 3500
cm−1. During the dissolution experiments, spectra were collected between
1055 and 1725 cm−1 as a function of time across an area of 500 × 500
µm with a grid spacing of 50 µm along both the x and y axes, a total of
121 spectra per map. As each individual spectrum was collected for 3 s,
repeated once in order to automatically remove the spikes due to cosmic
rays, the whole map required approximately 15 min.
For Raman data analysis, spectra from each time-point map were inte-
grated to generate a single averaged spectrum. Averaging facilitated the
determination of any spectral changes occurring to the solid form during
the dissolution test.
Ultraviolet-visible UV-Vis data were collected using a combined minia-
ture light source-flow cell-spectrometer system. A Z-shaped flow cell (FIA-
Z-SMA, Ocean Optics, USA) with a 10 mm pathlength was simultaneously
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connected through optical fibers to a deuterium light source (DT-MINI-2,
Ocean Optics, USA) and a CCD spectrometer (USB2000+, Ocean Optics,
USA). The dissolution profiles of indomethacin were obtained by measur-
ing the absorbance at 318 nm every 1 min. The scheme of the Raman
UV-Vis flow cell system is shown in Figure 6.2. A peristaltic pump (IPS,
ISMATEC, Switzerland) pumped the relevant dissolution medium through
the Z-shaped UV-Vis flow cell and the Raman flow cell in a closed loop
flow.
Figure 6.2: Scheme of the experimental configuration employed to
monitor in real time the dissolution of the extrudates by UV-Vis spec-
trophotometry and Raman spectroscopy. The arrows indicate the direc-
tion of the flow of the buffer solution.
6.2.3.4 Optical imaging
The optical imaging method has been previously described in Chapter 3,
Section 3.2.3.4.
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6.3 Results and discussion
6.3.1 Optical imaging
Optical images from the dissolution experiment of the indomethacin and
copovidone extrudates, 100% copovidone and both the 100% amorphous
and 100% γ forms of indomethacin are presented in Figures 6.3 and 6.4.
Firstly, it is important to notice the different time-scales between dissolu-
tion of 100% copovidone and the 5% extrudate (Figure 6.3), and the other
indomethacin-copovidone extrudates (from 15% to 90% drug loading), the
100% amorphous and 100% γ forms of indomethacin (Figure 6.4). The for-
mer were observed in pH 2 HCl buffer for 90 min, after which the images
show that both compacts are completely dissolved. Photographs of the lat-
ter were taken after 120 min in pH 2 HCl buffer, followed by switching to
pH 6.8 phosphate buffer for the rest of the test with images being collected
for another 380 min.
Figure 6.3: Photographs taken through the dissolution experiment in
pH 2 HCl buffer of 100% copovidone and the 5% extrudate.
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Figure 6.4: Images collected during the dissolution experiment of the
indomethacin-copovidone extrudates (from 15% to 90% drug loading),
and the 100% amorphous and 100% γ forms of indomethacin.
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From the images it is clear that the extrudates containing ≥ 15% in-
domethacin and the 100% amorphous and 100% γ forms of indomethacin
do not appreciably erode when the buffer is pH 2 HCl. Further analysis
of the images reveals that the 15%, 30% and 50% extrudates exhibit signs
of swelling as confirmed by plotting the surface area of the compacts as a
function of time (Figure 6.5). It is apparent that the surface area of the
15% and 30% extrudates show a similar increase after 120 min. It is also
possible to observe an increase in the surface area of the 50% extrudate,
however the onset of swelling begins later and is of a lesser extent compared
to that of the 15% and 30% extrudates.
The images in Figure 6.4 also show that all the extrudates begin to dissolve
when the pH 2 HCl medium is switched to pH 6.8 phosphate buffer. The
15%, 30% and 50% extrudates are entirely dissolved by 500 min, whereas
residues from the 70% and 90% extrudates remain at this time-point.
Images of the 100% amorphous and 100% γ forms of indomethacin illus-
trate that these compacts do not significantly dissolve at a pH both below
and above the indomethacin pKa of 4.5, pointing to the important role of
copovidone of improving the dissolution performance of indomethacin.
The optical imaging experiments revealed that only 100% copovidone and
the 5% extrudate are entirely dissolved when the medium is pH 2 HCl
buffer. The situation with the other compacts is different because none of
them show clear evidence of erosion at a pH below the indomethacin pKa
of 4.5. In contrast, the images indicated swelling only of the 15%, 30% and
50% extrudates suggesting water ingress into these compacts, attributed
to the higher amount of water-soluble copovidone in the extrudate which
promotes the water absorption. When the medium is switched to pH 6.8
phosphate buffer, all the extrudates begin to dissolve with a different rate.
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Figure 6.5: Trends showing how the compact surface changes as a
function of time in pH 2 HCl dissolution medium. Trends of 100%
copovidone and the 5% extrudate are shown in (a), while those from
the other indomethacin-copovidone extrudates (from 15% to 90% drug
loading), the 100% amorphous and 100% γ forms are illustrated in (b).
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6.3.2 Rotating disk dissolution rate test
The RDDR test was performed at pH 2 and 6.8 to determine the effect of
pH on the dissolution rate of poorly soluble indomethacin formulated as
extrudate. The partial RDDR values determined at pH 2 and 6.8 along
with the index of performance of all indomethacin-copovidone extrudates
are reported in Table 6.1. The IDR values of 100% copovidone and the
100% γ form of indomethacin experimentally determined at pH 2 and 6.8
are also shown in Table 6.1 for comparison with the partial RDDR values
of the extrudates. The dissolution profiles of all materials can be seen in
Figures 6.6 (pH 2) and 6.7 (pH 6.8).
Material Dissolution rate (n = 2) (mg/(min · cm2))
pH 2 pH 6.8
Indomethacin Copovidone Index of performance Indomethacin Copovidone Index of performance
100% copovidone 3.66 (±0.50) 3.05 (±0.16)
5% extrudate 0.12 (±0.01) 4.12 (±0.40) 0.55 (±0.07) 0.18 (±0.01) 3.17 (±0.21) 1.06 (±0.09)
15% extrudate approx. 0 0.30 (±0.07) n/a 0.35 (±0.03) 2.02 (±0.16) 0.99 (±0.10)
30% extrudate approx. 0 0.36 (±0.04) n/a 0.63 (±0.04) 1.42 (±0.08) 1.02 (±0.07)
50% extrudate approx. 0 approx. 0 n/a 1.16 (±0.04) 1.02 (±0.02) 1.06 (±0.04)
70% extrudate approx. 0 approx. 0 n/a 0.80 (±0.05) 0.38 (±0.04) 0.97 (±0.09)
90% extrudate approx. 0 approx. 0 n/a 0.67 (±0.04) 0.16 (±0.06) 0.90 (±0.01)
100% γ form approx. 0 0.04 (±0.01)
Table 6.1: Partial RDDR values at pH 2 and 6.8 of indomethacin
and copovidone formulated as extrudates along with the index of per-
formance. The IDR values at pH 2 and 6.8 of the 100% indomethacin γ
form and 100% copovidone are also reported.
Starting with the experiments conducted in pH 2 HCl buffer (LHS of Table
6.1), it is possible to see that the partial RDDR values of indomethacin
and copovidone from the 5% extrudate are 0.12 and 4.12 mg/(min · cm2)
respectively and the resulting index of performance is 0.55. The amount of
indomethacin released from the rest of the extrudates (from 15% to 90%
drug loading) at this pH was undetectable using the present experimental
set-up, while copovidone is released only from the 15% and 30% extrudates
with a partial RDDR of 0.30 and 0.36 mg/(min · cm2) respectively. The
IDR value of 100% copovidone was found to be 3.66 mg/(min · cm2), while
the IDR of the 100% indomethacin γ form was undetectable at a pH below
the pKa of 4.5.
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Turning to the experiments performed in pH 6.8 phosphate buffer (RHS of
Table 6.1), the partial RDDR of indomethacin increases linearly with the
drug loading up to 50% (Figure 6.8), and then reduces for the 70% and
90% extrudates. The partial RDDR of copovidone decreases as a function
of the drug loading, and the resulting index of performance values are close
to unity for all the extrudates, essentially indicating that the drug release
at pH 6.8 is non-dependent on the drug loading and this is due to the
drastic increase of the indomethacin aqueous solubility in neutral/alkaline
pH conditions compared to acidic conditions.
From the RDDR data and also from the photos it is clear that the in-
domethacin extrudates show a pH-dependent dissolution behaviour. In-
domethacin is released from the 5% extrudate at both pH 2 and 6.8 with a
dissolution rate and resulting index of performance higher at pH 6.8 com-
pared to pH 2, which is consistent with the higher indomethacin aqueous
solubility at neutral/alkaline pH compared to acidic conditions. For the
higher drug-loaded extrudates (≥ 15% w/w) the amount of drug released
at a pH below the indomethacin pKa of 4.5 was undetectable under the
current experimental set-up, while a detectable amount of copovidone is
only released from the 15% and 30% extrudates at pH 2. At pH 6.8, all
the extrudates behave similarly with the best performance from the 50%
extrudate, which exhibits a 29 fold increase in dissolution rate compared
to the 100% indomethacin γ form. It is also interesting to notice that the
90% extrudate shows approximately a 17 fold increase in dissolution rate
compared to the 100% indomethacin γ form, indicating that even a small
amount of copovidone in the ASD significantly enhances the dissolution
performance.
The dramatic difference in dissolution behaviour of the indomethacin ex-
trudates at pH 2 and 6.8 is entirely reasonable as the aqueous solubility of
indomethacin is known to significantly increase from acidic to neutral pH
(from 1.5 µg·mL−1 at pH 1.2 to 105.2 µg·mL−1 at pH 7.4).137
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Figure 6.6: Dissolution profiles obtained from the RDDR and IDR
experiments conducted in pH 2 HCl buffer. For copovidone in the
5% extrudate, trends of both experiments rather than the average are
shown due to the significant difference in behaviour. The amount of in-
domethacin released from the 15% and 30% extrudates was undetectable
in the present experimental set-up.
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Figure 6.7: Dissolution trends of all materials obtained from the
RDDR and IDR experiments conducted at pH 6.8.
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Figure 6.8: Partial RDDR of indomethacin at pH 6.8 as a function
of the indomethacin weight fraction for all the extrudates (from 5% to
90% drug loading).
At pH 6.8 the drug is released from all the drug loadings, while at pH 2
the drug is released only from the 5% extrudate due to the high amount of
highly water-soluble copovidone in the formulation, i.e. polymer-controlled
drug release.87
Although the RDDR test clearly indicates that the indomethacin-copovidone
extrudates behave very differently at a pH below and above the pKa of 4.5,
it does not provide a physicochemical explanation of the poor dissolution
performance at low pH. Therefore, Raman spectroscopy and in-line UV-Vis
were employed to study the system.
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6.3.3 Raman ultraviolet-visible flow cell experiments
6.3.3.1 Ultraviolet-visible
The dissolution profiles of indomethacin released from the extrudates and
both the 100% amorphous and 100% γ forms of indomethacin obtained
from the flow cell experiments are presented in Figure 6.9. These data are
in good agreement with the RDDR test, although the shear forces generated
in the two techniques are clearly different, and indicate that the dissolution
performance of the extrudates is intrinsic to the formulation rather then
the technique employed to measure it.
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Figure 6.9: Dissolution profiles of indomethacin released from the ex-
trudates and profiles of the pure materials (100% amorphous and 100%
γ forms of indomethacin).
5% extrudate is the only formulation that gives increasing solution con-
centration of indomethacin (up to approximately 40% of cumulative drug
amount in solution) when the pH is 2. 100% of cumulative drug amount
in solution is reached within a few minutes after the dissolution medium is
switched to pH 6.8 phosphate buffer.
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The other extrudates (from 15% to 90% drug loading) along with the 100%
amorphous and 100% γ forms of indomethacin do not show any detectable
(within the limits of detection of the present experimental set-up) drug
release at pH 2.
These extrudates and the pure materials begin to release indomethacin
only after the medium is changed to pH 6.8 phosphate buffer. The 15% and
30% extrudates reach the maximum indomethacin solution concentration at
about 400 min. The release of the 50% extrudate is slightly slower giving
increasing solution concentrations up to a maximum at about 440 min.
Both the 70% and 90% extrudates do not reach the maximum indomethacin
solution concentration within 500 min, with the first releasing 60% and the
second 40% at this time-point. The 100% amorphous and 100% γ forms
of indomethacin show very similar dissolution profiles, with a cumulative
drug amount in solution still increasing at the end of the experimental
time-frame, having reached a value of 3% and 2% respectively at 500 min.
The UV-Vis data are in agreement with the images and the RDDR data,
and showed that only the 5% extrudate exhibits a detectable dissolution
rate at a pH below the pKa of indomethacin. The other drug loadings and
the pure materials do not release any detectable (in the current experi-
mental set-up) indomethacin when the dissolution medium is pH 2 HCl.
The buffer switch then promotes the drug release given that the aqueous
solubility of indomethacin greatly increases (approximately two orders of
magnitude higher at pH 7.4 compared to pH 1.2)137 at a pH above the
indomethacin pKa of 4.5. The 15% and 30% extrudates begin to release
the drug approximately at the same time and this can be linked to the
similar swelling and therefore water ingress observed at pH 2. For the 50%
extrudate, the release of the drug begins later and this is consistent with a
minor and retarded swelling at pH 2 as seen in Figure 6.5.
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6.3.3.2 Raman spectroscopy
Raman spectroscopy was used to monitor the physicochemical changes that
occurred during the dissolution of the indomethacin-copovidone extrudates
under similar conditions to those outlined above.
Reference spectra Before commencing a full discussion of the data,
it is useful to notice the differences between Raman spectra of the raw
materials. Raman spectra of the extrudates, the 100% amorphous form
of indomethacin, and the 100% ‘dry’ and ‘wet’ copovidone are presented
in Figure 6.10. The spectrum of the 100% ‘wet’ copovidone was collected
immediately after immersing compressed powder of copovidone in water.
Raman spectra of the extrudates approximate to a linear combination of
amorphous indomethacin and dry copovidone in the region between 1100
and 1750 cm−1 (Figure 6.10). The peak from dry copovidone at 1425 cm−1
is clearly evident in the spectra of the 5%, 15% and 30% extrudates, while
it is greatly reduced in the spectrum of the 50% extrudate, and falls below
the limit of detection in the spectra of the 70% and 90% extrudates. This
is reasonable as copovidone is known to be a weaker Raman scatterer than
indomethacin.6
It is also important to notice that Raman spectra of ‘dry’ and ‘wet’ copovi-
done are different. The bands deriving from the carbonyl stretching mode
of the vinylpirrolidone and vinylacetate blocks move to a lower Raman shift
in the spectrum of ‘wet’ copovidone (1651 and 1717 cm−1) compared to
that of ‘dry’ copovidone (1673 and 1734 cm−1). These shifts likely arise
from the inter-molecular hydrogen bonding interactions between copovi-
done and the water molecules. In addition, it is possible to note differences
in the spectral region deriving from the bending modes of the methylene
functional groups. The band at 1425 cm−1 is sharper in the spectrum of
100% wet copovidone compared to that of 100% dry copovidone.
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Figure 6.10: Raman spectra of raw materials (1100–1750 cm−1 re-
gion). Spectra were variance-scaled before plotting.
Moreover, a peak at 1450 cm−1 appears clearly in the spectrum of 100%
wet copovidone that is not present in 100% dry copovidone. These spectral
differences can be ascribed to conformational changes that occur when dry
copovidone is immersed in water.
In the low-wavenumber region (40–400 cm−1, Figure D.4 of the Appendix
D), spectra of all materials show the typical broad distribution expected
for amorphous solids.118–120 Raman spectra of the γ and α indomethacin
polymorphs are shown in Figure D.2 of the Appendix D. The γ polymorph
is the thermodynamically stable form and the α polymorph is the most
commonly observed metastable form.178 Due to the different conformations
of indomethacin, Raman spectra of the γ and α polymorphs significantly
differ both in the 1100–1750 cm−1 (Figure D.2a) and 40–400 cm−1 (Figure
D.2b) regions. Raman spectra of the two indomethacin polymorphs are
consistent with those previously reported by others.69,178
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Dissolution: time-resolved spectra The variation in the averaged
spectra collected during the dissolution of the extrudates is now discussed
(Figure 6.11). Starting with 100% copovidone and the 5% extrudate (Fig-
ure 6.11a and b), it is apparent that no evidence of form change occurs dur-
ing the entire dissolution test conducted at pH 2. All the spectra present
two clear bands at 1425 and 1450 cm−1 which are typical of wet copovi-
done, indicating that the compacts are fully hydrated during the entire
dissolution experiment at pH 2.
Turning to the 15% extrudate (Figure 6.11c), it is possible to see that at
pH 2 the band due to copovidone at 1425 cm−1 decreases in intensity as
a function of time. Comparison of the averaged spectrum collected at 93
min with the reference spectra indicates a strong correlation with the 100%
amorphous indomethacin reference form. When the pH is switched to 6.8,
i.e. above the indomethacin pKa of 4.5, the two distinctive bands of wet
copovidone at 1425 and 1450 cm−1 appear (averaged spectra collected after
168 min). The situation with the 30% extrudate (Figure 6.11d) is largely
identical to that of the 15% extrudate. Spectra collected at pH 2 between 7
and 112 min become more similar to that of the 100% amorphous reference
form of indomethacin, and spectra collected at pH 6.8 between 174 and 318
min present the characteristic bands of wet copovidone at 1425 and 1450
cm−1. At pH 2, Raman data indicate that for the extrudates with 15% or
higher drug loading hydrophilic copovidone preferentially dissolves from the
exterior of the compact leaving an amorphous drug-rich and hydrophobic
shell, which acting as an in situ formed enteric coating inhibits the drug
release. The depletion of copovidone at low pH from the 15% and 30%
extrudates is confirmed by the RDDR test. The pH switch from below to
above the pKa increases the aqueous solubility of indomethacin which in
turn removes the shell and enables the drug release. The dissolution model
described here is schematically reported in Figure 6.12.
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Figure 6.11: Spatially-averaged Raman spectra of the dissolution ex-
periment of (a) 5%, (b) 15%, (c) 30% and (d) 50% extrudates. Data
were variance-scaled before plotting. Y-axis offsets have been applied
for presentational purpose and vary between panels.
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Figure 6.12: Schematic model depicting the dissolution mechanism
of the indomethacin-copovidone extrudates in pH 2 HCl and pH 6.8
phosphate buffer.
The dissolution for 100% copovidone and the 5% extrudate at pH 2 (Figures
6.11a and b), and the 15% and 30% extrudates at pH 6.8 (Figures 6.11c and
d) is clearly associated with the appearance of hydrated copovidone after
water ingress. This is clear by observing the characteristic bands of wet
copovidone at 1425 and 1450 cm−1. The dissolution process observed here,
i.e. dry→ hydration→ dissolution, is consistent with dissolution-controlled
release mechanisms from medium-soluble carriers.137 The build-up of an
amorphous drug-rich shell seen for the 15% and 30% extrudates at pH 2 has
been previously observed also for ASDs of indomethacin and PEG.174 It was
proposed that, based on ATR-FTIR spectroscopic imaging experiments, the
initial rapid dissolution of PEG leaded to the accumulation of amorphous
indomethacin which re-crystallised into the γ form due to an increase in
molecular mobility.
For the 50% (Figure 6.13a), 70% (Figure 6.13b) and 90% (Figure 6.13c) ex-
trudates, the amount of copovidone in the extrudate is too low to generate
well-resolved bands and therefore Raman spectra of these materials can not
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be differentiated from the spectrum of the 100% amorphous reference form
of indomethacin. For the 70% and 90% extrudates it is possible to observe
a peak shift after approximately 280 min from 1676 to 1670 cm−1 along
with a change in peak shape (Figures 6.13b and 6.13c). The sharp band at
1670 cm−1 corresponds to a crystalline form that has been previously ob-
served by Greco et al. during the dissolution of amorphous indomethacin.175
Using PLM they demonstrated that needles of this crystalline form of in-
domethacin were present at the end of the dissolution test. The presence of
sharp bands in the low-wavenumber region (Figure 6.14) confirms the drug
re-crystallisation. The data indicate that for the 70% and 90% extrudates
a lower ratio of copovidone to indomethacin at the surface in contact with
water induces the drug re-crystallisation and as a result the drug release
is reduced. Averaged spectra of the dissolution experiment of the 100%
amorphous form of indomethacin are presented in Figure 6.13d. The real
time data acquisition was in this case extremely difficult due to the high
fluorescence emission of this material. The remaining compact was there-
fore removed from the flow cell after 4440 min of immersion in dissolution
medium and analysed by Raman and XRPD. Both Raman spectrum (Fig-
ure 6.13d) and XRPD pattern (Figure 6.15) show high similarity with those
of the α reference form of indomethacin, pointing to the re-crystallisation of
the amorphous material. The re-crystallisation of amorphous indomethacin
into the metastable α polymorph in aqueous environments has been previ-
ously reported and is in agreement with the Ostwald’s rule of stages which
states that the least stable polymorph tends to crystallise first, in this case
the α form.175,178
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Figure 6.13: Spatially-averaged Raman spectra of the dissolution ex-
periment of (a) 50% extrudate, (b) 70% extrudate, (c) 90% extrudate
and (d) 100% amorphous indomethacin, with data being variance-scaled
before plotting. Y-axis offset has been applied for presentational effect.
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Figure 6.14: Phonon-mode Raman region of the 70% extrudate com-
pact collected under dry conditions and after 499 min of immersion in
dissolution medium.
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Figure 6.15: XRPD patterns of the α reference form and the 100%
amorphous residue recovered after the dissolution experiment.
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6.4 Conclusions
In this chapter the dissolution performance of the indomethacin-copovidone
extrudates was tested as a function of both the drug loading and the pH
of the dissolution medium. Raman spectroscopy along with in-line UV-vis
were employed to directly relate changes in the amount of drug in solution
to physicochemical changes that occur to the solid form during the test.
The RDDR test was also used to simultaneously measure the dissolution
rate of both indomethacin and copovidone from the molecular dispersion.
The experiments were performed at pH 2 to mimic the stomach conditions
and pH 6.8 to simulate the post-stomach conditions. Only the 5% extru-
date exhibited a detectable dissolution rate at pH 2, pointing to a drug
release mechanism dependent on the highly water-soluble copovidone. Ra-
man data showed that the 5% extrudate remained hydrated across the
entire experiment at pH 2, and this behaviour is consistent with those pre-
viously observed for low drug-loaded ASDs of felodipine (Chapter 3) and
bicalutamide (Chapter 4). For the rest of drug loadings (15% or higher), the
poor dissolution performance at pH 2 is related to the in situ formation of
an amorphous and hydrophobic enteric coating of drug which further limits
drug release from the interior of the compact. The formation of an amor-
phous drug-rich shell has been also observed during the dissolution of high
drug-loaded extrudates of felodipine (Chapter 3) and bicalutamide (Chap-
ters 4 and 5). The pH switch from below to above the indomethacin pKa
of 4.5 dissolved this coating and enabled the dissolution of the extrudates.
Chapter 7
Conclusions and future work
The aim of the work in this thesis was to investigate the use of Raman
spectroscopy as primary technique to obtain additional information on
the dissolution performance of ASDs. Gaps in the current knowledge of
ASDs include a lack of understanding of the dissolution performance due
to the complexity of the mechanisms by which the drug is released and
the outlined limitations of the conventional dissolution testing. The nov-
elty of using Raman arises from obtaining in real time and in situ highly
spatially-resolved chemical images of the solid form changes during the dis-
solution process. This was done by using point-by-point Raman mapping
and a flow cell system placed below the Raman microscope. The Raman
information were also complemented by data obtained from a number of
other techniques/methodologies, including optical imaging, the RDDR test,
quantitative suppressed-water 1H NMR spectroscopy and MRI.
The dissolution performance of three ASD model systems (manufactured
by hot HME) including felodipine, bicalutamide and indomethacin, all
poorly soluble drugs, with copovidone was explored. The complexity of
the model systems was being built-up through the chapters, starting with
a well-documented poorly soluble drug model, i.e. felodipine (Chapter 3),
then investigating bicalutamide which is known to exist in at least two
polymorphic forms (form I and form II) with different physicochemical
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properties (Chapters 4 and 5), and finally testing the dissolution of in-
domethacin whose aqueous solubility significantly changes between acidic
and neutral/alkaline conditions (Chapter 6).
In Chapter 3 the dissolution behaviour of amorphous felodipine solid disper-
sions was tested as a function of the drug loading (5% vs 50% w/w). Optical
imaging and for the first time the RDDR test were used to complement the
Raman data. The RDDR test uses HPLC to separate and quantify both the
drug and the polymer and ultimately enables an index of performance to be
obtained. For the 5% extrudate, felodipine and copovidone were shown to
erode with approximately the same rate from the molecular dispersion and
real time Raman data did not show any significant changes across the entire
dissolution experiment. This indicated a dissolution mechanism strongly
dependent on the high water solubility of copovidone, with the drug release
rate being dictated by the dissolution of the polymer. In contrast, the 50%
extrudate compact was shown to swell rather then erode/dissolve. In agree-
ment with the optical images, the partial RDDRs of both felodipine and
copovidone were found to be extremely low, pointing to a dissolution mech-
anism dependent on the low aqueous solubility and high hydrophobicity of
felodipine. Raman data indicated that felodipine within the 50% extrudate
re-crystallised and that the re-crystallisation followed the formation of an
amorphous drug-rich shell around the compact via copovidone dissolution
in the initial part of the test. These two transformations, i.e. the forma-
tion of an amorphous drug-rich shell and the drug re-crystallisation, were
determined to be responsible for the limited dissolution performance ob-
served for the 50% extrudate. Raman maps of the re-crystallisation event
were generated using the MCR model. The novelty of this mathematical
approach derives from the use of concatenated Raman maps to explicitly
probe the changes as a function of time as well as space.
In Chapter 4 the same combination of analytical techniques used in Chap-
ter 3, i.e. Raman spectroscopy, the RDDR test and optical imaging, was
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employed to explore the dissolution behaviour of another ASD model sys-
tem which includes poorly soluble bicalutamide and highly water-soluble
copovidone. The dissolution performance of the bicalutamide-copovidone
ASD was tested as a function of the drug loading (5% vs 50% w/w). Bi-
calutamide and copovidone in the 5% drug loading, similarly to the low
drug-loaded felodipine ASD, were shown to erode/dissolve with the same
rate, pointing to a polymer-dependent dissolution performance. In con-
trast, the drug and the polymer in the 50% extrudate dissolved with sig-
nificantly lower dissolution rates, pointing to a dissolution dependent on
the physicochemical properties of the drug, i.e. low solubility and high
hydrophobicity. This limited dissolution performance, similar to that ob-
served for the high drug-loaded felodipine ASDs, was due to the build-up
of bicalutamide-rich amorphous material on the compact surface followed
by the drug re-crystallisation. Highly spatially-resolved chemical Raman
maps generated by the MCR model indicated that amorphous bicalutamide
crystallised first into metastable polymorphic form II and then into stable
polymorphic form I. Raman spectroscopy, due to the high chemical speci-
ficity, was able to discriminate between the three different solid forms of
bicalutamide, i.e. amorphous, form II and form I. In addition, by fitting a
kinetic model to the data extracted from the Raman maps it was possible
to understand the re-crystallisation mechanisms by which the low energy
form I appeared. Form I was shown to crystallise preferentially from the
amorphous form in a random nucleation mechanism, rather than from the
crystalline form II.
In Chapter 5 the dissolution performance as a function of the drug loading
(5% and 30% w/w) of the bicalutamide-copovidone extrudates was further
investigated using a suite of state-of-the-art analytical techniques, including
a combined MRI/UV-Vis flow cell system to allow changes in dissolution
profile to be related to physical changes occurring in the solid material,
and for the first time quantitative suppressed-water 1H NMR spectroscopy
was applied to ASD formulations. 1H NMR, due to the high chemical
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selectivity, allowed the dissolution profiles and rates of both the drug and
the polymer from the molecular dispersion to be simultaneously obtained.
In agreement with the Raman and RDDR data showed in Chapter 4, the
5% compact was shown to erode linearly (MRI images) with bicalutamide
and copovidone being released at similar rate (UV-Vis and 1H NMR data),
pointing to a polymer-controlled drug release. In contrast, the dissolution
rates of both bicalutamide and copovidone were found to be significantly
lower in the 30% extrudate due to a slower water ingress into the compact,
pointing to a drug-controlled dissolution mechanism. The lower and slower
water ingress was thought to be due to the formation of an amorphous
drug-rich shell which has been previously observed and hypothesised for
the dissolution of high drug-loaded extrudates of felodipine (Chapter 3)
and bicalutamide (Chapter 4).
In Chapter 6 the behaviour during dissolution of another ASD model system
which includes indomethacin and copovidone was explored. Indomethacin
presents a pH-dependent solubility and dissolution rate, so in addition to
the drug loading (from 5% to 90%), the dissolution performance was tested
also as a function of the dissolution medium pH. This was done by switching
the dissolution medium from pH 2 HCl (to mimic the stomach conditions)
to pH 6.8 phosphate buffer (to mimic the post-stomach conditions) dur-
ing the dissolution test. In addition, an in-line UV-Vis spectrophotometer
was connected to the Raman flow cell system to enable changes in dissolu-
tion trend (monitored by UV-Vis) to be directly related to physicochemical
changes that occur to the extrudate (monitored by Raman). The 5% ex-
trudate was shown to be the only drug loading to exhibit a detectable
dissolution rate at pH 2, and this was found by Raman to be due to the
compact remaining hydrated across the entire experiment at pH 2. For the
rest of drug loadings (15% or higher), the poor dissolution performance ob-
served at pH 2 was related to the in situ formation of an amorphous and hy-
drophobic enteric coating due to the low aqueous solubility of indomethacin
at this pH. Raman data indicated that the dissolution medium switch to
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pH 6.8 phosphate buffer removed the shell and enabled drug release due to
the significant increase of the aqueous solubility of indomethacin in neu-
tral/alkaline pH conditions. Raman spectroscopy for this particular study
was able to discriminate between water ingress/not water ingress and ulti-
mately to provide a mechanistic explanation on the dissolution performance
as a function of pH conditions and drug loading.
In summary, a number of methodologies were discussed in this thesis to pro-
vide additional and complementary information on the drug release mech-
anisms from ASDs of felodipine, bicalutamide and indomethacin. From
the data generated it was possible to make a number of potential expla-
nations regarding the effects of drug loading and environmental pH on the
dissolution performance of ASDs.
The first potential continuation of the work presented in this thesis is to
complement the Raman data on the indomethacin-copovidone model sys-
tem by using the MRI method. MRI could provide very useful physical
information on the rate of water ingress at pH 2 and 6.8 which could be
linked to the chemical transformations observed by Raman. In addition,
the composition of the indomethacin dispersions could be changed and the
dissolution performance investigated. For example, adding a water-soluble
compound such as caffeine to the indomethacin-copovidone dispersion could
help to elucidate the formation of the hydrophobic enteric coating. The
quick dissolution at pH 2 of the water-soluble molecule from the surface
and the resulting formation of the amorphous drug-rich shell should be
readily detected by both Raman and UV-Vis. Then, a second polymer such
as Eudragit EPO could be added to the indomethacin-copovidone disper-
sion. Eudragit EPO is a cationic polymer soluble in gastric fluid up to pH
5, which could potentially facilitate to maintain the material hydrated in
acidic conditions.
A very interesting correlation and consistency in performance has been ob-
served between the different ASD model systems. A future work is to apply
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the RDDR test to other binary model solid dispersions. The dissolution
rate of both the drug and the polymer could be tested as a function of
well-selected factors such as the number of hydrogen bonds between the
drug and the polymer in the dispersion. This will enable a correlation be-
tween those properties and the dissolution behaviour of the drug and the
polymer to be built. The ultimate aim is to generate information that al-
low formulators to specifically select a certain polymer or composition for
a drug in development and therefore to obtain a formulation strategy with
the desired controlled drug release.
Another important consideration is that a number of different techniques
including solution-based and solid-based methods have been combined in-
line and off-line to provide complementary information on the drug re-
lease. This paradigm could be further exploited in future works, and other
techniques for providing more information could be implemented, with the
ultimate aim to assure the quality of performance of formulations. For ex-
ample, to study the dissolution from ASD formulations, an ideal dissolution
set-up may include Raman spectroscopy and MRI to obtain chemical and
physical information directly from the dosage form, UV-Vis and 1H NMR
to quantify the amount of drug and polymer in solution, and a particle
size analyser (e.g. dynamic light scattering and image analysis) to deter-
mine the drug precipitation. The latter is of particular importance for ASD
formulations as it is well known that the amorphous form due to its thermo-
dynamic instability tends to precipitate into the crystalline form. Overall,
the combination of a number of complementary analytical techniques will
allow several information and therefore a clearer understanding of the drug
release mechanisms to be obtained from a single dissolution experiment.
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Figure A.1: XRPD patterns of the extrudates and the crystalline ref-
erence form (“Felodipine as received”).
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Figure B.1: XRPD patterns of the raw materials. Raw data were
variance-scaled before plotting.
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Figure B.2: Fingerprint (a) and phonon-mode (b) regions of the av-
eraged Raman spectra collected during the dissolution of the 50% ex-
trudate, with raw materials spectra in blue. Y-axis offsets have been
applied for presentational purposes and differ between panels.
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Figure B.3: Remaining time-point maps collected through the disso-
lution experiment of the 50% extrudate.
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Figure C.1: Variance-scaled XRPD pattern of the 30% extrudate.
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Figure C.2: Variance-scaled Raman spectrum of the 30% extrudate.
Figure C.3: 1H NMR spectra of reference solutions of 5% and 30%
extrudates.
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Figure C.4: Magnetic resonance images (second experiment) showing
the changes as a function of time in one cross sectional slice of the
extrudates containing 5% (a) and 30% (b) of bicalutamide.
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Figure D.1: Variance-scaled XRPD data of the γ and α indomethacin
reference forms.
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Figure D.2: 1100–1770 cm−1 (a) and 40–400 cm−1 (b) Raman regions
of γ and α crystalline indomethacin forms. Data have been variance-
scaled before plotting. Y-axis offsets were applied for presentational
purpose.
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Figure D.3: XRPD patterns of the dry indomethacin:copovidone
extrudates, 100% copovidone and the 100% amorphous form of in-
domethacin. Data were variance-scaled before plotting.
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Figure D.4: Raman phonon-mode region (40–400 cm−1) of raw ma-
terials. Spectra were variance-scaled before plotting.
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We have employed for the ﬁrst time Raman spectroscopic imaging along with multi-variate curve resolution
(MCR) analysis to investigate in real time and in-situ the dissolution mechanisms that underpin amorphous
solid dispersions, with data being collected directly from the dosage form itself. We have also employed a
novel rotating disk dissolution rate (RDDR) methodology to track, through the use of high-performance liquid
chromatography (HPLC), the dissolution trends of both drug and polymer simultaneously in multi-component
systems. Two formulations of poorly water-soluble felodipine in a polymeric matrix of copovidone VA64
which have different drug loadings of 5% and 50% w/wwere used asmodels with the aim of studying the effects
of increasing the amount of active ingredient on the dissolution performance. It was found that felodipine
and copovidone in the 5% dispersion dissolvewith the same dissolution rate and that no Raman spectral changes
accompanied the dissolution, indicating that the two components dissolve as single entity, whose behaviour
is dominated by water-soluble copovidone. For the 50% drug-loaded dispersion, partial RDDR values of
both felodipine and copovidone were found to be extremely low. MCR Raman maps along with classical
Raman/X-ray powder diffraction (XRPD) characterisation revealed that after an initial loss of copovidone from
the extrudate the drug re-crystallises, pointing to a release dynamics dependent on the low water solubility
and high hydrophobicity of felodipine. Raman imaging revealed different rates of transition from amorphous
to crystalline felodipine at different locations within the dosage form.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
A high number of new chemical entities emerging from the drug de-
velopment process show pharmacological activity, but at the same time
are characterised by poor dissolution and solubility proﬁles [1]. As a re-
sult, there is a strong push to develop innovative formulations for the
delivery of such compounds so that the desired oral bioavailability
and pharmacological effects are achieved. An increasingly popular
class of formulation is represented by amorphous solid dispersions,
which are prepared by co-processing the drug and a water-soluble or
water-swellable polymeric carrier, commonly via spray drying or hot
melt extrusion [2,3]. The resultant dispersion, as widely demonstrated
for several poorly soluble compounds, has an improved dissolution
proﬁle and consequently bioavailability compared to the pure drug
[4]. This is attributed to the fact that the drug within the dispersion ex-
ists in the amorphous form, which gives a higher dissolution rate than
the corresponding crystalline form, and also due to the presence of the
water-soluble polymer [5,6].
One of the key challenges for deploying amorphous solid dispersions
in real-world formulations is the understanding of the dissolution per-
formance. Although this is very relevant, due to the fact that the disso-
lution performance limits the in vivo efﬁcacy, relatively few studies
have been conducted to investigate the dissolution mechanisms that
underpin these systems. As reported by Craig, [7] the dissolutionmech-
anism of amorphous solid dispersions is characterised by a number of
critical processes, which primarily depend on the chemical nature of
the components and on the drug-to-polymer ratio. In relation to these
parameters, Craig classiﬁed the drug release from amorphous solid dis-
persions as polymer-controlled or drug-controlled. It has been demon-
strated that the re-crystallisation of the drug either in the solid state
or after precipitation in solution, [8,9] the formation of nano- and
micro-particles during the dissolution [10] and also the behaviour of
the polymer itself, [11] strongly contribute to the ﬁnal dissolution
performance. Amorphous solid dispersion dissolution mechanisms are
extremely difﬁcult to de-convolute due to several processes occurring
simultaneously.
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Classical methods of investigating drug release such as the use
of USP dissolution apparatuses [12] do not offer any chemical or
spatially-resolved information on potential changes of the solid form
(e.g. from amorphous to crystalline, polymorphic transformations or
formation of hydrate states) during the dissolution, since the data are
collected from the solution, rather than directly from the solid dosage
form itself. Given the limitations of the conventional dissolution appara-
tuses, innovative methods have been developed in an attempt to pro-
vide a more complete picture of the drug release. Such methods have
included mid-IR, [13,14] near-IR [15,16] and magnetic resonance imag-
ing (MRI) [8,17]. Mid-IR and near-IR provide chemical information, but
also have a signiﬁcant drawback; they are very sensitive towaterwhich
clearly limits the use of these techniques in aqueous environments. MRI
is attractive as it can offer three-dimensional information, however it
provides little chemical speciﬁcity.
Raman spectroscopy, theoretically, offers advantages/complemen-
tarities compared to these techniques. It provides chemically detailed
and two-dimensional spatial information (‘hyper-spectral data’, one
spectrum per pixel) and is able to readily differentiate between amor-
phous and crystalline solid forms [18,19]. These properties are signiﬁ-
cant since the chemical and physical forms of the drug can change
during the course of the dissolution test [8,9,14]. Moreover, with respect
to mid-IR and near-IR, Raman spectroscopy is relatively insensitive to
water [20]. Raman spectroscopy is therefore an appropriate technique
to investigate how the solid state properties of the drug affect its release
and for this reasonwas employed in thiswork to understand the perfor-
mance of amorphous solid dispersions during dissolution in aqueous
media.
An amorphous solid dispersion of felodipine, the active ingredient, in
a polymericmatrix of copovidoneVA64,was used asmodel formulation.
Felodipine is an antihypertensive drug, characterised by high permeabil-
ity and low water solubility (lower than 0.5 mg/lt) [21]. Copovidone
VA64 is a highly water-soluble polymer (solubility higher than
100 mg/lt), [22] recognised as a chemical analogue of polyvinylpyrroli-
done (PVP). In previous studies, PVP and copovidone VA64 have been
successfully used to prepare one-phase amorphous felodipine binary
mixtures over a range of composition (0–70% drug loading), showing
the ability to inhibit re-crystallisation and to increase the dissolution
rate of poorly soluble felodipine [23–27]. The physical mixture of
crystalline felodipine and copovidone VA64 has been shown instead
to have a small increase in dissolution rate when compared to pure
crystalline felodipine, further demonstrating how the physical state
of the active ingredient (e.g. amorphous vs. crystalline) affects the
whole dissolution performance regardless the presence or absence
of the polymer in the formulation [8]. This work follows on from
the recent paper by Langham et al., where the use of a combined
spectrophotometric and magnetic resonance imaging technique to
investigate the dissolution mechanisms of felodipine–copovidone
spray-dried amorphous solid dispersions was described [8]. It was
found that the dissolution behaviour of the high drug-loaded amor-
phous solid dispersions is governed by the low aqueous solubility of
felodipine and by the re-crystallisation (conﬁrmed by off-line XRPD)
of the drug.
In the present work, we investigated formulations which have dif-
ferent drug loadings (5% and 50%w/w), with the aim of studying the ef-
fects of increasing the amount of active ingredient on the dissolution
performance. Two different approaches were employed to probe the
dissolution performance of amorphous solid dispersions. The ﬁrst used
Raman spectroscopy and the second uses a rotating disk dissolution
rate (RDDR) test. Our RDDR method, with respect to conventional
intrinsic dissolution rate (IDR) test described in the USP and in the
European Pharmacopoeia, [12,28] employs HPLC to separate the drug
from the polymer and ultimately allows us tomeasure the performance
in aqueous media of multi-component systems.
The aim of this work is to investigate whether Raman spectroscopy
provides additional chemical and spatial information regarding the
dissolution mechanisms that underpin amorphous solid dispersions,
used in conjunction with RDDR dissolution test.
2. Materials and methods
2.1. Preparation of amorphous felodipine and extrudate solid dispersions
The amorphous form of felodipinewas obtained by heating the drug
as received (AstraZeneca, Macclesﬁeld, United Kingdom) in the oven to
160 °C and, after melting, cooling back to room temperature. Visual in-
spection and Raman spectroscopy conﬁrmed the formation of the amor-
phous form and the absence of crystalline material within the detection
limits (ca. 0.5% or better). 5% and 50% drug-loaded amorphous solid dis-
persions of felodipine in copovidone (BASF, Ludwigshafen, Germany)
were prepared using a co-rotating twin-screw extruder (Thermo Scien-
tiﬁc HAAKEMiniLab II). Felodipine and copovidone were pre-mixed for
20 min in a Turbula T2F mixer (Willy A. Bachofen AG Mashinefabrik).
The extruder was manually fed with the physical mixture. The screw
speedwas set to 150 rpmand the temperature to 160 °C. The extrudates
with spaghetti shape were then collected, cooled to room temperature
and manually milled to ﬁne powder. X-ray powder diffraction con-
ﬁrmed the formation of the amorphous solid dispersion and the absence
of crystalline material (Figure S1).
2.2. X-ray powder diffraction (XRPD)
XRPD patternswere obtained using a PANalytical CubiX PRO diffrac-
tometer. Samples were exposed to Cu-Kα radiation at a voltage of 45 kV
and a current of 40 mA. After being smeared onto the holder, samples
were scanned from 2° to 40° 2θ, with a step size of 0.02° 2θ.
2.3. Rotating disk dissolution rate (RDDR)
RDDR testing was carried on using the rotating disk system, also
known as ‘Woods apparatus’. The die cavity has a diameter of 8 mm
with subsequent exposed sample surface area of 0.5 cm2. About
250 mg of extrudate powder was compressed under a compression
force of 2000 kg using a manual IR press (Specac). The experiment
was performed in a Sotax AT7 semi-automated dissolution bath
equipped with an automated sample collector. Compressed discs were
immersed in 500ml of deionised water at 37 °C (±0.5), at 100 rpm ro-
tational speed. The automated sample collector removed aliquots of
sample from the dissolution medium at regular time intervals over
120min. The sampleswere then analysed by reverse phase high perfor-
mance liquid chromatography (RP-HPLC). Both the experiments for 5
and 50% extrudateswere performed in triplicate. HPLC analysiswas car-
ried out using a Agilent 1100 with UV detection at 210 nm, equipped
with an Agilent PLRP-S 300 Å 3 μm 50 mm column (polystyrene/
divinylbenzene stationary phase). The ﬂow rate was set to 1.0 ml/min
and the temperature of the column was kept at 40 °C. A linear gradient
elution was used starting at 40% acetonitrile/60% deionised water and
ending at 90% acetonitrile/10% deionisedwater after 3.5min,with chro-
matograms collected up to 5 min. A series of standard solutions of
felodipine and copovidone were prepared to generate a calibration
curve covering the concentration range of dissolved sample. The partial
RDDR of both drug and polymer was calculated using linear regression
analysis [12,28]. The partial RDDR of the substance tested was deter-
mined from the slope of the regression line.
2.4. Raman spectroscopy
We investigated the dissolution performance of compressed
extrudate powder. Spherical compacts with a diameter of 5 mm and a
weight of 50 mg were prepared with a manual IR press (Specac) using
a compression force of ca. 20 kN. The dissolution test was performed
in a ﬂow cell, which is illustrated in Figure S2. Deionised water was
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used as dissolutionmediumand theﬂow ratewas set to 10 ml/min. The
ﬂow cell was placed under the objective of the Raman microscope and
data were collected as function of time using a Horiba LabRAMHR con-
focal microscope/spectrometer. The system has an automated xyz stage
(Märzhäuser) for mapping. In all the experiments, a near-IR laser
(785 nm) of 250 mW power was employed. Spectra were acquired
using a 50 × objective and a 300 μm confocal hole. A 600 lines/mm
rotatable diffraction grating along a path length of 800 mm was used
to simultaneously scan a range of frequencies. Raman spectra were
collected using a SYNAPSE CCD detector (1024 pixels). During the
dissolution experiment, before each map being acquired, the z-axis
position of the sample was adjusted to maximise the Raman signal.
For both formulations (5% and 50% felodipine), spectra were obtained
mapping an area of 500 × 500 μm with a grid spacing of 50 μm along
both x-axis and y-axis, a total of 121 spectra for map. As each individual
spectrum was collected for 1 s, repeated once in order to automatically
remove the cosmic rays, the whole map required only 5 min. For the 5%
extrudate compact, eight maps were acquired across a 70 minute time
frame in the spectral range from 1100 to 1750 cm−1 (ﬁnger print
region). For the 50% extrudate compact, eight maps were acquired
over 1705 min (28 h25) in the phonon-mode (30–400 cm−1) and
ﬁnger print (1100–1750 cm−1) regions using a ﬁxed grating to allow
relatively rapid mapping. In the latter case, the phonon-mode range
was also scanned because it is extremely sensitive to the different
solid forms (amorphous, crystalline, etc.) and therefore the potential
drug re-crystallisation can be readily detected [18,19]. All the spectra
from each map were integrated to produce a single averaged spectrum
corresponding to each time point. In this way, it was possible to deter-
mine any spectral changes occurring during the dissolution test.
To obtain spatially-resolved information from the 50% extrudate
compact, the dissolution experiment was repeated increasing signiﬁ-
cantly the spatial resolution. Seven maps were acquired over 1705 min
(28 h25) in the spectral range between 1100 and 1750 cm−1, across a
500 × 1000 μm area at a grid spacing of 15 μm along the x-axis, and
30 μmalong the y-axis, a total of 1156 spectra permap. As the data acqui-
sition time was 2 s for each spectrum, repeated once, each map required
1 h and 30 min for acquisition. False colour maps were generated using
multi-variate curve resolution (MCR). A single data matrix, comprising
all the spectra collected across the entire dissolution experiment (8092
spectra), was produced in order to probe changes as a function of both
xy-position and time. Numerical codes for statistical analyses were writ-
ten in the ‘R’ language, which is open-source and freely available [29].
Data were scaled prior to analysis and plotting using variance scaling
and mean centering standard methods, as per standard practice [20] to
reduce the effect of variability in Raman scattering efﬁciency. For multi-
variate curve resolution analysis, the ‘ALS-MCR’ module (alternating
least-squares algorithm) was employed, while hierarchical agglomera-
tive clustering is part of the standard package in R. All numerical routines
along with the raw data are included in the supplementary material for
information and reference.
2.5. Optical imaging
Photographic images of the compact during the dissolution were
taken at regular time intervals using a CoolSNAP-Pro CF camera
(Media Cybernetics) equipped with a Nikon AF Micro NIKKOR 60 mm
lens. The same experimental setup described in the previous section
was used, with the ﬂow cell placed under the camera instead of the
Raman microscope.
3. Results and discussion
3.1. Optical imaging
Before commencing a full discussion of the RDDR and Raman data, it
is important to observe the optical images taken through the dissolution
experiment for the 5% and 50% drug-loaded compacts (Fig. 1a and b).
Prior to the dissolution test, both formulations appear similar, being yel-
lowish compacts. It is important to notice the different experimental
time-scales used for the two formulations. The 5% extrudate dissolution
experiment was carried out for 80 min after which time the images
show that the compact is completely dissolved. For the 50% drug-
Fig. 1. Optical images taken through the dissolution experiment of the 5% extrudate (a) and 50% extrudate (b) compacts.
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loaded formulation, the time-scale was signiﬁcantly longer. In total, the
compact was observed in the ﬂow cell for 1705 min, remaining intact
even after the end of this period. An in depth observation of the images
from the 50% extrudate shows that the compact swells and increases in
size during the ﬁrst 316 min, then slightly reduces and remains intact
until the end of the experiment. This suggests that the initial hydration
leads to swelling of the compact rather than to dissolution/erosion, due
to the high content of poorly soluble felodipine in the extrudate (images
until 316 min). This behaviour was previously described by Langham
et al [8]. In Fig. 7 of their paper, they reported MRI sequences showing
that the 50% felodipine-loaded spray-dried material swells as a result
of water ingress from the dissolution medium. The visual observation
of the optical images relative to the 50% extrudate is conﬁrmed by the
kinetic trend generated by counting the number of pixels of the com-
pact during the dissolution test (Figure S3). The trend is characterised
by an increase in pixel number until 316 min, which corresponds to
the observed increase in the compact size. Following this, the number
of pixels decreases with the rate of decrease falling to near-zero
between 1093 and 1705min, conﬁrming that the size of the compact re-
duces after an initial swelling. The reduction of the compact size after an
initial swelling was not previously seen in the MRI images reported by
Langham et al [8]. This change in behaviour may be related to the differ-
ent conditions during preparation via hot melt extrusion compared
to spray drying (e.g. high temperatures, absence of solvents, formulation
bulk density, etc) whichmay affect the ﬁnal physico-chemical properties
of amorphous solid dispersions and thus their performance in aqueous
media.
3.2. Rotating disk dissolution rate (RDDR)
The intrinsic dissolution rate (IDR) test has been widely used
in biopharmaceutics formeasuring the dissolution rate of pure active in-
gredients [30,31]. It is an important biopharmaceutics screening tool,
and requires far less material than a traditional dissolution test. IDR
measurements yield a dissolution rate normalised to the exposed
surface area of thematerial. Formally, IDR applies only to pure drug sub-
stances [12]. Here we extend the IDR concept to formulations. By anal-
ogy with disk IDR, we deﬁne a ‘rotating disc dissolution rate’ RDDR.
By simply coupling an IDR apparatus to a HPLC system, the partial
RDDR of both the pure drug substance and the excipients (in thepresent
case copovidone) can bemeasured and compared for different formula-
tions. The partial RDDR for the drug and polymer in the different
formulations are shown below to provide valuable information on the
mechanism of drug release.
The dissolution rate values for the 5% and 50% drug-loaded formula-
tions are summarised in Table 1. The dissolution proﬁles can be
inspected in Figure S4 of the supplementary information. Partial RDDR
was calculated using the ﬁrst 20 minute time period, where the trend
is relatively linear, in accordance with USP procedures [12]. Looking at
the formulation with 5% drug loading, the partial RDDR value for
felodipine is 0.17 mg/min/cm2, while the partial RDDR for copovidone
is 3.10 mg/min/cm2. The intrinsic dissolution rate value of pure crystal-
line felodipine has been previously found to be 0.00064 mg/min/cm2 in
pH 6.5 FaSSIF medium, so in comparison the 5% extrudate exhibits
approximately a 265 fold increase in dissolution rate [32]. The signiﬁ-
cant improvement in dissolution is in agreement with literature
on felodipine amorphous solid dispersions [27,33]. The dissolution
rate of the polymer allows calculation of an index of performance of
the formulation which essentially shows how the two components of
the amorphous solid dispersion behave during the dissolution process.
The equation to calculate the index of performance is reported in
Table 1. The index of performance for the low drug-loaded extrudate
results in a value of 1, indicating that felodipine and copovidone have
the same dissolution trend and thus they effectively dissolve as single
entity, the molecular dispersion of felodipine in copovidone. Given the
very low solubility of felodipine, the release of the 5% extrudate is clear-
ly dependent on the high water solubility of the polymer.
Turning now to the formulation with high drug loading, it is imme-
diately evident that both felodipine and copovidone have partial RDDR
values signiﬁcantly lower when compared to those calculated for the
5% extrudate (Table 1). The index of performance is also very
low (0.07), indicating that the dissolution rates of felodipine and
copovidone are in this case very different, suggesting that the two com-
ponents of the formulation are not behaving as a single entity but as two
separate components. Compared to the IDR value of pure extruded
copovidone (5.20 mg/min/cm2 in pH 6.8 blank FaSSIF medium,
Figure S4), copovidone present in the 50% extrudate shows approxi-
mately a 21 fold decrease in dissolution rate. RDDR data suggest that
the drug release is felodipine-dependent, where low solubility in
water and high hydrophobicity of the drug contribute to decrease the
wettability and to slow the water uptake in the formulation.
Summarising, the 5% drug-loaded extrudate showed polymer-
dependent dissolution behaviour with felodipine dissolving simulta-
neously with copovidone. For the 50% extrudate, the rate of felodipine
release is considerably lower than that observed for the 5% drug-
loaded formulation. Although the RDDR test gives a comprehensive ex-
planation about the dissolution trend observed for the low drug-loaded
formulation, it does not clearly explainwhy felodipine shows a very low
dissolution rate for the 50% extrudate. To obtain a better understanding
of the chemical changes that occur during dissolution of the formula-
tion, Raman spectroscopic imagingwas used to interrogate the samples.
3.3. Raman spectroscopy
3.3.1. Dry raw materials spectra: visual observation
The Raman spectra of the rawmaterials are shown in Fig. 2a (ﬁnger
print) and 2b (phonon-mode). Starting with the pure components, it is
evident that the spectrum of felodipine is characterised by sharp bands
and a good signal/noise ratio, whereas the spectrum of copovidone
shows less-deﬁned bands. At ﬁrst approximation, the amorphous solid
dispersion spectra appear as a linear combination of melt quenched
felodipine (amorphous reference form) and copovidone. In the 5%
extrudate spectrum, copovidone bands are predominant, while in the
50% extrudate bands related to felodipine prevail. In the latter case
two slight shifts appear when comparing to the spectrum of melt
quenched felodipine: the band at 1209 cm−1 moves to a lower wave-
number, while the band at 1497 cm−1 appears at higher wavenumber.
These changes can be ascribed to the formation of molecular interac-
tions between the drug and the polymer coupledwithminor conforma-
tional changes, as has been previously reported for amorphous solid
dispersions of felodipine and PVP [11].
Turning now to the felodipine spectra, we can see signiﬁcant differ-
ences between the amorphous (melt quenched felodipine) and the
crystalline (felodipine as received) solid forms. Firstly, the bands of
the crystalline form appear more intense and sharper than those of
the amorphous form, due to the disorganised molecular environment
of the amorphous solid state. Furthermore, a detailed observation
highlights that the intra-molecular vibration bands at 1213, 1492
and 1645 cm−1 of the amorphous form slightly shift to higher
Table 1
Partial RDDR values of felodipine and copovidone for the 5% and 50% extrudate formula-
tions. The index of performancewas obtained dividing thepartial RDDR value of felodipine
by the total RDDR value of formulation (felodipine plus copovidone) and then normalising
by the felodipine mass fraction.
RDDR (mg/min/cm2)
Time Felodipine Copovidone Total Index of
performancea
5% extrudate b20 min 0.17 (±0.02) 3.10 (±0.43) 3.26 1.0
50% extrudate b20 min 0.01 (±0.01) 0.25 (±0.01) 0.26 0.07
a Index of performance = (Partial RDDR felodipine / Total RDDR) / drugmass fraction.
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wavenumber. In the phonon-mode region, which results from inter-
molecular vibration, the two felodipine solid forms have different spec-
tra. The amorphous form spectrum is characterised by broad bands and
a continuous distribution of inter-molecular vibrations. In the crystal-
line form, sharp bands are present at 94 and 168 cm−1, due to the
quantised nature of the inter-molecular vibrations in the crystallinema-
terial. Thus, as reported in literature, [18,19] the phonon-mode region
represents an area of the Raman spectrumwhere it is possible to rapidly
distinguish between different solid forms.
3.3.2. Dissolution experiments
3.3.2.1. Averaged spectra: visual observation. Raman averaged spectra
for the 5% extrudate dissolution are presented in Figure S5. Examination
of the data does not reveal signiﬁcant changes in the spectra across
the entire period covered by these data (0–70 min), beyond a reduc-
tion in spectral intensity as the compact dissolves (as seen in the
optical images Fig. 1a). The ratio between the band of felodipine at
1650 cm−1 and that of copovidone at 1426 cm−1 is preserved through-
out the whole dissolution process. The Raman data essentially show
that felodipine and copovidone dissolve as a single entity rather than
as two separate components. This is in accordance with the RDDR
data, which illustrated that felodipine and copovidone dissolve with
the same rate. Therefore, it seems reasonable to suggest that the disso-
lution occurs from the molecular dispersion, with the overall behaviour
being dependent on the highly-soluble polymer.
Raman data of the 50% extrudate dissolution are shown in Fig. 2c
(ﬁnger print region) and d (phonon-mode region). Raman data show
that the spectrum does not change after 10 min (Fig. 2c, 10 min). Bands
relative to felodipine (1497 unit cm−1) and copovidone (1426 cm−1)
preserve the same ratio as in the spectrum of the compact ‘Dry’. Proceed-
ing with the analysis, after 65 min the intensity of copovidone band
at 1426 cm−1 appears to decrease in relation to that of felodipine at
1497 cm−1. A comparison with the ‘50% extrudate’ reference spectrum
reveals that the band at 1209 cm−1moves to slightly higherwavenumber
and that at 1497 cm−1 shifts to lower wavenumber. Figure S6 presents
‘difference spectra’ obtained by subtracting each averaged spectrum cor-
responding to each time point from the averaged spectrum of the com-
pact ‘Dry’, which was used in this case as reference spectrum.
‘Difference spectra’ between 65 and 316 min are characterised by nega-
tive bands at 1213 and 1492 cm−1 which correspond to the observed
shifts in Fig. 2c. These spectral shifts, which were previously denoted in
the visual observation of the raw ingredients spectra (Fig. 2a), unambigu-
ously indicate a strong correlation with the melt quenched (amorphous)
felodipine spectrum. It is likely that the faster dissolution of copovidone
with respect to felodipine from the drug:polymer dispersion leads to a
build-upof felodipine-rich amorphousmaterial on the surface of the com-
pact. The second important change occurs at 522 min. It is immediately
obvious that the averaged spectrum, after 522 min, corresponds to the
crystalline form of felodipine. When compared to melt quenched
felodipine, intra-molecular bands at 1202, 1484 and 1642 cm−1 shift to
lower wavenumber as well as they appear more intense and sharper.
These spectral changes were previously seen in Fig. 2a, revealing the for-
mation of crystalline felodipine. In the phonon-mode region (Fig. 2d),
well-deﬁned bands appear at 94 and 168 cm−1 after 522min, essentially
conﬁrming that amorphous felodipine begins to re-crystallise by this
time-point.
3.3.2.2. Averaged spectra: hierarchical agglomerative clustering (HAC). In
this sectionwe describe the use of an objective statistical analysismeth-
od to validate our subjective interpretation of the Ramandata. HAC is an
automated method of cluster analysis which calculates a distance, also
called ‘degree of dissimilarity’, between datasets, [34] including
Raman spectra [19]. The dendrogram obtained applying HAC to the 21
datasets is shown in Fig. 3. It is immediately evident that the overall
structure of the dendrogram is governed by two branches: spectra rela-
tive to the dissolution of the 5% extrudate with the 5% extrudate
and copovidone reference spectra, and spectra relative to the dissolu-
tion of the 50% extrudate with the remaining reference spectra (‘50%
extrudate’, ‘Melt quenched felodipine’ and ‘Felodipine as received’).
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Startingwith the branch of the 5% extrudate (LHS of plot), it is clear that
all the spectra relative to the dissolution can be classiﬁed by only one
cluster, as they are characterised by a high degree of similarity. This
trend is in a good agreement with the visual inspection of the data. As
noted earlier (Figure S5), signiﬁcant changes were not observed in the
spectra collected during the dissolution of the 5% extrudate compact.
Turning now to the other portion of the dendrogram, that relative to
the high drug-loaded formulation (RHS of plot), the presence of three
main clusters is immediately apparent. The ﬁrst includes ‘50% extrudate
dry’ and ‘50% extrudate 10 mins’ spectra,which showhigh similarity for
the 50% extrudate reference. The second cluster includes spectra
collected between 65 and 361 min, with the reference spectrum of
melt quenched (amorphous) felodipine. The last cluster includes
spectra collected from 522 min until the end of the experiment along
with the reference crystalline form of felodipine. Again, HAC conﬁrms
the visual inspection of the data, further demonstrating that two
transformations occur during the dissolution of the high drug-loaded
extrudate. The ﬁrst involves the conversion, via dissolution of
copovidone, ofmixed extrudate into felodipine-rich amorphousmateri-
al on the surface of the compact, indeed spectra collected between 65
and 361 min showed high similarity for the melt quenched reference
form. The other is the re-crystallisation of the amorphous felodipine
after 522 min. The ﬁrst transformation clearly explains the extremely
low partial RDDR values observed during the dissolution of the
50% extrudate. Copovidone cannot drive the dissolution of felodipine
due to an insufﬁcient polymer to drug ratio, resulting in formation of
felodipine-rich hydrophobic amorphous areas on the compact surface.
The disruption of the drug–polymer molecular dispersion system
through loss of copovidone then induces the drug re-crystallisation.
We conclude by stating that HAC widely validated all our subjective
observations of Raman data, adding to them an objective and impartial
component.
3.3.2.3. Multi-variate curve resolution (MCR).Wenowdiscuss the spatial-
ly resolved images of the crystallisation event observed for felodipine
present in the high drug-loaded formulation. Raman maps of the 50%
extrudate compact, obtained byMCR analysis of all the spectra collected
across the entire dissolution test (8092 spectra), are presented in Fig. 4.
MCR results can be presented as loadings which provide the spectral
phase of a speciﬁc component, and score plots that illustrate the spatial
distribution of the corresponding component. Three components were
required to deconvolute the mapped data. Comparison with the refer-
ence spectra unambiguously indicates that the ﬁrst component, MCR1,
can be associated with the extrudate and the second, MCR2, with the
crystalline form of felodipine. The excellent peak to peak correlation
between loadings and reference spectra conﬁrms the utility of MCR as
the statistical method to analyse spatial–temporal Raman data. MCR3
mostly picked up the background noise which characterises areas
where no compact is present. The score plots show that the extrudate
(MCR1) is homogenously distributed throughout the mapped compact
surface before immersion in water. The corresponding MCR2 score plot
indicated no traces of crystallinematerial in themapped area of the dry
compact. Then, the amount of crystalline felodipine (MCR2) rapidly in-
creases at the expense of the extrudate (MCR1) after 316min, and this is
reﬂected by the re-crystallisation kinetic shown in Fig. 5. It is interesting
to notice the complementarity of MCR1 and MCR2 score plots at 316
and 522 min, which denotes the coexistence of the extrudate and crys-
talline felodipine. Regions where the extrudate (MCR1) is present to its
maximumare indicated bywhite or red colour,while the corresponding
crystalline regions (MCR2) are characterised by blue colour, and vice
versa. The re-crystallisation of amorphous felodipine evidently occurs
at different rates in different regions of the compact surface, suggesting
that the crystal growth stage follows an initial stage of heterogeneous
nucleation. The nucleation/crystallisation process is likely linked with
loss of copovidone from the extrudate. It is well known that the poly-
meric carrier in amorphous solid dispersion formulations not only has
the function to improve the dissolution properties of poorly soluble
drugs, but also inhibits crystal growth of the amorphous form, via
antiplasticisation effect or hydrogen-bonding interactions between
drug and polymer [25]. It is therefore likely that loss of copovidone dur-
ing the ﬁrst 316 min, previously observed in the averaged Raman spec-
tra (Fig. 2c), promotes heterogeneous nucleation followed by
crystallisation of felodipine-rich amorphous material in the compact
surface.
At the end of the experiment, after 1705min, the residue of the com-
pact was recovered and analysed using Raman and XRPD. MCRmaps of
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the core (after breaking the compact into two parts) and surface are
presented in Figure S7. Two components were required in this case to
deconvolute the data, with the ﬁrst component (MCR1) corresponding
to amorphous felodipine and the second (MCR2) corresponding to crys-
talline felodipine. The score plots show that felodipine is predominantly
amorphous in the core, whereas in the surface is completely crystalline.
Raman data suggest that the crystallisation begins from the compact
surface exposed to water and propagates towards the core, where
only a little amount of crystalline drug was found. The XRPD pattern
of the compact after grinding it into powder can be seen in the supple-
mentary material (Figure S1). The pattern appears as a combination of
sharp bands, typical of the crystalline materials, and a broad halo
which characterises the amorphousmaterials. XRPD therefore indicates
that felodipine sampled from the entire compact after the dissolution
experiment is a mixture of crystalline and amorphous. This is in full
agreement with Raman results, which indicated a crystalline outer sec-
tion and an amorphous inner section of the compact.
4. Conclusions
We have demonstrated that Raman imaging offers an appropriate
method to investigate in real time the dissolution process and provides
additional spatial information regarding the dissolution mechanisms
that underpin amorphous solid dispersions, when compared to USP dis-
solution testing and classical Raman spectroscopy.We have successfully
employed a RDDR method which allows us to track the dissolution
proﬁles of both drug and polymer simultaneously and ultimately to
measure the dissolution performance in multi-component systems.
We have widely consolidated the previous ﬁndings described in
Langham et al. work, [8] by generating spatially-resolved MCR Raman
maps of the re-crystallisation of felodipine present in the 50% extrudate
formulation. MCR Raman maps showed that amorphous felodipine
crystallises at different rates in different regions of the compact surface,
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indicating that crystallisation follows an initial stage of heterogeneous
nucleation. The re-crystallisation of felodipine leads to large variations
in the Raman spectrum and thus it is readily detectable. In particular
in the phonon-mode region, the spectrum of the crystalline form is
characterised by clear and sharp bands, while that of the amorphous
form by a broad halo. The nucleation/crystallisation process proceeds
from the surface towards the core and is likely linked to loss of
copovidone from the extrudate. For the 5% drug-loaded extrudate,
Raman spectroscopy did not show any signiﬁcant changes in the spectra
collected during the course of the dissolution test. This demonstrates
that felodipine and copovidone dissolve as a single entity, in accordance
with the RDDR data.
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ABSTRACT: Real-time in situ Raman mapping has been
employed to monitor, during dissolution, the crystallization
transitions of amorphous bicalutamide formulated as a
molecular dispersion in a copovidone VA64 matrix. The
dissolution performance was also investigated using the
rotating disc dissolution rate methodology, which allows
simultaneous determination of the dissolution rate of both
active ingredient and polymer. The dissolution behavior of two
bicalutamide:copovidone VA64 dispersion formulations, con-
taining 5% (w/w) and 50% (w/w) bicalutamide, respectively,
was investigated, with the aim of exploring the eﬀect of increasing the bicalutamide loading on the dissolution performance.
Spatially time-resolved Raman maps generated using multivariate curve resolution indicated the simultaneous transformation of
amorphous bicalutamide present in the 50% drug-loaded extrudate into metastable polymorphic form II and low-energy
polymorphic form I. Fitting a kinetic model and spatially correlating the data extracted from the Raman maps also allowed us to
understand the re-crystallization mechanisms by which the low-energy form I appears. Form I was shown to crystallize mainly
directly from the amorphous solid dispersion, with crystallization from the metastable form II being a minor contribution.
KEYWORDS: bicalutamide, poorly soluble drugs, amorphous solid dispersions, dissolution, solid-state transformations,
polymorphic changes, Raman mapping, multivariate curve resolution, kinetic modeling, spatial correlations
1. INTRODUCTION
An increasing number of drug candidates emerging from
pharmaceutical development pipelines are characterized by
poor dissolution and solubility proﬁles.1 In light of this, there is
a requirement for the pharmaceutical industry to develop
innovative formulations to achieve the desired oral bioavail-
ability and in vivo eﬃcacy. A common strategy to improve the
apparent solubility of poorly soluble drugs is to generate the
amorphous form of the drug.2,3 Amorphous solids consist of
disordered arrangements of molecules and do not possess a
distinguishable crystal lattice. As a result, the dissolution rate of
the amorphous form is higher than in its crystalline
counterpart.4 However, the amorphous form is thermodynami-
cally unstable and therefore tends to convert into the crystalline
form over time, thereby compromising the drug bioavail-
ability.5,6 An increasingly popular strategy to stabilize the
amorphous state is the use of solid dispersions and solid
solutions in which the drug is molecularly mixed with a water-
soluble or water-swellable carrier, typically via hot melt
extrusion or spray drying.7,8
Although the physical stability of amorphous solid dispersion
formulations has been widely probed, particularly focusing on
the use of diﬀerent polymers to inhibit drug re-crystalliza-
tion,9,10 few studies have been conducted speciﬁcally to
understand their performance in a dynamic aqueous environ-
ment.11,12 Drug release from amorphous solid dispersions has
been classiﬁed as polymer-controlled or drug-controlled,
depending on the chemical nature of the components and on
the carrier-to-drug ratio.13 Several processes have been
demonstrated to be involved during the dissolution of
amorphous solid dispersion formulations. The nucleation and
crystallization of the drug either in the solid state or from a
super-saturated state in solution, the generation of nano- and
microparticles suspended in the dissolution medium, and the
behavior of the carrier itself can signiﬁcantly aﬀect the overall
dissolution performance.11,14−16 Due to the number of
processes involved, the dissolution mechanisms of amorphous
solid dispersions are extremely diﬃcult to deconvolute.
Classical methods of investigating drug release, such as the
use of USP dissolution apparatuses, involve dissolving a tablet
in water or other biorelevant media and measuring the drug
content in solution as a function of time using UV spectroscopy
or HPLC.17 Data are not collected directly from the dosage
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form itself, and therefore solution-based methods do not oﬀer
any chemical or spatially resolved information on potential
changes in the solid form during dissolution (e.g., recrystalliza-
tion of the amorphous form, polymorphic transformations, or
formation of hydrate states), which may be extremely important
for developing reliable medicines with well-understood
dissolution performance.
Given the limitations of classical solution-based methods,
there have been a number of attempts to provide a full and
clear picture of the drug release. Methods have included
confocal ﬂuorescence microscopy,18 mid-infrared (mid-IR),19,20
near-infrared (near-IR),21,22 and magnetic resonance imaging
(MRI).23,24 The ﬁrst three oﬀer some chemical information,
while MRI provides relatively low chemical speciﬁcity, but it is
the only one of these methods that can provide three-
dimensional information. Although near-IR and mid-IR are
characterized by the highest chemical selectivity among the
techniques mentioned (“multivariate data”, one spectrum per
pixel), their radiation is strongly absorbed by water molecules,
which is not ideal for imaging in aqueous environments but can
be worked around by integrating only bands for each
component which appear distant from the absorption of
water, as Kazarian et al. have shown.19,20,25
Raman mapping has been demonstrated to be a useful tool to
investigate the distribution of multiple components in solid
dosage forms during dissolution.26,27 In a recent work, Strachan
et al. employed coherent anti-Stokes Raman scattering (CARS)
microscopy to image in situ the solid-state changes during
dissolution in oral dosage forms contaning theophylline
anhydrate.28 In CARS, compared to spontaneous Raman
spectroscopy, two pulsed lasers are focused on the sample to
generate a coherent anti-Stokes signal.28 CARS requires very
specialized equipment, while laboratory-based Raman requires
only one laser and is therefore much more readily accessible.
One of the key advantages of Raman spectroscopy is the access
to the low-wavenumber region that has been demonstrated to
be extremely sensitive to diﬀerences between amorphous and
crystalline forms and among diﬀerent polymorphic
forms.12,29,30 In addition, Raman spectroscopy can, in principle,
achieve a spatial resolution at the sub-micrometer level, while
the maximum spatial resolution possible with the IR and near-
IR radiations is diﬀraction-limited to 0.5 and 1−2 μm,
respectively, although in practice it has been reported that
the maximum spatial resolution for IR is 4 μm and that for
near-IR is 6 μm.26 In comparison to mid-IR and near-IR,
Raman spectroscopy is relatively insensitive to water, oﬀering
therefore some potential advantages over the other state-of-the-
art methods for investigating drug release from tablets in water.
Conventional Raman spectroscopic mapping was employed
in the present work to deconvolute the dissolution mechanisms
of bicalutamide:copovidone VA64 amorphous solid dispersions.
Bicalutamide (Figure 1) is an important front-line treatment for
prostate cancer. It is a non-steroidal anti-androgen that has an
extremely low aqueous solubility (lower than 5 mg/L) and
belongs to class II (low solubility, high instestinal permeability)
of the biopharmaceutics classiﬁcation system.31,32 Bicalutamide
exists in two known crystalline phases (polymorphs I and II):
form I is currently marketed, whereas form II is metastable and
therefore can convert into form I in appropriate conditions.33
The polymorphic forms of bicalutamide have been thoroughly
characterized by Vega et al.,34 who reported single-crystal X-ray
stuctures and showed that low-energy form I relates monotropi-
cally to metastable form II; i.e., under standard conditions form
I is more stable than form II at all temperatures. Due to the
diﬀerent crystal structures, forms I and II have diﬀerent
physicochemical properties. The melting points have been
found by Vega et al. to be 192 °C for form I and 189 °C for
form II, and form II has been demonstrated to be 2.4 times
more water-soluble than form I at room temperature.34
Researchers have also characterized forms I and II using
Raman spectroscopy. They observed several diﬀerences
between the two polymorphic forms in the ﬁngerprint region
because the two polymorphs contain diﬀerent conformations of
bicalutamide. Copovidone VA64 is a highly water-soluble
polymer (solubility higher than 100 mg/L) that has been
widely used to prepare single-phase amorphous solid
dispersions of poorly soluble drugs.11,12,35
The aim of the work presented below was to investigate the
eﬀects of increasing the amount of bicalutamide on the overall
performance in water of the solid dispersion. For this reason,
two bicalutamide:copovidone VA64 dispersions containing 5%
(w/w) and 50% (w/w) bicalutamide were prepared. The
rotating disc dissolution rate (RDDR) test, which is an
extension of the standard intrinsic dissolution rate (IDR) test,
was employed. The IDR test is an important biopharmaceutics
screening tool to measure the dissolution rate normalized to the
exposed surface area of a material.36 Formally, IDR applies only
to pure drug substances. By coupling an IDR apparatus to a
HPLC system, the partial RDDR of both the drug substance
and the excipients can be measured and compared for diﬀerent
formulations. The RDDR test has been recently demonstrated
to be a useful tool for investigating the dissolution behavior of
amorphous solid dispersions.12 Real-time and in situ Raman
mapping was also employed to monitor the solid-state
transformations that occur during the dissolution of amorphous
bicalutamide dispersions.
2. EXPERIMENTAL SECTION
2.1. Materials and Methods. Crystalline bicalutamide
form I was provided by AstraZeneca (Macclesﬁeld, United
Kingdom). The polymorphic purity of form I was veriﬁed by
Raman spectroscopy and XRPD. Copovidone (Kollidon VA64)
was supplied by BASF (Ludwigshafen, Germany) and used as
received, without any further puriﬁcation.
2.2. Preparation of Amorphous Form and Crystalline
Bicalutamide Form II. The amorphous form of bicalutamide
was obtained by heating form I to 200 °C and quench-cooling
the melt at room temperature. Raman spectroscopy and XRPD
conﬁrmed the formation of the amorphous form and the
absence of crystalline material. Crystalline bicalutamide form II
was produced according to patent, by heating the amorphous
form to 175 °C.37 Raman spectroscopy and XRPD conﬁrmed
the formation of polymorphic form II. Raman spectra and
XRPD patterns from forms I and II and the amorphous form of
bicalutamide are consistent with those previously reported by
other workers.31−34
2.3. Preparation of Bicalutamide:Copovidone Amor-
phous Solid Dispersions. A co-rotating twin-screw extruderFigure 1. Molecular structure of bicalutamide.
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(Thermo Scientiﬁc HAAKE MiniLab II) was used to prepare
the amorphous solid dispersions of bicalutamide and
copovidone (5% and 50% w/w bicalutamide). Bicalutamide
as received (form I) and copovidone were pre-mixed for 20 min
in a Turbula T2F mixer (Willy A. Bachofen AG Mashinefabrik).
The physical mixture was extruded at a temperature of 170 °C
and a screw speed of 150 rpm. The materials were then cooled
to room temperature and manually milled with a T&G
CrushGrind mill to ﬁne powders. Raman spectroscopy and
XRPD conﬁrmed the formation of the amorphous form and the
absence of crystalline material.
2.4. X-ray Powder Diﬀraction (XRPD). XRPD patterns
were obtained using a PANalytical CubiX PRO diﬀractometer
(λ = 1.5418 Å). Samples were spun at 30 rpm and measured
over the scan range from 2° to 40° 2θ, with a 25 s exposure per
0.02° 2θ increment. The X-rays were generated by a copper
long-ﬁne focus tube operated at a voltage of 45 kV and a
current of 40 mA.
2.5. Rotating Disc Dissolution Rate (RDDR) Measure-
ments. RDDRs were determined using the “Woods apparatus”
rotating disc system. The die cavity has a diameter of 8 mm
with an exposed surface area of 0.5 cm2. Testing was carried out
in a Sotax AT7 semi-automated dissolution bath. About 250 mg
of each sample was compressed under a force of ca. 20 kN for 1
min using a Specac manual hydraulic press. Compressed discs
were immersed in 500 mL of dissolution medium (pH 6.8
blank fasted state simulated intestinal ﬂuid) at 37 °C (±0.5),
and the rotational speed was set to 100 rpm. Samples were
taken manually at regular time intervals over 120 min and then
analyzed by reverse-phase high-performance liquid chromatog-
raphy (RP-HPLC). All experiments were carried out in
duplicate. All HPLC measurements were carried out on an
HP Agilent 1100 instrument, equipped with an Agilent PLRP-S
300 Å/3 μm/50 mm column (polystyrene/divinylbenzene
stationary phase). The ﬂow rate was 1 mL/min, the column
temperature was 40 °C, and the UV detection wavelength was
set to 210 nm. A linear gradient elution was used starting at
40% acetonitrile/60% deionized water and ending at 70%
acetonitrile/30% deionized water after 2 min, with chromato-
grams collected for 3.5 min. A series of standard solutions were
prepared in the relevant medium to generate a standard curve
covering the concentration range of the dissolved sample. For
each experiment, standards were analyzed alongside the RDDR
samples. The partial RDDR of both drug and polymer was
calculated using linear regression analysis. The partial RDDR of
the material was obtained from the slope of the regression line.
For the 5% extrudate RDDR was calculated using the ﬁrst 20
min time period, where the trend is linear. For the 50%
extrudate RDDR was obtained using the time interval between
40 and 120 min, where the trend of both bicalutamide and
copovidone is linear, in accordance with Pharmacopoeia
procedures.36,38
2.6. Raman Spectroscopic Mapping. The dissolution
performance of compressed extrudate powders was inves-
tigated. Circular compacts with a diameter of 5 mm and a
weight of 50 mg were prepared with a Specac manual hydraulic
press using a force of ca. 20 kN. The dissolution test was carried
out using a ﬂow cell previously described by Tres et al.12
Deionized water was used as dissolution medium with the ﬂow
rate set to 5 mL/min. Data were acquired as a function of time
using a HORIBA Jobin Yvon LabRAM HR confocal micro-
scope/spectrometer. The system is equipped with an
automated xyz stage (Mar̈zhaüser) to allow mapping. All
samples were illuminated with a near-IR (785 nm) laser.
Spectra were collected using a 50× objective (Olympus BX51)
and a 300 μm confocal pinhole. All experiments used a 600
lines/mm rotatable diﬀraction grating along a path length of
800 mm to simultaneously scan a range of frequencies, and the
spectra were detected using a SYNAPSE CCD detector (1024
pixels). The system was calibrated before collecting spectra
with the Rayleigh line at 0 cm−1, as well as using a standard
silicon band at 520.7 cm−1. For the raw materials, spectra were
acquired in the wavenumber range from 30 to 4000 cm−1, with
the lower limit corresponding to the cutoﬀ of the Rayleigh
rejection ﬁlter. During the dissolution tests, prior to each map
being collected, the z-axis position of the sample (i.e., level of
sample perpendicular to optical axis) was adjusted to maximize
the Raman signal. The time frames, dimensions of the mapped
areas, and acquisition times for the 5% and 50% experiments
are depicted in Table 1.
For Raman data analysis two approaches were adopted. First,
to rapidly evaluate any spectral changes occurring during the
dissolution tests, all the spectra from each map were integrated
to generate a single averaged spectrum corresponding to each
time point. Second, to obtain spatial information for the 50%
extrudate compact dissolution experiment, false color maps
were generated using multivariate curve resolution (MCR). In
order to monitor changes as a function of both time and xy-
position, a single data matrix was generated which includes all
the spectra collected across the entire dissolution experiment
time scale (16 184 spectra). Stastistical analyses were
performed using R software, which is open-source and well-
documented software for statistical computing and graphics.39
For MCR, the separate alternating least-squares algorithm
(ALS)-MCR library was employed, with raw data being scaled
prior to analysis using variance-scaling and mean-centering
standard methods. All the raw data along with the numerical
routines written in the R language are included in the
Supporting Information for reference. An interested reader
should therefore be able to reproduce all the data analysis
presented in this paper.
2.7. Optical Imaging. A CoolSNAP-Pro CF camera
(Media Cybernetics) equipped with a Nikon AF Micro
NIKKOR 60 mm lens was employed to collect the photo-
graphic images during the dissolution of the extrudate
formulations. The same ﬂow cell experimental conditions
previously described for the dissolution tests using Raman
mapping were employed. For the dissolution test of the 50%
extrudate, the “imgThreshold” function part of “biOps” package
in R was employed to count the number of pixels above a pre-
deﬁned color threshold of the images collected during the
Table 1. Experimental Details for Raman Map Acquisition
during the Dissolution Experiments of the 5% and 50%
Extrudates
5% extrudate 50% extrudate
time frame, minutes 80 2946
total no. of maps 7 14
total no. of spectra per map 121 1156
acquisition time per spectrum, seconds 2 2
acquisition time per map, minutes 8 90
mapped area, μm 500 × 500 500 × 1000
grid spacing x-axis, μm 50 15
grid spacing y-axis, μm 50 30
Molecular Pharmaceutics Article
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dissolution experiment. This allowed us to focus only on the
pixels of the compact and build a trend which shows how the
surface area of the compact changes as a function of time. An
example of a thresholded image can be seen in Figure S1 in the
Supporting Information.
3. RESULTS AND DISCUSSION
3.1. Optical Imaging and Rotating Disc Dissolution
Rate. Before commencing a full discussion of the results, a key
point needs to be made. Extrinsic factors such as hydro-
dynamics (e.g., disc rotation speed and ﬂuid ﬂow) and test
conditions (e.g., temperature and pH of the medium) certainly
diﬀer between the RDDR test and Raman/optical imaging
experiments. The primary aim of the present work is simply to
investigate whether or not the combination of these techniques
can provide a full and clear understanding of the bicalutamide
release from solid dispersions.
Figure 2 shows the optical images observed during the
dissolution under ﬂow of the 5% and 50% drug-loaded
extrudates. It is important to note the diﬀerent time scales
between the two experiments which is due to the diﬀerence in
dissolution rates. The 5% extrudate formulation was completely
dissolved after approximately 85 min, whereas the 50% drug-
loaded extrudate remained intact after 3000 min. The optical
imaging experiment does not provide any chemical information,
but clearly shows that the two diﬀerent drug loadings behave
very diﬀerently in aqueous media. The 5% extrudate compact
undergoes erosion and is completely dissolved by 85 min from
the beginning of the experiment. The 50% extrudate compact
swells during the ﬁrst 600 min of the dissolution experiment
and remains intact even after 3000 min. The initial swelling is
conﬁrmed by the kinetic trend generated by plotting the surface
area of the compact vs time (Supporting Information, Figure
S2). The swelling of a high drug-loaded extrudate has been
previously observed for amorphous solid dispersions of
felodipine and copovidone.11,12
RDDR measurements were then carried out in order to
determine the amount of drug and polymer released into
solution as a function of time. The RDDR method, as described
previously,12 uses HPLC to separate the active ingredient from
the polymer and track the dissolution trend of both entities.
The dissolution proﬁle of the polymeric carrier provides
valuable information in the case of binary systems, as the carrier
can signiﬁcantly aﬀect the dissolution performance of the
poorly soluble active ingredient.2,3 The dissolution rate of the
polymer allows us to calculate an index of performance for the
formulation, which illustrates how the drug and the polymer
behave during the course of the dissolution experiment. The
index of performance was deﬁned by dividing the partial RDDR
of bicalutamide by the total RDDR of the fomulation
(bicalutamide and copovidone) and then normalizing by the
bicalutamide mass fraction. The equation to calculate the index
of performance is reported in Table 2, along with the RDDR
values for both 5% and 50% extrudates. Dissolution trends of
the extrudates and pure crystalline form of bicalutamide are
presented in the Supporting Information (Figures S3 and S4).
For the 5% extrudate, the partial RDDR value for
bicalutamide is 0.24 mg/(min·cm2), and that for copovidone
is 4.85 mg/(min·cm2). Compared to the IDR of pure crystalline
bicalutamide (0.003 mg/(min·cm2), Figure S3), bicalutamide
present in the 5% extrudate shows an 80-fold increase in
dissolution rate. The index of performance results in a value
close to unity, indicating that the two components have very
similar dissolution trends and thus they dissolve simultaneously
from the molecular dispersion. Given the low water solubility of
bicalutamide, the overall behavior of the 5% bicalutamide-
loaded solid dispersion is clearly dominated by water-soluble
copovidone. Considering the 50% extrudate formulation, it is
immediately apparent that the partial RDDR values of both
bicalutamide and copovidone are much lower than those
observed for the 5% extrudate. The partial RDDR of
bicalutamide (0.008 mg/(min·cm2)) is comparable with the
IDR of pure crystalline bicalutamide (0.003 mg/(min·cm2)).
Optical images and RDDR data therefore suggest that the
dissolution behavior of the 50% extrudate is dominated by the
physicochemical properties of bicalutamide. The low water
solubility and high hydrophobicity of the drug prevents the
wetting and water uptake of the compact due to an insuﬃcient
ratio of copovidone to bicalutamide at the diﬀusion layer.32 As a
result, the dissolution of both bicalutamide and copovidone is
very limited.
Summarizing, the overall dissolution performance of the 5%
drug-loaded extrudate is clearly polymer-dependent, with
bicalutamide dissolving simultaneously with the hydrophilic
polymer. For the 50% extrudate, optical images and RDDR
measurements indicate that the behavior in water of the
amorphous solid dispersion is dependent on the physicochem-
Figure 2. Optical images collected through the dissolution experiment
for the 5% (a) and 50% (b) extrudate formulations.
Table 2. Partial RDDR Values along with the Index of Performance for 5% and 50% Extrudates
RDDR, mg/(min·cm2)
drug loading bicalutamide copovidone total index of performancea
5% 0.24(±0.005) 4.85(±0.127) 5.09(±0.127) 0.94(±0.030)
50% 0.008(±0.001) 0.025(±0.001) 0.033(±0.001) 0.48(±0.064)
aThe index of performance was calculated by dividing the partial RDDR of bicalutamide by the total RDDR (bicalutamide plus copovidone) and
then normalizing by the bicalutamide mass fraction: index of performance = (partial RDDR bicalutamide/total RDDR)/drug mass fraction.
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ical properties of the hydrophobic bicalutamide. However, this
does not clearly explain which processes occur during the
course of the dissolution test, as data are not being collected
directly from the dosage form, nor do the RDDR data provide
any direct chemical explanation of the diﬀerences in dissolution
rates between the 5% and 50% compacts. For this reason, real-
time in situ Raman spectroscopic mapping along with oﬀ-line
XRPD were used to investigate the samples.
3.2. Raman Spectroscopy. 3.2.1. Raman Spectra of
“Dry” Raw Materials. Raman spectra of the dry raw materials
are available in Figure 3. The three solid forms of bicalutamide
present spectra with clear and obvious diﬀerences. Considering
the region between 1055 and 1724 cm−1 (Figure 3a), the
diﬀerences between the crystalline forms are reasonable, given
that they are known to be conformational polymorphs. The
band deriving from the stretching mode of the carbonyl group
moves to higher wavenumber in form II (1709 cm−1)
compared to form I (1686 cm−1). Due to the diﬀerent
conformation of forms I and II, the oxygen of the carbonyl
group is involved in diﬀerent intramolecular hydrogen bond
interactions, which lead to the observed peak shift. Atoms are
also involved in intermolecular interactions. The hydrogen
bonding between the N−H of the amide group and one of the
oxygen atoms of the sulfonyl group determines the formation
of a dimer in the molecules of form II. This interaction would
explain why an intense single band at 1517 cm−1 corresponding
to the N−H bending and C−N stretching modes of the amide
group is replaced by three peaks with inferior intensity
appearing at 1428, 1493, and 1520 cm−1 in form II. In
addition, the particular conformation of form II enables π−π
stacking interactions between the two rings. Due to this extra
interaction form II presents a small peak at 1579 cm−1 (ring
stretching mode) which is not present in the spectrum of form
I. The schematic of the structural conformations of forms I and
II is shown in the Supporting Information (Figure S5).
The amorphous (melt quench) form presents a spectrum
more similar to that of crystalline form II than form I (e.g.,
bands at 1428 and 1493 cm−1 are present in the amorphous
spectrum and the form II spectrum but not in the form I
spectrum). This spectral similarity with form II suggests that
the molecular conformation of the amorphous form is more
similar to that of the metastable form II than that of highly
stable form I. The amorphous form also exhibits greater peak
widths than for the crystalline forms I and II, which is expected
due to the molecular disorder inherent in the amorphous form
but not present in the two crystalline forms. The spectra for the
two extrudates are at ﬁrst approximation simply a linear
combination of the spectra for the amorphous drug and the
polymer. A detailed inspection reveals some subtle diﬀerences,
including a shift of the bands of the N−H bending mode at
1490 and 1516 cm−1 for the 50% extrudate, and at 1490 cm−1
for the 5% extrudate. These likely arise from the intermolecular
hydrogen-bonding interactions between the amide of bicalut-
amide (N−H, proton donor) and the oxygen atoms of the
carbonyl groups of copovidone (proton acceptor).32
In the low-wavenumber region between 40 and 400 cm−1
(Figure 3b), the two crystalline forms of bicalutamide present
clear, well-resolved bands, and the spectra are easily distinguish-
able from each other. This is wholly consistent with previous
work by ourselves and other workers on low-wavenumber
Raman spectroscopy applied to polymorphs.29,30 The melt-
quenched bicalutamide, the two extrudates, and the pure
polymer exhibit the typical broad boson peak at low
wavenumber expected for amorphous materials,29,30 with the
diﬀerences between these amorphous forms being subtle in this
spectral region.
In summary, the various pure forms of bicalutamide and the
extrudates can be distinguished using the reference Raman
spectra, especially the region from 1055 to 1724 cm−1. The low-
wavenumber data (40−400 cm−1) allow the crystalline forms to
be distinguished both from each other and from the various
amorphous forms. Bicalutamide form II and the amorphous
form present similar spectra in the region between 1055 and
1724 cm−1, and all amorphous forms (pure bicalutamide and
the extrudates) exhibit similar spectra at low wavenumber.
3.2.2. Raman Spectroscopic Mapping. In order to gain
good chemical and spatial detail on the dissolution processes in
the compacts, Raman mapping was undertaken as a function of
time in the region between 1055 and 1724 cm−1. The data for
the 5% extrudate are presented in the Supporting Information
(Figure S6). No changes were observed during the dissolution
beyond a reduction in the overall Raman intensity, which may
result from the presence of the medium, loss of focus, and the
surface changing from ﬂat and even to relatively rounded and
uneven as the dissolution proceeds. These factors will reduce
the amount of sample in the Raman confocal plane and lead to
a reduction in signal.
For the 50% compact, analysis indicated that signiﬁcant
changes occurred in the Raman spectra as the dissolution
progressed. A univariate analysis (e.g., one peak intensity) is
diﬃcult due to the similarity in the bicalutamide spectra already
noted between forms II and the amorphous form, as well as due
Figure 3. The 1055−1724 cm−1 (a) and 40−400 cm−1 (b) regions of
the Raman spectra of “dry” raw materials. Data were variance-scaled
and mean-centered before plotting. Y-oﬀsets have been applied for
presentation purpose and diﬀer between the two panels.
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to the multicomponent nature of the formulation. To spatially
and spectrally deconvolute the changes in the patterns for the
50% compact, we therefore employed MCR, which is a very
well-established component analysis method and has been
employed to resolve ToF-SIMS, IR, near-IR, and Raman data
from pharmaceutical samples.40−43 MCR requires input of a
body of spectral data in a matrix format, each spectrum being
tagged with a set of labels (e.g., x,y position), which is resolved
by the MCR method into a number of components. The only
user input is the requested number of components; i.e., MCR is
Figure 4. MCR Raman maps collected as a function of time through the dissolution experiment for the 50% extrudate formulation. Here presented
are the loadings (with reference spectra in black) and the scores plots for the ﬁrst three MCR components. White/red colors indicate areas where a
particular phase is present to its maximum, while black/blue colors represent areas where it is present at its minimum. Areas with variable weighting
of that phase are indicated by a continuum of white-red-orange-yellow-cyan-blue-black colors. Raw data were variance-scaled and mean-centered
before MCR analysis was performed.
Molecular Pharmaceutics Article
DOI: 10.1021/mp500829v
Mol. Pharmaceutics 2015, 12, 1512−1522
1517
D
ow
nl
oa
de
d 
by
 5
.6
7.
14
.9
7 
on
 S
ep
te
m
be
r 1
5,
 2
01
5 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Ap
ril
 21
, 2
01
5 | 
doi
: 1
0.1
021
/m
p50
082
9v
a model-free method. Outputs from MCR include loadings
(which in the present case correspond to Raman spectra of the
resolved components) and scores (which provide the spectral
weighting of a given component for the relevant unique set of
labels). Labels typically comprise x and y positions, but there is
no reason why they cannot include more information. To
include time in our analysis, we simply concatenated all xy
spectral maps together and included a time label for each input
spectrum, in addition to the usual x and y labels. Our MCR
results are reproducible for multiple runs, despite a diﬀerent
randomly generated set of numbers being employed as a
starting model for each run. This provides conﬁdence that our
results are robust, which is important in the context of the well-
known rotational ambiguities present in the MCR method-
ology.44,45 In our analysis, trial runs indicated that a suitable
choice for number of components was three, and intensity
thresholding was employed so that only the spectra from the
compact were included in the analysis; i.e., the surrounding
solution was excluded.
The results of our MCR analysis are presented graphically in
Figure 4. Note that half the maps are shown for reasons of
space, i.e., every second one starting at 9 min; however, the
analysis included all maps, and the remaining time-point maps
can be found in Supporting Information (Figure S7).
Comparison of MCR loadings with reference spectra clearly
indicates that the data have been resolved into components
which correspond remarkably well with crystalline bicalutamide
forms I and II, and the bicalutamide:copovidone extrudate. The
variation in the scores as a function of space (within each map)
and time (between maps, vertically descending) indicates that
the starting materialthe extrudatedecreases in weighting as
time passes. In the early stages of the experiment, crystalline
form II appears and grows in weighting, while after
approximately the 592 min time point the weighting of form
I increases. Form I continues to increase in weighting at the
expense of both the extrudate and form II, with the latter
reducing in weighting after 889 min. The crystallization of
amorphous bicalutamide into form II has been reported
previously,33,34 and the hypothetical sequence amorphous →
metastable form II → stable form I is in accord with the long-
standing Ostwald’s rule of stages. We note, however, that the
results presented so far do not allow us to distinguish between
the linear pathway amorphous → form II → form I and an
alternative parallel pathway whereby amorphous→ form II and
amorphous → form I occur independently, with the
crystallization to form I having a longer induction period
than the crystallization to form II.
At the end of the experiment, the remaining compact was
removed from the ﬂow cell, cut through the center, and
analyzed by Raman spectroscopy and visually. Data are
presented in Figure 5. The recrystallization of the drug to a
mixture of forms I (dominant at the end of the experiment) and
form II occurs from the outside of the compact, with the
interior being unchanged bicalutamide:copovidone extrudate.
XRPD data from a powdered compact (Supporting Informa-
tion, Figure S8) are in full accord with these ex situ Raman data.
The Raman mapping results, for the 50% extrudate,
considered alongside the RDDR analysis, clearly indicate the
hydrophilic polymer preferentially dissolves from the exterior of
the compact. This leaves a drug-rich (therefore hydrophobic)
shell on the outside of the compact, which is initially
amorphous. The decrease in polymer concentration and
increase in (amorphous) drug naturally leads to a crystallization
of the drug. To address directly the question of the
crystallization mechanism, we undertook a kinetic analysis of
the crystallization processes, which we now outline.
Figure 5. MCR Raman maps of the inner and outer sections of the compact. Here presented are the loadings (with reference spectra in black) and
the scores plots of the ﬁrst three MCR components, with data being variance-scaled and mean-centered prior to plotting.
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While the MCR results are very useful for gaining a
qualitative understanding of the spectral changes occurring,
they are less useful for a quantitative analysis as the proportion
of the spectral weighting cannot be related to the actual
concentration without suitable standards. We therefore under-
took a simple three-level classiﬁcation procedure and assigned
each spectrum at every xy time point to extrudate, form I, or
form II, based upon the calculated correlations between the
three reference spectra and the relevant experimental spectrum
with its unique xy time labels. To remove the eﬀect of the
compact expanding/moving, the results are reported as
percentages. Only the area corresponding to the compact was
included in this analysis.
Results for the kinetic analysis are presented in Figure 6 both
for the classiﬁcation (i.e., experimental data) and for the kinetic
model. The kinetic model included ﬁrst-order rate constants for
the processes A → II, A → I, and II → I, which were adjusted
according to the least-squares method until an optimized model
was arrived at. To summarize, the rates of conversion A → II
and A → I are similar, both being around 10−3 min−1. The rate
of conversion II → I is found to be approximately an order of
magnitude lower, and therefore the analysis distinctly points
toward a mixed crystallization mechanism. The appearance of
form I directly from the amorphous form is favored compared
to the conversion II → I. The robustness of the analysis was
cross-checked by constraining the rate constant for A→ I to be
0 min−1, and the resulting model (Figure S9) is clearly far
inferior to the unconstrained model in which the rate constant
for A→ I is found to be of order 10−3 min−1. We can therefore
conclude that the parallel crystallization mechanism is
dominant compared to the serial one in terms of kinetics.
Spatial correlations were then employed to fully understand
the re-crystallization mechanism by which form I appears.
Theory suggests that the serial route (A → II → I) should
involve a strong spatial correlation between form II and form I,
and a strong anti-correlation between amorphous and form I.46
The parallel route (A → II and A → I) is expected to be
random nucleation and growth of both forms II and I from
amorphous. Each nearest “tablet” neighbor pixel to each
“tablet” pixel has been classiﬁed (A/II/I) and counted as a
function of time, so that transformations in polymorph can be
monitored. To model the parallel route (random nucleation of
forms I and II) a similar analysis was performed, diﬀering only
in that the neighboring pixels were replaced one-for-one by
pixels selected randomly from across the compact (excluding
the speciﬁc pixel of interest) at the relevant time point. The
number of pixels with neighbors of which sort they are (A/II/I)
at each time point is presented in Figure 7. The experimentally
determined number of neighbors of each type is in good
agreement with the modeled “random nucleation”, i.e., in
accord with a predominantly parallel crystallization mechanism
(A → II and A → I rather than A → II → I).
To summarize, both kinetic modeling of the classiﬁcation
data and detailed spatial analysis point toward the predom-
inance of a non-Ostwald “parallel” crystallization mechanism, in
which crystalline form I bicalutamide nucleates directly from
the amorphous extrudate rather than from form II. Given that
the amount of form II decreases after 889 min the pathway II
→ I clearly has some importance, but the main route for
formation of form I appears to be direct random nucleation
from the amorphous extrudate.
4. CONCLUSIONS
We have employed optical observation, rotating disc dissolution
rate, and real-time Raman mapping to investigate the
dissolution of bicalutamide:copovidone compacts for 5% and
50% drug loadings. The 5% sample dissolution mechanism
involves the hydrophilic polymer and the hydrophobic drug
Figure 6. Experimental (dotted plots) and ﬁtted (line plots) data of the three-step kinetic model. The induction period represents the ﬁrst 360 min
of the experiment. Estimated uncertainties are shown in parentheses.
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dissolving at the same rate, and the compact is completely
dissolved after 85 min. In contrast, the 50% sample remains
intact even after 3000 min. This is shown to be due to
preferential dissolution of the hydrophilic polymer, which, we
hypothesize, leads to a shell of amorphous hydrophobic drug
around the exterior of the compact. Our data indicate that this
shell transforms ﬁrst to metastable crystalline form II and then
stable form I. Form I crystallizes preferentially from the
amorphous form in a random nucleation mechanism, rather
than from the crystalline form II. The interior of the compact is
Figure 7. Spatial correlations between the “tablet” pixels and (a) amorphous, (b) form II, and (c) form I neighbors. The red circles indicate the
experimental data, the black lines a set of 10 analyses in which neighbor spectra are replaced one-for-one by randomly selected pixels from that time
map.
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protected from water ingress by the shell of hydrophobic drug
and remains a copovidone:bicalutamide molecular dispersion,
even after ca. 50 h immersion in ﬂowing water. The dissolution
behavior observed here and the hypothesized water-resistant
“hydrophobic shell” of drug are likely to have signiﬁcant
implications for drug delivery and bioavailability optimization,
and are likely to apply to a wide range of molecular dispersion
formulations.
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Abstract: We have investigated the dissolution performance of amorphous solid dispersions
of poorly water-soluble bicalutamide in a Kollidon VA64 polymeric matrix as a function of
the drug loading (5% vs. 30% bicalutamide). A combined suite of state-of-the-art analytical
techniques were employed to obtain a clear picture of the drug release, including an
integrated magnetic resonance imaging UV-Vis flow cell system and 1H-NMR. Off-line
1H-NMR was used for the first time to simultaneously measure the dissolution profiles and
rates of both the drug and the polymer from a solid dispersion. MRI and 1H-NMR data
showed that the 5% drug loading compact erodes linearly, and that bicalutamide and Kollidon
VA64 are released at approximately the same rate from the molecular dispersion. For the
30% extrudate, data indicated a slower water ingress into the compact which corresponds to
a slower dissolution rate of both bicalutamide and Kollidon VA64.
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Keywords: bicalutamide; poorly soluble drugs; amorphous solid dispersions; hot
melt extrusion; solid-state transformations; magnetic resonance imaging; suppressed
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1. Introduction
Due to an increasing number of poorly water-soluble molecules emerging from pharmaceutical
pipelines, there is a continual drive to develop formulations for the delivery of such compounds [1,2].
Conventional formulations using the crystalline form of the drug often do not achieve the desired oral
bioavailability and pharmacological effects. An alternative strategy is to exploit the higher apparent
solubility and dissolution rate of the amorphous form. However, this may convert into the crystalline
form over time as it is thermodynamically unstable [3,4]. A popular strategy to stabilise the amorphous
form is to use amorphous solid dispersions in which the drug is molecularly dispersed in a water-soluble
or water-swellable polymer. These are typically prepared by fusion (e.g., hot melt extrusion) or solvent
evaporation (e.g., spray drying) methods [5,6].
In recent years, a number of studies have been conducted to understand the performance of amorphous
solid dispersions during manufacturing, storage and in vitro dissolution [7–10]. The understanding of the
formulation performance during dissolution is of particular interest as it underpins the in vivo efficacy.
The dissolution mechanisms of amorphous solid dispersions are extremely difficult to deconvolute
as a number of processes are involved [11]. Dissolution can be classified as drug-controlled or
polymer-controlled depending on the physicochemical properties of the drug and the polymer, and the
drug-to-polymer ratio [11]. The dissolution behaviour of amorphous solid dispersions can therefore be
dependent on the polymeric carrier itself. The re-crystallisation of the drug in the solid state or from a
super-saturated solution and the formation of drug nano- and micro-particles can also contribute to the
final dissolution performance [9,10,12,13].
To gain a more complete picture of the drug release from amorphous solid dispersions, a number
of solid-state analytical methods have been developed and employed, with a strong focus on how the
solid state properties of the drug and polymer affect the drug release. These include ultraviolet (UV)
imaging [14,15], infrared (IR) and Raman spectroscopy [10,12,16,17], magnetic resonance imaging
(MRI) [9,18], 1H-NMR [19] and particle analysis (e.g., dynamic image analysis to monitor particle
size and number during dissolution) [20]. UV imaging provides spatially and temporally resolved
information, and in addition enables real time dissolution rates to be obtained. UV imaging has
been employed to monitor in real time the drug re-crystallisation processes of several poorly soluble
drugs [14,15]. IR and Raman spectroscopy can provide high chemical specificity (multi-variate data,
one spectrum per xy position) [10,12,16,17]. Raman spectroscopy, compared to IR, is relatively
insensitive to water which is clearly an advantage for imaging in aqueous environments. In addition,
the low-wavenumber data of the Raman spectrum allows easy differentiation between amorphous and
crystalline forms and between different polymorphic forms [10,21,22]. Coherent anti-Stokes Raman
scattering (CARS), a particular form of Raman spectroscopy which uses two pulsed lasers focused
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on the sample to generate a signal, has also been employed to image the solid-state changes during
dissolution of theophylline anhydrate [23]. In contrast, MRI offers relatively low chemical selectivity,
but can provide three-dimensional information on molecular mobility. In recent work by Langham et al.
magnetic resonance images were used to determine the erosion rates of a compact during dissolution [9].
Solution-state 1H-NMR has also recently been demonstrated to be a useful tool to monitor the
dissolution of pharmaceutical products [19], especially for chemical species lacking a UV chromophore
(e.g., soluble fillers), or medicines containing more than one active ingredient where quantification can
be challenging using UV absorbance data. 1H-NMR offers a high chemical selectivity and therefore is
capable of resolving signals from components through differences in their chemical shifts. In addition,
as 1H-NMR spectra obtained from a dissolution test can be referenced against a spectrum of a solution
with known concentration, quantification is possible [24,25].
While each of these techniques have been used to study the formulation dissolution performance,
a better understanding of drug release can be achieved when techniques are used in combination.
We have previously investigated the dissolution performance of 5% and 50% drug-loaded
bicalutamide-Kollidon VA64 extrudates using Raman mapping [12]. Bicalutamide (Figure 1) is an
anti-androgen used for the treatment of prostate cancer and belongs to class II of the biopharmaceutics
classification system (BCS), i.e., it is characterised by low water solubility (less than 5 µg·mL−1) and
high intestinal permeability [26,27]. Raman data indicated that amorphous bicalutamide present in the
50% extrudate re-crystallised into polymorphic forms II and I. As a result, the dissolution profiles
of both bicalutamide and Kollidon VA64 (coPVP) were found to be extremely limited. We have also
hypothesised that the re-crystallisation event follows the formation of an amorphous drug-rich shell due
to the preferential dissolution of the hydrophilic polymer. In contrast, the dissolution performance of the
5% extrudate indicated the hydrophilic polymer and the hydrophobic drug dissolving at the same rate.
Figure 1. Molecular structure of bicalutamide.
In the present paper we further explore the dissolution performance of bicalutamide: coPVP
amorphous solid dispersions using a suite of analytical techniques. We investigated the 5% extrudate
(low drug loading) and this time the 30% extrudate (intermediate drug loading), with the aim of obtaining
additional information on how the drug amount affects the dissolution performance. A combined
MRI/UV-Vis flow cell system was used, allowing changes in dissolution profile to be related to physical
changes occuring in the solid material. Off-line 1H-NMR was also employed for the first time to
simultaneously measure the dissolution profiles and rates of both the drug and the polymer from the
molecular dispersion.
Molecules 2015, 20 16407
2. Results and Discussion
2.1. Solution-State Assays
2.1.1. UV-Vis Flow Cell Experiments
The UV-Vis dissolution profiles of the 5% and 30% extrudates are presented in Figure 2. The
experiments were repeated twice for each drug loading to obtain an indication of the reproducibility
in dissolution performance. A good reproducibility was observed in the two experiments of the 5%
extrudate. Both profiles are characterised by two regions which correspond to the dissolving bicalutamide
followed by the drug precipitation. In contrast, the two dissolution profiles of the 30% extrudate appear
highly non-reproducible, i.e., they are characterised by a different number of regions, but both show
two pronounced “turning points” at 350 and 700 min (first experiment) and 250 and 500 min (second
experiment) where the rate of drug dissolution increases. Overall, the UV-Vis data indicate a lack of
controlled release for the 30% extrudate compared to the 5% extrudate.
Figure 2. UV-Vis dissolution profiles of bicalutamide released from the 5% and 30%
extrudates. (a,c) Drug release for the 5% extrudate expressed in Cumulative drug amount
in solution (µg·mL−1) and Cumulative drug amount in solution (%) respectively; (b,d) Drug
release for the 30% extrudate expressed in Cumulative drug amount in solution (µg·mL−1)
and Cumulative drug amount in solution (%) respectively. The dissolution rates of the initial
time-points were calculated using linear regression analysis. Linear best fits for the 5% and
30% dissolution experiments are included.
These data indicate that there is a significant difference in dissolution behaviour between the two
drug loadings. For example in the first experiment the 5% extrudate reaches a maximum concentration
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of 8.5 µg·mL−1 (which corresponds to approximately 59% of total release) at 95 min, with an initial
dissolution rate of 0.12 µg·mL−1·min−1. The 30% extrudate achieves a maximum concentration
in solution of 14.1 µg·mL−1 (≈16% of total release) at 1179 min and an initial dissolution rate of
0.01 µg·mL−1·min−1. For both drug loadings, the concentration of bicalutamide in solution declines
after reaching the maximum concentration. The final measured concentration at 1319 min is
4.1 µg·mL−1 (≈28% of total release) and 13.6 µg·mL−1 (≈15% of total release) for the 5% extrudate
and 30% extrudate respectively.
In accordance with previous work, the dissolution behaviour of the bicalutamide extrudates is clearly
dependent on the drug loading [9,10,12]. At low drug loading (i.e., 5% extrudate), the performance
is dependent on the high aqueous solubility of the polymer. The drug is quickly released and the
maximum concentration corresponding to approximately 59% of total release is reached within 95 min.
For the extrudate containing a higher proportion of bicalutamide (i.e., 30% extrudate), the dissolution
performance is dominated by the physicochemical properties of the drug (e.g., low aqueous solubility
and high hydrophobicity). As a result, the initial dissolution rate is approximately one order of magnitude
lower (0.01 µg·mL−1·min−1 vs. 0.12 µg·mL−1·min−1) and the maximum concentration corresponding
to 16% of total release is achieved only after 1179 min.
The UV-Vis data also show that the bicalutamide content in solution for both the 5% and 30%
extrudates decreases after achieving the maximum concentration at 95 and 1179 min respectively,
indicating that the drug super-saturation in solution is not maintained by the presence of coPVP across
the entire dissolution test. In addition, in both experiments this reduction is accompanied by an increase
of the absorbance at 350 nm (Figure S1 of SI), which is related to the scattering as well as absorption
contributions of insoluble particles [13]. The formation of these particles, which cause the subsequent
reduction in solution concentration, has been previously observed also for amorphous spray-dried solid
dispersions of felodipine and coPVP [9].
It is also important to note that the 30% bicalutamide extrudate exhibited a markedly superior
dissolution profile compared to the corresponding drug loading of amorphous spray-dried solid
dispersions of felodipine and coPVP [9]. This can be attributed to the higher aqueous solubility of
bicalutamide over felodipine [10,12], although the manufacturing route (hot melt extrusion vs. spray
drying) may also be a factor.
2.1.2. Off-Line 1H-NMR
In this section we employ off-line 1H-NMR to complement the UV-Vis data for understanding the
dissolution performance of the bicalutamide extrudates. With respect to standard UV-Vis measurements,
1H-NMR allows us to simultaneously determine the amount of drug and polymer in solution. As the
dissolution performance of poorly soluble drugs can be largely dependent on that of the polymeric
carrier, quantitative measurements of the latter provide valuable information [3,4]. In addition, similarly
to the previously employed rotating disk dissolution rate (RDDR) methodology which uses HPLC to
separate and therefore track the dissolution trends of both drug and polymer, the dissolution rate of
the polymer allows us to determine an index of dissolution performance of the extrudate [10,12]. The
index of performance shows how the drug and polymer behave during the dissolution test and it is
defined by dividing the dissolution rate of bicalutamide by the total rate of the extrudate (bicalutamide
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plus coPVP) and normalising by the bicalutamide mass fraction (e.g., 0.05 for the 5% extrudate). The
temporal evolution of NMR spectra for the 5% and 30% extrudates are presented in Figure 3, while
the spectra from the reference solutions are shown in Figure S2 of SI. For each spectrum, two integrals
from bicalutamide and coPVP were generated and then scaled to integrals obtained from the reference
solutions of known concentration. The spectra from the reference solutions were obtained using identical
experimental conditions. The release profiles of the individual species are shown in Figure 4.
Figure 3. Portions of the 1H-NMR spectra acquired during the dissolution of the 5%
and 30% extrudates. Bicalutamide and coPVP data were obtained from single integrals
at 7.06–7.14 ppm (two aromatic protons of fluorobenzene) and 1.2–2.6 ppm (protons of
pyrrolidone ring and methylene chains) respectively.
For the 5% extrudate (e.g., first experiment), bicalutamide exhibits an initial dissolution rate of
0.16 µg· mL−1·min−1 and that of coPVP is 3.84 µg·mL−1·min−1. The index of performance resulted in
a value of 0.8, indicating that the drug and polymer dissolve approximately with the same rate from the
dispersion. The index of performance obtained from the 1H-NMR system is similar to that previously
obtained from the RDDR test (value of 0.94) [12].
For the 30% extrudate, the dissolution rates of both bicalutamide and coPVP are lower with values
of 0.009 µg·mL−1·min−1 and 0.18 µg·mL−1·min−1 respectively. In agreement with these data, the
dissolution rates of bicalutamide and coPVP from the 50% extrudate were also found extremely low
using the RDDR test [12]. The index of performance of the 30% extrudate is also far inferior (0.15)
compared to that of the 5% extrudate, indicating that for this drug loading the higher content of
bicalutamide limits the dissolution performance of both bicalutamide and coPVP.
The dissolution rates of bicalutamide obtained from the 1H-NMR experiments (0.16 mL−1·min−1
for the 5% extrudate and 0.009 mL−1·min−1 for the 30% extrudate) are in a good agreement with those
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obtained from the UV-Vis (0.12 mL−1·min−1 for the 5% extrudate and 0.009 mL−1·min−1 for the
30% extrudate).
From Figure 4 it is also apparent that for both the 5% and 30% extrudates, whilst coPVP achieves
a dissolution release plateau, the bicalutamide concentration declines after reaching a maximum. In
addition, for the 5% extrudate the bicalutamide precipitation begins before the coPVP dissolution is
complete. This, in agreement with the previous UV-Vis data, clearly indicates that the super-saturation
of the drug is not maintained by the polymer across the entire dissolution test.
Figure 4. Release profiles obtained from the 1H-NMR spectra of bicalutamide and coPVP
from the 5% and 30% extrudates. (a,c) Release for the 5% extrudate expressed in
Cumulative drug amount in solution (µg·mL−1) and Cumulative drug amount in solution
(%) respectively; (b,d) Release for the 30% extrudate expressed in Cumulative drug amount
in solution (µg·mL−1) and Cumulative drug amount in solution (%) respectively. Data were
scaled using the reference standard solutions. Linear best fits for the dissolution profiles of
the 5% and 30% extrudates are included.
2.2. Solid-State Assays
MRI Flow Cell Experiments
The solution-state measurements obtained from the UV-Vis and 1H-NMR data are then complemented
with solid-state measurements, i.e., magnetic resonance imaging. The magnetic resonance images
showing the temporal changes in one cross sectional slice of the 5% and 30% extrudates during the
dissolution test are shown in Figure 5 (first experiment) and Figure S3 of SI (second experiment). The
measured dimensions of the compacts as a function of time are presented in Figure 6. In this MRI
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experiment the image contrast is due to differences in molecular mobility. As a result, protons in a solid
environment have a faster T2 relaxation time and therefore the solid materials appear dark in the images.
Protons in solution have a significantly slower T2 relaxation time and thereby they generate a bright
image, while, for example, protons in a hydrating gel give an intermediate brightness [9].
Figure 5. Magnetic resonance images (first experiment) showing the changes as a function
of time in one cross sectional slice of the extrudates containing 5% (a) and 30% (b)
of bicalutamide.
Figure 6. Evolution of the compact dimensions as a function of time for the 5% extrudate
and 30% extrudate. Linear best fit to the data for the 5% extrudate is included. For the 30%
extrudate, to facilitate the comparison with the 5% extrudate, the dimensions of the compact
core (solid material) without considering those of the hydrated layer were measured. Data
were collected only up to approximately 300 min due to the compact falling off from the
support and being out of the instrumental field of view after this time-point.
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The images presented in Figure 5, for example, show significantly different dissolution behaviours
for the 5% extrudate (Figure 5a) and 30% extrudate (Figure 5b). The 5% extrudate undergoes erosion
and it is almost entirely dissolved over a period of 56 min, while the 30% extrudate swells and remains
intact after 265 min (it is then no longer attached to the support due to its swelling and expansion and
as a consequence it is out of the instrumental field of view). These results are in full accord with the
UV-Vis and 1H-NMR solution-state data.
Throughout the experiments, the 30% extrudate exhibits a well-defined region of intermediate MRI
contrast, which is either not present, or hardly present, in the 5% extrudate (Figure 7). This region is
due to water ingress into the compact. It is clear that for the 5% sample the rates of water ingress and
dissolution are similar, which prevents the formation of the intermediate contrast region, whereas for
the 30% compact dissolution is markedly slower than water ingress. Our previous Raman spectroscopy
studies on a 50% sample [12] indicated that the preferential dissolution of coPVP led to formation of
a drug-rich shell which crystallised and appeared to strongly inhibit further erosion and dissolution of
the compact. We therefore suggest that this region of intermediate contrast in the magnetic resonance
images of the 30% sample is due to water partially dissolved in the coPVP matrix, which does not lead
to dissolution and drug release due to a drug-rich, likely crystalline shell which prevents further water
ingress and thus greatly reduces the dissolution rate of the compact. Formation of a gel-layer can be
ruled out on the basis of the optical images previously collected during the dissolution test of the 50%
drug loading [12]. The drug re-crystallisation is likely to be one of the main factors which determines
lack of controlled release observed in the UV-Vis profiles for the 30% drug loading.
Figure 7. Zoom of the images collected for the 5% extrudate (28 min) and 30% extrudate
(162 min) to highlight the well-defined region of intermediate MRI contrast present in the
30% extrudate.
It is important to note that the images in Figure 5 show some ghosting artefacts which are a likely
consequence of the wash in/wash out effect of the flowing medium with nuclei moving between two
consecutive spatially selective RF excitations. The artefacts do not interfere with the determination of
the compact dimensions. The overall contrast of the flowing bulk dissolution medium seems to gradually
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decrease for the 30% loading sample and this is thought to be a consequence of the wash in/wash out
effects of the flowing medium rather than due to any change in its mobility. If the intensity of the bulk
medium in the initial image of 5% extrudate is compared with that for the 30% compact at 265 min
they are similar. As the dissolution experiment proceeds, however, the difference in mobility and hence
contrast between the hydrated compact and the bulk medium is reduced. In addition, bright halos on the
outer edges of the compact as well as air bubbles are visible in the images of Figure 5. The origins of
these are not fully understood but are likely to be due to magnetic susceptibility effects which are known
to occur at interfaces. These effects are often observed with gradient echo imaging based sequences such
as FLASH, which has been used in this work, and result in spatial mis-mapping of the MR signal, often
presented as regions of very bright signal resulting from “piling up” of signal at the interface.
The difference in dissolution performance between the two drug loadings is reflected in Figure 6. The
5% extrudate quickly erodes with a linear erosion rate of 1.1 mm2·min−1, while the erosion rate for the
30% extrudate is slower and not linear due to the presence of the hydrating layer.
At the end of the dissolution test of the 30% extrudate (approximately after 1700 min), we noted
abundant presence of undissolved material in the flow cell. This residue was removed from the flow cell
and shown by Raman spectroscopy to contain crystalline bicalutamide form I (Figure S4), pointing to
the drug re-crystallisation.
The MRI images are in agreement the UV-Vis and 1H-NMR data, indicating that for the 5% extrudate
the release of bicalutamide is a polymer-controlled process whereby the dissolution is governed by the
fast hydration of the highly water-soluble coPVP. For the 30% extrudate, the dissolution is dependent on
the physicochemical properties of bicalutamide. The low aqueous solubility and high hydrophobicity of
the drug contribute to a slower water uptake into the compact which corresponds to a slower dissolution
rate of both bicalutamide and coPVP.
3. Experimental Section
3.1. Materials
Bicalutamide was provided by AstraZeneca (Macclesfield, UK) and shown to be polymorphic
form I by Raman spectroscopy and X-ray powder diffraction (XRPD). Kollidon VA64 (coPVP) was
supplied by BASF (Ludwigshafen, Germany). All materials were used as received and without any
further purification.
3.2. Sample Preparation
3.2.1. Preparation of the Amorphous Reference form of Bicalutamide
The amorphous form of bicalutamide was prepared by heating form I to 200 °C and quench cooling
the melt to room temperature [12]. The formation of the amorphous form was confirmed by Raman
spectroscopy and XRPD (Figures S4 and S5 of SI).
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3.2.2. Preparation of the Bicalutamide: coPVP Extrudates
Extrudates of bicalutamide in coPVP (5% and 30% w/w bicalutamide) were prepared using a
co-rotating twin-screw extruder (Thermo Scientific HAAKE MiniLab II). Bicalutamide form I and
coPVP were pre-mixed for 20 min in a Turbula T2F mixer (Willy A. Bachofen AG Mashinefabrik).
The materials were extruded at a screw speed of 150 rpm and a temperature of 170 °C, then cooled to
room temperature and manually milled with a T & G CrushGrind mill to fine powders. The formation
of the amorphous form was confirmed by Raman spectroscopy and XRPD (Figures S4 and S5 of SI).
3.3. Analytical Methods
3.3.1. Raman Spectroscopy
Data were acquired on a HORIBA Jobin Yvon LabRAM HR confocal microscope/spectrometer.
A near-IR (785 nm) laser was employed to illuminate the samples, and spectra were collected using
a 50× objective and a 300 µm confocal pinhole. A 600 lines·mm−1 rotatable diffraction grating along
a path length of 800 mm was used to simultaneously scan a range of Raman shifts, and spectra were
detected using a SYNAPSE CCD detector (1024 pixels). Spectra were collected in the range from 1055
to 1725 cm−1.
3.3.2. X-ray Powder Diffraction (XRPD)
X-ray powder diffraction data were collected on a PANalytical CubiX PRO diffractometer
(λ = 1.5418 Å). Powders were smeared onto zero-background silicon wafer sample holders and measured
over the scan range from 2◦ to 40◦ 2θ, with a 25 s exposure per 0.02◦ 2θ increment. Samples were spun
at 30 rpm and exposed to a radiation generated by a copper long-fine focus tube operated at a voltage of
45 kV and a current of 40 mA.
3.3.3. MRI UV-Vis Flow Cell System
The dissolution performance of circular compacts with a diameter of 10 mm and a weight of
approximately 290 mg was investigated. Powders were compressed using a Specac manual hydraulic
press using a compression force of ca. 50 kN. The dissolution tests were performed in a USP IV-type
flow cell previously described by Langham et al. [9]. 1 L of pH 6.5 phosphate buffer dissolution
medium maintained at a temperature of 37 °C using a temperature-controlled water bath was circulated
continuously at a flow rate of 15 mL·min−1.
The dissolution profile of bicalutamide was obtained by recording the absorbance of the unfiltered
dissolution medium at 275 nm (wavelength maxima of bicalutamide) and 350 nm (no observed
absorbance, for correction for any suspended particles) at regular time intervals using a Agilent
8453 UV-Vis spectrophotometer with a 10 mm quartz flow cell (Starna Scientific, Ilford, UK). The
dissolution data were calibrated against the absorbance of a series of standard solutions of bicalutamide
in water–acetonitrile 75/25 (v/v).
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The flow cell was sited in the probe of a 400 MHz Bruker Avance NMR spectrometer fitted with a
Micro2.5 imaging accessory fitted with a 25 mm O.D. RF coil. The images were collected as a function
of time using a FLASH (Fast Low Angle Shot) protocol to generate 16× 1 mm2 concatenated axial slices
with a field of view of 25 mm. The echo time was 3.0 ms and the repetition time was 500 ms giving a
scan time of 1 min 4 s for each 16 slice experiment. A data matrix size of 128× 128 pixels was recorded
giving a resolution of 0.0195 cm/pixel in the read direction. Data were processed using ParaVision™
software v4.0. Changes in the size of the compacts were followed by measuring the dimensions of a
single slice as a function of time.
3.3.4. 1H-NMR Spectroscopy
All NMR measurements were performed on a Bruker Avance III 500 MHz NMR spectrometer fitted
with a 5 mm QCI cryoprobe. The spectra from the dissolution samples and the reference solutions were
acquired at 300.0 K with a spectral width of 10 kHz, with 64 k data points in the time domain. A recycle
delay of 4 s was used and the peak due to water was suppressed using a 1D NOESY pulse program with
presaturation and spoil gradients (noesygppr1d) and with irradiation at the water frequency during the
recycle and mixing time delays. The receiver gain was set to 128 and kept the same for each experiment.
Data were processed using the Bruker Topspin 3.0 software. Interactive zero order phase correction was
applied to all the spectra and the “Use lastscale for calibration” functionality was employed to directly
compare integrals across multiple spectra.
4. Conclusions
A combination of solution-state and solid-state analytical techniques were employed to fully
understand the dissolution performance of amorphous bicalutamide solid dispersions at two different
drug loadings (5% and 30% bicalutamide). The integrated MRI UV-Vis system enabled us to relate
changes in dissolution profile to physical changes occurring to the solid material. The MRI data indicated
that the 5% extrudate erodes linearly, while for the 30% extrudate the water ingress is significantly
slower which corresponds to a slower dissolution of both bicalutamide and coPVP. We also employed
for the first time 1H-NMR spectroscopy to simultaneously measure the dissolution profiles and rates
of both drug and polymer. 1H-NMR has been demonstrated to be a valid alternative to the previously
employed rotating disk dissolution rate (RDDR) methodology for tracking the dissolution profiles in
multi-component systems. 1H-NMR data showed that for the 5% extrudate, bicalutamide and coPVP
dissolve with approximately the same rate pointing to a matrix-controlled release, while for the 30%
drug loading they dissolve very differently and at a significantly lower rate. For the 30% extrudate the
dissolution performance is dominated by the physicochemical properties of the drug.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/09/16404/s1.
Molecules 2015, 20 16416
Acknowledgments
AstraZeneca and EPSRC are acknowledged for funding through grant EP/I01375X/1 (via the joint
Center for Doctoral Training in Targeted Therapeutics and Formulations Sciences).
Author Contributions
All the authors conceived and designed the experiments. F.T., S.R.C., A.R.P., L.P.H. and S.A.C.W.
performed the experiments. F.T., S.A.C.W., J.W.A. and J.C.B. analysed the UV-Vis and Raman data.
F.T., S.R.C., A.R.P., L.P.H. and S.A.C.W. analysed the 1H-NMR data. F.T. and L.P.H. analysed the MRI
images. F.T. wrote the paper. All the authors revised the manuscript and approved the final version.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Babu, N.J.; Nangia, A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals.
Cryst. Growth Des. 2011, 11, 2662–2679.
2. Di, L.; Fish, P.V.; Mano, T. Bridging solubility between drug discovery and development.
Drug Discov. Today 2012, 17, 486–495.
3. Hancock, B.C.; Parks, M. What is the true solubility advantage for amorphous pharmaceuticals?
Pharm. Res. 2000, 17, 397–404.
4. Hancock, B.C.; Zografi, G. Characteristics and significance of the amorphous state in
pharmaceutical systems. J. Pharm. Sci. 1997, 86, 1–12.
5. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur. J.
Pharm. Biopharm. 2000, 50, 47–60.
6. Serajuddin, A.T.M. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent
problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88, 1058–1066.
7. Ivanisevic, I. Physical stability studies of miscible amorphous solid dispersions. J. Pharm. Sci.
2010, 99, 4005–4012.
8. Van den Mooter, G.; Wuyts, M.; Blaton, N.; Busson, R.; Grobet, P.; Augustijns, P.; Kinget, R.
Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone
K25. Eur. J. Pharm. Sci. 2001, 12, 261–269.
9. Langham, Z.A.; Booth, J.; Hughes, L.P.; Reynolds, G.K.; Wren, S.A.C. Mechanistic insights into
the dissolution of spray-dried amorphous solid dispersions. J. Pharm. Sci. 2012, 101, 2798–2810.
10. Tres, F.; Treacher, K.; Booth, J.; Hughes, L.P.; Wren, S.A.C.; Aylott, J.W.; Burley, J.C.
Real time Raman imaging to understand dissolution performance of amorphous solid dispersions.
J. Control. Release 2014, 188, 53–60.
Molecules 2015, 20 16417
11. Craig, D.Q.M. The mechanisms of drug release from solid dispersions in water-soluble polymers.
Int. J. Pharm. 2002, 231, 131–144.
12. Tres, F.; Patient, J.D.; Williams, P.M.; Treacher, K.; Booth, J.; Hughes, L.P.; Wren, S.A.C.;
Aylott, J.W.; Burley, J.C. Monitoring the dissolution mechanisms of amorphous bicalutamide solid
dispersions via real-time raman mapping. Mol. Pharm. 2015, 12, 1512–1522.
13. Van Eerdenbrugh, B.; Alonzo, D.; Taylor, L. Influence of particle size on the ultraviolet spectrum
of particulate-containing solutions: Implications for in-situ concentration monitoring using UV/vis
fiber-optic probes. Pharm. Res. 2011, 28, 1643–1652.
14. Boetker, J.P.; Savolainen, M.; Koradia, V.; Tian, F.; Rades, T.; Müllertz, A.; Cornett, C.;
Rantanen, J.; Østergaard, J. Insights into the early dissolution events of amlodipine using UV
imaging and raman spectroscopy. Mol. Pharm. 2011, 8, 1372–1380.
15. Nielsen, L.H.; Gordon, S.; Pajander, J.P.; Østergaard, J.; Rades, T.; Müllertz, A. Biorelevant
characterisation of amorphous furosemide salt exhibits conversion to a furosemide hydrate during
dissolution. Int. J. Pharm. 2013, 457, 14–24.
16. Chan, K.L.A.; Kazarian, S.G. FTIR spectroscopic imaging of dissolution of a solid dispersion of
nifedipine in poly(ethylene glycol). Mol. Pharm. 2004, 1, 331–335.
17. Wray, P.S.; Clarke, G.S.; Kazarian, S.G. Dissolution of tablet-in-tablet formulations studied with
ATR-FTIR spectroscopic imaging. Eur. J. Pharm. Sci. 2013, 48, 748–757.
18. Chen, Y.Y.; Hughes, L.P.; Gladden, L.F.; Mantle, M.D. Quantitative ultra-fast MRI of HPMC
swelling and dissolution. J. Pharm. Sci. 2010, 99, 3462–3472.
19. Coombes, S.R.; Hughes, L.P.; Phillips, A.R.; Wren, S.A.C. Proton NMR: A new tool for
understanding dissolution. Anal. Chem. 2014, 86, 2474–2480.
20. Wilson, D.; Wren, S.; Reynolds, G. Linking dissolution to disintegration in immediate release
tablets using image analysis and a population balance modelling approach. Pharm. Res. 2012, 29,
198–208.
21. Brillante, A.; Bilotti, I.; Della Valle, R.G.; Venuti, E.; Girlando, A. Probing polymorphs of organic
semiconductors by lattice phonon Raman microscopy. CrystEngComm 2008, 10, 937–946.
22. Al-Dulaimi, S.; Aina, A.; Burley, J.C. Rapid polymorph screening on milligram quantities of
pharmaceutical material using phonon-mode Raman spectroscopy. CrystEngComm 2010, 12,
1038–1040.
23. Fussell, A.; Garbacik, E.; Offerhaus, H.; Kleinebudde, P.; Strachan, C. In situ dissolution analysis
using coherent anti-Stokes Raman scattering (CARS) and hyperspectral CARS microscopy. Eur. J.
Pharm. Biopharm. 2013, 85, 1141–1147.
24. Bharti, S.K.; Roy, R. Quantitative 1H-NMR spectroscopy. Trends Anal. Chem. 2012, 35, 5–26.
25. Dalitz, F.; Cudaj, M.; Maiwald, M.; Guthausen, G. Process and reaction monitoring by low-field
NMR spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 2012, 60, 52–70.
26. Abu-Diak, O.A.; Jones, D.S.; Andrews, G.P. Understanding the performance of melt-extruded
poly(ethylene oxide)-bicalutamide solid dispersions: Characterisation of microstructural properties
using thermal, spectroscopic and drug release methods. J. Pharm. Sci. 2012, 101, 200–213.
Molecules 2015, 20 16418
27. Andrews, G.P.; AbuDiak, O.A.; Jones, D.S. Physicochemical characterization of hot melt extruded
bicalutamide-polyvinylpyrrolidone solid dispersions. J. Pharm. Sci. 2010, 99, 1322–1335.
Sample Availability: Samples of the compounds used in this study are available from the authors.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).
